Document:

<PAGE>
                                                                    EXHIBIT 10.1

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                             COLLABORATION AGREEMENT

      THIS COLLABORATION AGREEMENT dated as of December 18, 2002, between Pfizer
Inc. ("Pfizer") a corporation organized under the laws of the State of Delaware
of 235 East 42nd Street, New York, New York 10017-5755, and Neurocrine
Biosciences, Inc. ("Neurocrine") a corporation organized under the laws of the
State of Delaware, 10555 Science Center Drive, San Diego, California 92121-1102.

      WHEREAS, the parties have executed a License Agreement dated as of the
date hereof (the "License Agreement") with respect to Neurocrine's compound
generically known as indiplon; and

      WHEREAS, the parties would like to set forth the terms and conditions
pursuant to which the parties will collaborate in connection with the
commercialization of Products in the Territory (as both terms are defined
below), and with respect to certain other matters as described herein.

      NOW, THEREFORE, the parties agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS

      Any capitalized terms used herein which are not expressly defined in this
Agreement shall have the meaning set forth in the License Agreement. For
purposes of this Agreement, the following definitions shall also be applicable:

1.1   "Act" means both the Federal Food, Drug and Cosmetic Act, as amended, and
      the regulations promulgated under the foregoing.

1.2   "Affiliate" means any entity directly or indirectly controlled by,
      controlling, able to control, or under common control with, a party to
      this Agreement, but only for so long as such control shall continue. For
      purposes of this definition, "control" (including, with correlative
      meanings, "controlled by", "controlling" and "under common control with")
<PAGE>
      means possession, direct or indirect, of (a) the power to direct or cause
      direction of the management and policies of an entity (whether through
      ownership of securities or partnership or other ownership interests, by
      contract or otherwise), or (b) at least fifty percent (50%) of the voting
      securities (whether directly or pursuant to any option, warrant or other
      similar arrangement) or other comparable equity interests. For the
      avoidance of doubt, neither of the parties to this Agreement shall be
      deemed to be an "Affiliate" of the other solely as a result of their
      entering into this Agreement.

1.3   "Approval" means receipt of a final Approval Letter from FDA authorizing
      marketing and sale of Products.

1.4   "Bankruptcy Code" means 11 USC Sections 101-1330, as amended.

1.5   "Baseline Threshold" is defined in Section 8.2(b).

1.6   "beneficial ownership" (and other correlative terms) means beneficial
      ownership as defined in Rule 13d-3 under the United States Securities and
      Exchange Act of 1934, as amended; it being understood and agreed that
      "beneficial ownership" shall also include any securities: which any person
      or any of such person's Affiliates has the right to acquire (whether such
      right is exercisable immediately or only after the passage of time in no
      event to exceed six months from any applicable date) pursuant to any
      agreement, arrangement or understanding, or upon the exercise of
      conversion rights, exchange rights, rights, warrants or options, or
      otherwise.

1.7   "Business Day" means a day that is not a Saturday, Sunday or a day on
      which banking institutions in New York, New York or San Diego, California
      are authorized by Law to remain closed.

1.8   "Change in Control" or "Acquisition" means an event where:

      (a)   any person or group of persons (as the term "group" is interpreted
            pursuant to Rule 13d-5 of under the Securities Exchange Act of 1934,
            as amended) acquires beneficial ownership of capital stock of
            Neurocrine entitling the holder(s) thereof

                                       2
<PAGE>
            to more than fifty percent (50%) of the voting power of the then
            outstanding capital stock of Neurocrine with respect to the election
            of directors of Neurocrine pursuant to a tender offer for Neurocrine
            securities, or

      (b)   Neurocrine enters into a merger, consolidation, reorganization or
            similar transaction with another person (a "Business Combination
            Person"), whether or not Neurocrine is the survivor in such
            transaction and thereafter any of Neurocrine, the Business
            Combination Person or any other resulting person that is the
            surviving entity, as applicable, thereafter is (i) no longer
            generally engaged in drug discovery and development or (ii) in
            Pfizer's reasonable opinion, no longer able to perform its
            obligations hereunder or (iii) a direct or indirect division or
            subsidiary of a third party who is [***] (providing this shall not
            apply to a research and development joint venture between Neurocrine
            and [***] that does not otherwise fall within subparagraph (c)
            below) or (v) has at least [***] of any voting class of its capital
            stock beneficially owned, whether directly or indirectly (including
            as part of any group of persons), by any [***] or affiliate
            controlled by, controlling or under the common control of any [***]
            belongs (a "Group"), where such beneficial ownership by any such
            [***] or Group, as applicable, represents the largest percentage
            ownership of such capital stock by any single shareholder or Group
            of persons at such time; or

      (c)   Neurocrine or its Affiliate sells or otherwise transfers to any
            person(s) that is not an Affiliate in one or more related
            transactions not involving a merger, consolidation, reorganization
            or similar transaction, properties or assets representing more than
            fifty percent (50%) (except that with respect to any transfer that
            is a license, such license must represent of all or substantially
            all of

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3
<PAGE>
            Neurocrine's intellectual property assets) of (i) Neurocrine's
            consolidated total assets as reflected on its most recent Annual
            Report on Form 10-K or Quarterly Report on Form 10-Q, or (ii)
            Neurocrine's consolidated operating income for the most recent
            fiscal year as reflected on its most recent Annual Report on Form
            10-K, or (iii) any of the Neurocrine Technical Information or
            Neurocrine Patent Rights.

      For purposes of this definition of "Change in Control" (or "Acquisition"),
      references to Neurocrine shall be deemed to include all successors in any
      merger, consolidation, reorganization or similar transaction.

1.9   "CMC" means the chemistry, manufacturing and controls section of the
      Product NDA.

1.10  "Code" or "Codes" means the Code on Interactions with Healthcare
      Professionals promulgated by the Pharmaceutical Research and Manufacturers
      of America (PhRMA), and the American Medical Association Guidelines on
      Gifts to Physicians, as either of the foregoing may be amended, from time
      to time.

1.11  "Collaboration" means the collaboration between Neurocrine and Pfizer as
      set forth in this Agreement and the License Agreement.

1.12  "Combination Product" means any product which contains, in addition to the
      Product, one or more other therapeutically active ingredients.

1.13  "Commercialize" means directly or indirectly to market, sell, detail,
      promote or distribute, but in no event shall include an out-license or
      other divestiture of intellectual property to a person that markets,
      sells, details or distributes.

1.14  "Commercially Reasonable Efforts" means, those efforts and resources that
      Pfizer would use were it promoting and detailing its own pharmaceutical
      products which are of similar market potential as the Products, taking
      into account product labelling, market potential, past performance,
      economic return, the regulatory environment and competitive market
      conditions in the therapeutic area, all as measured by the facts and
      circumstances at the

                                       4
<PAGE>
      time such efforts are due. In evaluating economic return, Pfizer shall not
      consider the payments under this Agreement and the License Agreement to
      Neurocrine.

1.15  "Compound" means indiplon (NBI-34060) as more specifically described as
      Acetamide, N-Methyl-N-[3-[3-(2-thienylcarbonyl)_pyrazol - [1,5-a]
      pyrimidin-7-yl] phenyl] in any chemical form, including without
      limitation, salts, solvates, metabolites and prodrugs.

1.16  "Consensus Matter" shall be as defined in Section 3.9(b).

1.17  "Co-Promotion" or "Co-Promote" means the Detailing and Promotion of
      Products and Zoloft in the United States by Neurocrine and Pfizer as set
      forth in Article 6A.

1.18  "Co-Promotion Budget" is defined in Section 6A.3.

1.19  "Co-Promotion Term" means the period during which Neurocrine and Pfizer
      are Co-Promoting Products, Zoloft or other Pfizer Products under the terms
      and conditions set forth herein.

1.20  "Detail" means a face-to-face contact of either a Neurocrine or Pfizer
      Sales Representative, as the case may be, with a medical professional with
      prescribing authority (or, in the case of Sleep Specialists, medical
      professionals who are certified diplomates of the American Board of Sleep
      Medicine) during which scientific and/or medical information about the
      Products or Zoloft (as the case may be) is discussed. A Detail does not
      include a reminder or sample drop. Details shall be measured by each
      party's internal recording of such activity; provided that, such
      measurement shall be on the same basis as the recording party's
      measurement for its sales representatives detailing of such recording
      party's other products, consistently applied throughout the term of this
      Agreement. When used as a verb, the term "Detailing" means to engage in
      the activity of a Detail.

1.21  "Detail Report" is defined in Section 6A.4.

                                       5
<PAGE>
1.22  "Detail Requirement" means with respect to Neurocrine's Sales
      Representatives, [***].

1.23  "Development Costs" means the costs set forth in each relevant Development
      Plan; provided, however, for the avoidance of doubt, Development Costs
      shall in no event include any Out-of-Pocket Costs incurred or accrued by
      Neurocrine in the conduct of the Registration Program prior to the year
      2003 or any internal costs of Neurocrine.

1.24  "Development Plan" means collectively, the Registration Plan and the
      Supplemental Plan.

1.25  "Development Program" means collectively, the Registration Program and
      Supplemental Program.

1.26  "Effective Date" means the first date upon which the applicable waiting
      period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
      amended ("HSR Act") shall have expired or been terminated with respect to
      the License Agreement and this Agreement, as applicable, which in any
      event may only be a date no later than the 90th day following the date of
      this Agreement.

1.27  "FDA" means the United States Food and Drug Administration and any
      successor agency thereto.

1.28  "First Approval" means, with respect to IR Product or MR Product, the
      first Approval.

1.29  "Final Detail Requirement" is defined in Section 6A.4(b).

1.30  "GAAP" means US generally accepted accounting principles in effect from
      time to time.

1.31  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       6
<PAGE>
1.32  "GMP" means the Good Manufacturing Practices regulations and guidance
      promulgated by the FDA under the Act as of the time of manufacture of the
      applicable Products.

1.33  "Governmental Authority" means any court, agency, department or other
      instrumentality of any foreign, federal, state, county, city or other
      political subdivision.

1.34  "Initial Five Year Period" is defined in Section 2.3.

1.35  [***].

1.36  "IR Product" means the immediate release formulation of the Compound,
      characteristics as set forth in Exhibit A of the License Agreement or any
      formulation with equivalent release characteristics.

1.37  "Launch" means the shipping of commercial quantities of a Product for
      commercial sale to unaffiliated third parties.

1.38  "Law" or "Laws" means all laws, statutes, rules, Codes, regulations,
      orders, decrees, judgments and/or ordinances of any Governmental
      Authority.

1.39  "Marketing Plan" is defined in Section 6A.3(c).

1.40  "Medical and Marketing Expenses" means all Out-of-Pocket Costs, paid or
      accrued by a party pursuant to the Marketing Plan and directly related to
      the Co-Promotion of the Products in the US Territory, including those in
      connection with:

      (a)   [***];

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       7
<PAGE>
      (b)   [***];

      (c)   [***];

      (d)   [***]

      (e)   [***].

      [***]:

            (1)   [***]

            (2)   [***].

All other Out-of-Pocket Costs incurred in the Co-Promotion of the Products in
the US Territory, but not specifically identified above, but which have been
approved by the MC or provided for in the Marketing Plan, shall be accounted for
and deemed Medical and Marketing Expenses for all purposes of this Agreement.

1.41  "MR Product" means the modified release formulation of the Compound as set
      forth in Exhibit A of the License Agreement or any formulation with
      equivalent kinetic profile.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       8
<PAGE>
1.42  "Net Sales" means (a) gross sales of Pfizer, its Affiliates and
      sublicensees of Product to unaffiliated third parties in the applicable
      country, less (i) bad debts related to the Product and (ii) sales returns
      and allowances, including, without limitation, trade, quantity and cash
      discounts and any other adjustments, including, but not limited to, those
      granted on account of price adjustments, billing errors; rejected goods,
      damaged or defective goods, recalls, returns, rebates, chargeback rebates,
      fees, reimbursements or similar payments granted or given to wholesalers
      or other distributors, buying groups, health care insurance carriers or
      other institutions, adjustments arising from consumer discount programs,
      [***], customs or excise duties, sales tax, consumption tax, and other
      taxes (except income taxes) or duties relating to sales, and any payment
      in respect of sales to any governmental or regulatory authority in respect
      of any government-subsidized program; and (b) in the case of Combination
      Products, (aa) If Pfizer and/or its Affiliates separately sells in such
      country during such Year when it sells such Combination Product both (x)
      one or more Products as a single chemical entity and (y) other products
      containing active ingredient(s) as a single entity that are also contained
      in such Combination Product, the Net Sales attributable to such
      Combination Product during such Year shall be calculated [***]; (bb) if
      Pfizer and/or its Affiliates separately sells, in such country during such
      Year when it sells such Combination Product, one or more Products as a
      single chemical entity but do not separately sell, in such country, other
      products containing active ingredient(s) that are also contained in such
      Combination Product, the Net Sales attributable to such Combination
      Product during such Year shall be calculated by [***];

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       9
<PAGE>
      (cc) if Pfizer and/or its Affiliates do not separately sell each Products
      contained in the Combination Product, the Net Sales attributable to such
      Combination Product shall be calculated [***].

      With respect to the determination of Net Sales of Combination Products
      above and in considering the financial feasibility of Launching a
      Combination Product, if one or both of the parties determines that the
      formula in (aa), (bb) or (cc), as the case may be, will result in
      commercialization of the Combination Product not being economically
      feasible or equitable, the parties will meet and discuss in good faith
      adjustments or alterations to the applicable formulas above to address the
      concerns of such party(ies).

1.43  "Neurocrine Field Force" is defined in Section 6A.1(a).

1.44  "Neurocrine Sales Force" is defined in Section 6A.1(a).

1.45  "NDA" means a New Drug Application filed with the FDA with respect to each
      Product.

1.46  "Not-Approvable Letter" means a letter or other official communication
      from FDA providing notice that an application filed with FDA may not be
      approved, as defined in FDA regulations set forth in 21 C.F.R. 314.120.

1.47  "Out-of-Pocket Costs" means costs and expenses paid or accrued to third
      parties, other than Affiliates or employees, by either party after the
      Effective Date.

1.48  "Pfizer Field Force" means a Pfizer field force comprised of full time
      Sales Representatives in the US Territory who are trained to Detail
      Products to psychiatrists and/or to Sleep Specialists.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       10
<PAGE>
1.49  "Pfizer Quarter" means each of the periods ending on each of the four (4)
      thirteen (13) week periods as used by Pfizer as reported in its quarterly
      and annual filings with the Securities and Exchange Commission, the first
      commencing on January 1 of any year.

1.50  "Position" as used in this Agreement denotes the priority position in
      which a Neurocrine Sales Representative Details the products in accordance
      with their established field force practices; "First Position" means that
      the relevant product is Detailed with the highest priority in accordance
      with their established field force practices; and "Second Position" means
      that the relevant product is Detailed with the second highest priority in
      accordance with their established field force practices.

1.51  "Product" means all pharmaceutical formulations and dosage forms which
      contain the Compound either alone or in combination with other
      therapeutically active ingredients.

1.52  "Product Studies" mean clinical, preclinical, safety, epidemiological
      studies and modeling, pharmacoeconomic studies, in each case including any
      ancillary or incidental development, investigation or research scheme
      pertaining thereto, that are designed: (a) to support regulatory authority
      or other Governmental Authority approval for marketing of Products; or (b)
      to support publications, promotional and educational activities, future
      labeling changes or new indications of the Compounds or the Products.

1.53  "Promote" means those activities other than Detailing undertaken by a
      party to encourage sales of Products including but not limited to, journal
      advertising, direct mail programs, direct-to-consumer advertising,
      convention exhibits and other forms of advertising and promotion.

1.54  "Registration Plan" means the annual plan with respect to the US Territory
      created by the DC for those pre-clinical and clinical studies to be
      conducted as part of the Registration Program.

                                       11
<PAGE>
1.55  "Registration Program" means the development program with respect to the
      US Territory conducted by Neurocrine as set forth on Schedule 5.3(a), as
      may be amended by the DC in accordance with Section 5.2.

1.56  "ROW Territory" means all countries in the world outside the US Territory.

1.57  "Sales Representative" means an individual who engages in Detailing and
      other promotional efforts in the field with respect to the Products and
      who has been trained and is employed by either party, and in the case of
      Neurocrine, includes a member of the Neurocrine Field Force.

1.58  "Sleep Specialist" means a sleep medicine specialist who is a certified
      diplomate of the American Board of Sleep Medicine.

1.59  "Specifications" means the specifications for the manufacture and
      packaging of the Products.

1.60  "Supplemental Plan" means the annual plan with respect to the US Territory
      created by the DC and the MC for those preclinical and clinical studies to
      be conducted as part of the Supplemental Program.

1.61  "Supplemental Program" means the development program with respect to the
      US Territory conducted by Pfizer described in Section 5.3(b), as may be
      amended by the DC and the MC from time to time.

1.62  "Territory" means the US Territory and the ROW Territory.

1.63  "Trademarks" means any trademark associated with the Products in the
      Territory, which may be selected by the MC in the US Territory and by
      Pfizer in the ROW Territory.

1.64  "US Territory" means the United States of America, including its
      territories, possessions and Puerto Rico.

1.65  "Year" means each calendar year during the term of this Agreement.

                                       12
<PAGE>
1.66  "Zoloft" means the compound generically known as sertraline and which is
      promoted or sold under the trademark Zoloft(R) as a single entity.

1.67  "Zoloft Net Sales" means (1)(a) gross sales of Pfizer, its Affiliates and
      sublicensees of Zoloft to unaffiliated third parties in the US Territory
      less, (b) returns and allowances, including, without limitation, trade,
      quantity and cash discounts and any other adjustments, including, but not
      limited to, those granted on account of price adjustments, billing errors,
      rejected goods, damaged or defective goods, recalls, returns, rebates,
      chargeback rebates, fees, reimbursements or similar payments granted or
      given to wholesalers or other distributors, buying groups, health care
      insurance carriers or other institutions, adjustments arising from
      consumer discount programs, customs or excise duties, sales tax,
      consumption tax, and other taxes (except income taxes) or duties relating
      to sales, and any payment in respect of sales to any governmental or
      regulatory authority in respect of any government-subsidized program,
      multiplied by (2) [***].

1.68  "Zoloft Patent Expiration Date" means June 30, 2006, or such later date
      that U.S. Patent No. 4,536,518 may expire.

1.69  "Zoloft Trademark" means the trademark Zoloft(R) and/or any other
      trademark associated with Zoloft in the US Territory owned or otherwise
      held by Pfizer or one of its Affiliates.

Whenever in this Agreement the term "includes" or "including" is used, unless
expressly limited such terms shall be without limitation to the enumerated or
listed items.

                                    ARTICLE 2

                          GRANT OF CO-PROMOTION RIGHTS

2.1   Grant of Rights. Subject to the terms of this Agreement, Pfizer grants to
      Neurocrine:

      (a)   the exclusive right to Promote and Detail (but not to sell) the
            Product together with Pfizer in the US Territory to psychiatrists
            and Sleep Specialists, as well as to such other specialists as the
            parties may mutually agree; and

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       13
<PAGE>
      (b)   the non-exclusive right to Promote and Detail (but not to sell)
            Zoloft to psychiatrists in the US Territory, such right commencing
            on the date (in no event earlier than the filing with FDA of the NDA
            for the MR Product pursuant to Section 4.3) on which members of the
            Neurocrine Field Force (as defined below) successfully complete
            initial training in accordance with Schedule 2.5 attached hereto
            until the Zoloft Patent Expiration Date.

2.2   Compliance With Law and Codes.

      (a)   General. Both Pfizer and Neurocrine will Promote and Detail the
            Products and Zoloft in the US Territory in accordance with
            applicable Law, the terms of this Agreement and, with respect to the
            Product, the then-current Marketing Plan (except upon an event
            described in Section 3.5(c)). Neither party shall be required to
            undertake any action or inaction (including without limitation any
            Launch of any Product), or to incur expenditures in connection with
            any such action or inaction under this Agreement that it believes,
            in good faith, may violate any Law.

      (b)   Medical Education. Pfizer will in all material respects conform the
            practices and procedures for educating the medical community in the
            United States by Pfizer or Neurocrine representatives pursuant to
            the Marketing Plan to the Accreditation Council for Continuing
            Medical Education Standards for Commercial Support of Continuing
            Medical Education and any applicable FDA regulations, as the same
            may be amended from time to time (except with respect to grants for
            independent educational events which are not accredited, but for
            which the grantee certifies in writing to Pfizer or Neurocrine as to
            such grantee's independence).

2.3   Detailing Obligations. The Neurocrine Field Force shall Detail Products
      commencing on Launch of the first Product up to and including the end of
      the fifth full year (365 day period) from Launch of the first MR Product
      (such period, the "Initial Five Year Period"), in either the First
      Position or Second Position. After the Initial Five Year Period, [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       14
<PAGE>
2.4   Other Pfizer Products. Upon the Zoloft Patent Expiration Date, Pfizer and
      Neurocrine may discuss from time to time additional Pfizer products for
      the Neurocrine Field Force to co-promote and detail within the US
      Territory, provided that neither party shall be required to undertake any
      obligations with respect to such products unless mutually agreed.

2.5   Training.

      (a)   Pfizer shall, at its sole expense, provide initial sales and product
            training for Zoloft, and "launch track" training for the Product,
            for the initial two hundred (200) members of Neurocrine Sales Force
            as set forth in Schedule 2.5 and in accordance with Pfizer's
            existing training programs at such time. Pfizer shall not be
            obligated to provide any training for any additional Neurocrine
            personnel other than Neurocrine Field Force trainers. Pfizer shall
            provide ongoing training relating to the Product and Zoloft for
            trainers who at such time train the Neurocrine Field Force. Pfizer's
            training of the Neurocrine Sales Force will be conducted in
            accordance with applicable Law. The Neurocrine Sales Force will
            attend, at Neurocrine's expense, the United States national Product
            Launch meeting and periodic Product sales meetings along with the
            Pfizer sales force and Launch meetings in the ROW Territory. Except
            as provided above, the implementation of all ongoing training
            programs for the Neurocrine Sales Force will be the responsibility
            of Neurocrine, at its sole expense.

      (b)   Pfizer shall provide to Neurocrine mutually agreed upon quantities
            of training materials appropriate and adequate to train the
            Neurocrine Field Force for the Co-Promotion of the Products and
            Zoloft and consistent with the quantities of such materials used by
            Pfizer for the Pfizer Field Force. Pfizer shall at substantially

                                       15
<PAGE>
            the same time it begins use of such materials, provide to Neurocrine
            such agreed upon quantities of all Pfizer training materials,
            without charge to Neurocrine, relating to Products or Zoloft that
            are used by the Pfizer Field Force.

      (c)   Neurocrine shall at its own expense, comply with any training plan
            contained in the applicable Marketing Plan for post "launch track"
            Neurocrine Field Force training and any Zoloft training plan
            applicable to the Pfizer sales force Detailing Zoloft.

2.6   Promotional Materials. The Neurocrine Field Force and Pfizer Field Force
      will only utilize promotional, advertising, communication and educational
      materials (including all written, graphic, electronic, audio and video
      pieces and including journal advertisements, direct mail, direct to
      consumer advertising, internet postings, broadcast advertisements and
      sales aids (pens, cups, note pads and the like)) relating to the Products
      (collectively "Promotional Materials") and only conduct promotional
      activities for the Products which, in each case, have been approved in the
      Marketing Plan or otherwise by the MC (except following an event described
      in Section 3.5(c)). All Promotional Materials will be subject to
      regulatory review and approval by the MC (except following an event
      described in Section 3.5(c)). At substantially the same time any Product
      Promotional Materials and any Product related communication is sent in
      hard copy, electronically or by voicemail by Pfizer to the Pfizer Field
      Force, Pfizer will provide to Neurocrine with copies of all such materials
      (or notify Neurocrine as to such other communication, as applicable) for
      the Neurocrine Sales Force (which shall be equivalent to quantities of
      such materials provided to the Pfizer Field Force). Promotional Materials
      shall be allotted to Neurocrine according to Neurocrine's Detail
      Requirement for the applicable year. All promotional activities conducted
      by the Neurocrine Field Force and Pfizer Field Force shall be consistent
      with the Promotional Materials so approved and the then-current Marketing
      Plan. Pfizer shall own all rights to all Promotional Materials, including
      all copyrights thereto. Unless and until Promotional Materials are
      approved by the MC for publication or other general dissemination, each
      party shall maintain them in confidence pursuant to the terms of Article
      11. All Promotional Materials will bear the

                                       16
<PAGE>
      corporate names and logos/trademarks of Neurocrine and Pfizer in
      substantially equal prominence and frequency.

2.7   Samples. Following Launch of the first Product and in support of
      Neurocrine's Detailing and Promotional activities hereunder, Pfizer shall
      provide Neurocrine with Product samples as required in the applicable
      Marketing Plan, and Zoloft samples consistent with the allocation to the
      Pfizer Field Force. Samples will be allocated fairly between the
      Neurocrine Field Force and Pfizer sales force in accordance with the
      number of Details the respective field forces are required to undertake as
      set forth in the Marketing Plan. Pfizer shall ship such samples to a
      central location designated by Neurocrine. Neurocrine and Pfizer shall use
      samples strictly in accordance with the then-current Marketing Plan and
      shall store and distribute samples in full compliance, and otherwise fully
      comply, with all applicable Laws, including the requirements of the
      Prescription Drug Marketing Act of 1987, as amended (the "PDMA"). Pfizer
      and Neurocrine each will maintain those records required by the PDMA and
      all other Laws with respect to the samples allocated to each of them.
      Neurocrine and Pfizer shall be responsible for the filing of any necessary
      reports to FDA in connection with the PDMA with respect to the samples
      allocated to each of them. All costs and expenses associated with the
      manufacture, shipment and distribution (to Neurocrine's central location),
      warehousing and storage (until shipment to Neurocrine's central location),
      of Products samples shall be borne by Pfizer. Each party will destroy any
      samples not distributed by its Sales Representatives at its sole expense.

2.8   Responsibility for Medical and Marketing Expenses and Development Costs.
      Pfizer shall be responsible for all Medical and Marketing Expenses for the
      Products.

2.9   [Intentionally left blank].

2.10  Medical Inquiries. The MC and RC will provide the parties with information
      and materials relevant or appropriate to allow the parties' medical and
      sales professionals, as appropriate, to respond to those medical questions
      or inquiries from the medical and paramedical professions and consumers
      relating to any FDA approved use of the

                                       17
<PAGE>
      Products. Each of the parties will only use these materials, which shall
      be consistent with the relevant FDA-approved Product labeling, when
      answering such questions and inquiries so as to ensure that medical and
      sales professionals from both parties are responding to such questions or
      inquiries in the same manner. The MC and RC will provide the parties with
      information, materials and instructions to allow medical professionals
      from both parties to respond to medical questions or inquiries concerning
      matters not consistent with FDA approved Product labelling in accordance
      with applicable Pfizer procedures for responding to unsolicited medical
      inquiry requests on off-label use.

2.11  Meetings and Symposia and Marketing Activities. Neurocrine will have a
      role in implementing the marketing activities as set forth in the
      Marketing Plan. It is generally agreed that Product presentations,
      exhibits and booths at meetings and symposia will be a joint Pfizer and
      Neurocrine activity under the Marketing Plan and the cost thereof will be
      Medical and Marketing Expenses. To the extent not included within the
      Marketing Plan, Neurocrine at its sole expense shall have the right to
      make Product presentations and have its own exhibits and booths that
      feature the Products; provided that any such presentations, exhibits and
      booths are consistent with the Marketing Plan.

2.12  Commercially Reasonable Efforts. The parties covenant and agree to use, in
      the case of Pfizer, Commercially Reasonable Efforts, and in the case of
      Neurocrine, its commercially reasonable efforts, with respect to carrying
      out each of their respective decisions under Articles 2, 3, 4 (except as
      otherwise specified in Section 4.3(b)), 5, 6A and 6B, and their respective
      obligations under this Agreement.

                                    ARTICLE 3

                             MANAGEMENT OF ALLIANCE

3.1   Committees. In order to fulfill the objectives of this Agreement, the
      parties agree to establish a Steering Committee, a Joint Operating
      Committee ("JOC"), a Marketing Committee described in Article 6A ("MC"), a
      Development Committee described in Article 5 ("DC"), a Regulatory
      Committee described in Article 4 ("RC"), and a Product

                                       18
<PAGE>
      Supply Committee described in Article 6B ("PSC"), (collectively, the
      "Committees") and such other committees and subcommittees as may be
      established by mutual consent of Neurocrine and Pfizer. The members of
      each Committee and subcommittee, as designated by each party, shall be
      functionally aligned with each other, and each Committee shall have two
      co-chairpersons, one designated by each of Neurocrine and Pfizer.

3.2   Meetings. The co-chairpersons of the Steering Committee, the JOC, the MC,
      the DC, the RC, the PSC, or any other committee or subcommittee, shall
      call meetings quarterly (except the Steering Committee which shall meet at
      least three times annually), or as otherwise mutually agreed. Meetings may
      be held in person, by telephone, or by video conference call, and the
      location of each meeting shall alternate between sites selected by each
      co-chairperson, unless otherwise agreed. The decisions of each committee
      or subcommittee shall be by a vote of the co-chairpersons, each
      co-chairperson having one vote, and all decisions shall be by unanimous
      consent of the co-chairpersons, except as provided in Section 3.12.
      Additional participants may be invited by any representative to attend
      meetings when and where appropriate. The parties shall cause their
      respective representatives on the committees and subcommittees to use
      diligent efforts, acting in good faith, to resolve all matters presented
      to them as expeditiously as possible. In addition to the foregoing, either
      party may call a special meeting of the Steering Committee two (2) times
      per year, on fifteen (15) days notice to the other party. Meetings will
      alternate between the offices of the parties, unless otherwise agreed.
      Each party shall be responsible for expenses incurred by its employees and
      its members of the Steering Committee incurred in attending or otherwise
      participating in Steering Committee meetings.

3.3   Development Committee.

      (a)   The DC shall consist of research and development, new product
            development, regulatory and marketing/medical managers and such
            other relevant personnel involved in development of products (as
            needed) from each of Neurocrine and Pfizer, each of which shall
            confirm to the other its designees and which shall be

                                       19
<PAGE>
            responsible for oversight of the Development Program in the US
            Territory. The specific responsibilities of the DC are set forth in
            Section 5.2.

      (b)   Upon a material breach or material default of Neurocrine, the DC
            shall be disbanded and Pfizer shall have sole decision making
            authority and responsibility with respect to development of the
            Products, subject to Section 3.12.

      (c)   If the DC is unable to reach a decision on any issue within ten (10)
            Business Days after presentation, the issue shall be referred for
            resolution to the JOC.

3.4   Regulatory Committee.

      (a)   The RC shall consist of regulatory, research and development, safety
            and marketing medical managers and such other relevant personnel (as
            needed) from each of Neurocrine and Pfizer, each of which shall
            confirm to the other its designees and which shall be responsible
            for the regulatory compliance of the Development Program in the US
            Territory. The specific responsibilities of the RC are set forth in
            Section 4.2.

      (b)   If the RC is unable to reach a decision on any issue within ten (10)
            Business Days after presentation, the issue shall be referred for
            resolution to the JOC.

      (c)   Upon a material breach or material default of Neurocrine, the RC
            shall be disbanded and Pfizer shall have sole decision making
            authority and responsibility with respect to regulatory matters
            related the Products, subject to Section 3.12.

3.5   Marketing Committee.

      (a)   The MC shall consist of regulatory, and sales and marketing medical
            managers and such other relevant personnel (as needed) from each of
            Neurocrine and Pfizer, each of which shall confirm to the other its
            designees and which shall be

                                       20
<PAGE>
            responsible for marketing activities with respect to the Product in
            the US Territory. The specific responsibilities of the MC are set
            forth in Section 6A.3(b).

      (b)   Upon a material breach or material default of Neurocrine, the MC
            shall be disbanded and Pfizer shall have sole decision making
            authority and responsibility with respect to marketing the Products,
            subject to Section 3.12.

      (c)   Upon a reduction of Neurocrine's Co-Promotion activities pursuant to
            Section 6A.6(b), the MC shall be disbanded and Pfizer, subject to
            Steering Committee oversight with respect to marketing activities as
            would otherwise be provided in Section 3.12(b), shall have sole
            decision making authority and responsibility with respect to
            marketing the Product.

      (d)   If the MC is unable to reach a decision on any issue within ten (10)
            Business Days after presentation, the issue shall be referred for
            resolution to the JOC.

3.6   Product Supply Committee.

      (a)   The PSC shall consist of regulatory, clinical development, QA/QC,
            and pharmaceutical development and such other relevant personnel (as
            needed) from each of Neurocrine and Pfizer, each of which shall
            confirm to the other its designees and which shall be responsible
            for Product manufacturing and supply matters. The specific
            responsibilities of the PSC are set forth in Section 6B.1.

      (b)   Upon a material breach or material default of Neurocrine, the PSC
            shall be disbanded and Pfizer shall have sole decision making
            authority and responsibility with respect to marketing the Products,
            subject to Section 3.12.

      (c)   Upon Launch of both the IR Product and the MR Product, the PSC will
            be disbanded and Pfizer, subject to Steering Committee oversight
            with respect to marketing activities as would otherwise be provided
            in Section 3.12(b), will have sole decision making authority and
            responsibility for decisions related to manufacturing.

                                       21
<PAGE>
      (d)   If the PSC is unable to reach a decision on any issue within ten
            (10) Business Days after presentation, the issue shall be referred
            for resolution to the JOC.

3.7   Joint Operating Committee.

      (a)   The JOC will consist of the co-chairpersons of the each of the DC,
            the RC, the MC, and the PSC. The JOC shall be responsible for the
            following:

            (i)   Oversight of the development and commercialization of Products
                  hereunder in the US Territory;

            (ii)  Review and approval of the annual Registration Plans,
                  Supplemental Plans, Manufacturing Plans, Regulatory Plans and
                  Marketing Plans, and a review of quarterly updates from each
                  of the Committees;

            (iii) Review and discussion of the Critical Package (as defined in
                  Section 4.3(b)) and making all Go Decisions with respect to an
                  NDA Filing;

            (iv)  Resolution of disputes that cannot be resolved by the DC, the
                  RC, the MC and the PSC; and

            (v)   Raising disputes that cannot be resolved by the JOC to the
                  Steering Committee.

      (b)   Prior to each meeting of the JOC, the parties will distribute to
            each other written copies of all materials intended to be submitted
            at the JOC meeting plus, to the extent not set forth in the JOC
            materials, a written report from the Committees summarizing any
            other material data and information arising out of the development
            and marketing of Products. In the event that after receipt of any
            such report, either party shall request additional data or
            information, the party to whom such request is made shall promptly
            provide to the other party such data or information.

                                       22
<PAGE>
      (c)   Either party may call a special meeting of the JOC two (2) times per
            year, on fifteen (15) Business Days notice to the other party.
            Meetings will alternate between the offices of the parties, unless
            otherwise agreed. Each party shall be responsible for expenses
            incurred by its employees and its members of the JOC incurred in
            attending or otherwise participating in JOC meetings.

      (d)   Upon a material breach or material default of Neurocrine, the JOC
            shall be disbanded and Pfizer shall have sole decision making
            authority and responsibility with respect to manufacturing
            activities of the Products, subject to Section 3.12.

      (e)   If the JOC is unable to reach a decision on any issue within ten
            (10) Business Days after presentation, the issue shall be referred
            for resolution to the Steering Committee.

3.8   Steering Committee. The Steering Committee shall consist of an equal
      number of representatives from both Neurocrine and Pfizer with
      decision-making authority within their respective organizations.
      Neurocrine and Pfizer shall confirm to the other its designees. The
      Steering Committee shall address all of the significant and strategic
      issues within the purview of the various Committees, and shall be
      responsible for resolving any issues referred by the JOC. The Steering
      Committee will be presented with updates on the activities and
      achievements of the Committees and otherwise as provided below. Except as
      otherwise provided in Section 3.12, all decisions of the Steering
      Committee will be by unanimous vote of the co-chairpersons. Prior to each
      meeting of the Steering Committee, the parties will distribute to each
      other written copies of all materials intended to be submitted at the
      Steering Committee meeting plus, to the extent not set forth in the
      Steering Committee materials, a written report from the JOC summarizing
      any other material data and information arising out of the development and
      marketing of Products. In the event that after receipt of any such report,
      either party shall request additional data or information, the party to
      whom such request is made shall promptly provide to the other party such
      data or information. If the Steering Committee

                                       23
<PAGE>
      is unable to resolve any issue within thirty (30) days after presentation,
      the issue shall be referred for resolution pursuant to Section 3.9.

3.9   Final Decision Making Authority. If for any reason the Steering Committee
      cannot resolve any matter properly referred to it, the matter shall be
      referred to a senior pharmaceutical executive of Neurocrine and a senior
      pharmaceutical executive of Pfizer for resolution. Neither of such senior
      pharmaceutical executives shall at the time of determination be a member
      of any Committee or subcommittee, and at such time shall be senior to
      Committee or subcommittee members appointed by such party. If such senior
      pharmaceutical executives after discussing the matter in good faith and
      attempting to find a mutually satisfactory resolution to the issue, fail
      to come to consensus, the final decision-making authority shall be
      allocated as follows:

      (a)   The senior pharmaceutical executive of Neurocrine will have the
            final decision-making authority for decisions regarding:

            (i)   [***];

            (ii)  [***];

            (iii) [***]

            (iv)  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       24
<PAGE>
      provided, however, that Neurocrine's final decision-making authority with
      respect to the above-mentioned items shall terminate, and Pfizer shall
      thereafter assume final decision-making authority, with respect to each of
      the IR Product and the MR Product on the earlier of [***].

      (b)   The following matters will be matters with respect to which
            consensus decision making by the parties will be required
            ("Consensus Matters"). Consensus Matters must be by unanimous
            decision of the parties and neither party will have final decision
            making authority with respect to these matters. The following
            matters are Consensus Matters:

            (i)   [***];

            (ii)  [***]

            (iii) [***];

            (iv)  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       25
<PAGE>
      (c)   The senior pharmaceutical representative of Pfizer shall have the
            final decision-making authority with respect to the following:

            (i)   [***];

            (ii)  [***];

            (iii) [***];

            (iv)  [***]

            (v)   [***].

      (d)   If a committee or subcommittee has made a decision with respect to a
            matter without referral to the senior pharmaceutical executives as
            provided in this Section 3.9, a party cannot be deemed to have
            breached Section 2.12 of this Agreement with respect to such
            decision.

3.10  Decision-Making Authority. Notwithstanding anything to the contrary, none
      of the Committees or subcommittees contemplated by this Article 3, no
      senior executive of Neurocrine nor any senior pharmaceutical executive of
      Pfizer shall have authority to determine any of the matters for which (a)
      one or more of the parties is allocated decision-making authority
      elsewhere in this Agreement, (b) the Agreement provides is explicitly a
      Consensus Matter or for the mutual or joint agreement of the parties or
      (c) is in violation of any express provision of this Agreement or the
      License Agreement.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       26
<PAGE>
3.11  Alliance Managers. In addition to the Committees set forth above,
      Neurocrine and Pfizer each acknowledge and agree that it would be
      beneficial to the Collaboration for each to have a senior representative
      with a general understanding of the clinical, regulatory, manufacturing
      and commercial issues relating to Products to act as an alliance manager
      ("Alliance Manager"), and will appoint such a person to the extent each
      party in its sole discretion determines it is practical. It is envisioned
      that the Alliance Managers will serve as a single point of contact within
      each party with responsibility for facilitating communication and
      collaboration between the parties. The Alliance Managers may attend
      Committee meetings as appropriate and will be provided access to decision
      making representatives of both parties. Once appointed, each
      co-chairperson of each Committee will report any Committee issues,
      potential or pending disagreements and critical Committee decisions to its
      Alliance Manager. The Alliance Managers will work together to resolve such
      issues or potential disputes, and to enable the Committees to reach
      unanimous decisions with the intent of averting the escalation of such
      issues or potential disputes.

3.12  Committee Structure upon Neurocrine Material Default or Material Breach.
      Upon a material default or material breach of Neurocrine following the
      election of Pfizer under Section 13.3(c)(i) or (ii):

      (a)   Each of the MC (if not previously disbanded in accordance with
            Section 3.5), the PSC (if not previously disbanded in accordance
            with Section 3.6), the DC, the RC and the JOC will be disbanded, and
            each provision in this Agreement that refers to a decision,
            oversight or consultation with of any of the foregoing Committees,
            or requiring compliance or consistency with a Development Plan,
            Regulatory Plan, a Marketing Plan or a Manufacturing Plan, shall be
            deemed inoperative;

      (b)   The Steering Committee will remain in place. Pfizer will report to
            the Steering Committee prior to each scheduled meeting on the items
            set forth in Schedule 3.12 and the Steering Committee will make any
            decisions with respect to such matters reported requiring any
            decisions; provided, however, that if the co-

                                       27
<PAGE>
            chairpersons of the Steering Committee are unable to reach a
            decision on any issue within ten (10) Business Days after
            presentation, the Pfizer co-chairperson shall make the final
            decision;

      (c)   Pfizer shall make all decisions regarding the matters in Section
            3.9(a) and (b);

      (d)   Article 4, Article 5 and Article 6B shall be deemed amended such
            that Pfizer shall have sole responsibility and authority with
            respect to the matters described herein as being the responsibility
            of and/or under the authority of Neurocrine; and

      (e)   All other obligations of Pfizer under this Agreement, except as
            otherwise provided herein, shall survive until termination of this
            Agreement.

                                    ARTICLE 4

                         CLINICAL AND REGULATORY MATTERS

4.1   Clinical and Regulatory Matters in the U.S. Territory Prior to First
      Approval of Products. This Section 4.1 shall apply to clinical and
      regulatory matters prior to termination of Neurocrine's final
      decision-making authority pursuant to Section 3.9(a); and Neurocrine's
      activities hereunder will be under the guidance of the RC, whose
      activities are further described in Section 4.2 (and the JOC with respect
      to the matters in Section 4.3).

      (a)   Subject to the provisions of this Article 4, Neurocrine will retain
            all responsibilities as the sponsor of the Product IND until
            Approval, including, but not limited to, correspondence, reports and
            filings with FDA, responsibility for all clinical trials and data
            generated therefrom. Neurocrine will maintain the integrated
            database of all Product clinical trial data. All regulatory filings
            within the US Territory relating to the Products prior to First
            Approval of the IR Product and the MR Product shall be the property
            of Neurocrine and held in Neurocrine's or its Affiliate's name.

                                       28
<PAGE>
      (b)   Neurocrine will establish the timeline for and will prepare and file
            the NDA for IR Product and MR Product with the FDA (subject to
            Section 4.3).

      (c)   Notwithstanding anything in this Agreement to the contrary, in the
            event there is an Advisory Committee meeting with respect to the
            Product NDA, all preparations, strategies and actions with respect
            thereto will be a Consensus Matter.

      (d)   Notwithstanding anything in this Agreement to the contrary, all
            negotiations with FDA regarding Product labelling, including all
            pre-filing meetings and other meetings, teleconferences or other
            interactions with FDA concerning Product labelling, and all
            decisions regarding the proposed and final labelling included in the
            NDA filings will be a Consensus Matter.

      (e)   Notwithstanding anything in this Agreement to the contrary, the
            organization and strategies for responses to FDA inquiries with
            respect to the Registration Program and first NDA filing for IR
            Product and MR Product will be a Consensus Matter.

      (f)   Following NDA approval by the FDA, Pfizer will be responsible for
            communicating with the FDA regarding all NDA post-Approval
            requirements, activities and issues.

      (g)   Pfizer will be the sponsor of all filings with Governmental
            Authorities outside the US Territory; and within the US Territory
            with respect to the IR Product and the MR Product after First
            Approval of the IR Product and MR Product, respectively, and/or
            after Neurocrine's decision making shall have terminated in
            accordance with Section 3.9(a).

4.2   Regulatory Committee. The RC will operate within the framework of the
      governance structure set forth in Article 3. The responsibilities of the
      RC include, but are not limited to, the following:

                                       29
<PAGE>
      (a)   Overseeing the implementation of the plan for the registration and
            regulatory strategy (the "Regulatory Plan") for first NDA filing for
            IR Product and MR Product- in the US Territory as set forth on
            Schedule 4.2(a);

      (b)   Overseeing, monitoring and coordinating all regulatory (FDA) aspects
            of the (i) Registration Program and (ii) the Supplemental Program,
            including with respect to each, all regulatory actions,
            communications and filings (including matters pertaining to Product
            labelling) and submissions, including filings and submissions of
            supplements and amendments to FDA with respect to the Products;

      (c)   Facilitating the exchange of all US regulatory information and data
            between the parties;

      (d)   Establishing the schedule and implementation strategy for all FDA
            filings based on the Registration Program;

      (e)   Establishing the schedule and implementation strategy for all FDA
            filings based on the Supplemental Program;

      (f)   Providing updates on its activities and achievements to the JOC.

4.3   NDA Filing Decision.

      (a)   Neurocrine will make available to the JOC, and the JOC will track
            the completion of, each Registration Program clinical trial and will
            review all safety and efficacy data therefrom promptly following
            such data becoming available. The JOC will make all data available
            to representatives of Pfizer and Neurocrine senior management.
            Within thirty (30) days following such data availability from each
            Registration Program clinical trial, Pfizer and Neurocrine through
            their representatives on the JOC, will each report to the other any
            issues arising from the study that may require additional work. If
            any additional work is required as a result of such data, the JOC as
            a Consensus Matter will identify mutually agreed

                                       30
<PAGE>
            upon changes to the Registration Program to support the NDA filing,
            and such changes will be implemented by Neurocrine at Pfizer's cost.

      (b)   [***].

      (c)   Neurocrine shall not file an NDA with respect to any Product unless
            the parties have made a Go Decision in 4.3(b) above. Following any
            Go Decision, Neurocrine will have responsibility for preparing the
            complete and final NDA filing for the IR Product and/or MR Product
            as set forth in this Section 4.3(c) (the "NDA Package"). [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       31
<PAGE>
      (d)   [***].

      (e)   Subject to Section 4.3(d), Pfizer shall have the obligation to
            Launch such Product within ninety (90) days of such Approval;
            provided, however, that Pfizer's obligation to Launch within such
            time period will be delayed to the extent its failure to Launch is
            related to [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       32
<PAGE>
      (f)   In the event either party shall make a No Go Recommendation, the
            party making such recommendation will outline with specificity the
            basis for such recommendation and what data such party in good faith
            believes will be required to be added to the Registration Program to
            support an acceptable NDA filing. The Parties will mutually agree as
            a Consensus Matter on a clinical plan describing the supportive
            clinical program ("the Supportive Clinical Program") that will be
            required to support a Go Decision by the parties, Neurocrine will
            conduct and Pfizer will bear the costs of the Supportive Clinical
            Program under the same terms and conditions agreed for conduct of
            the Registration Program, and the Supportive Clinical Program will
            be deemed to be part of the Registration Program as set forth
            herein. Following completion of the Supportive Clinical Program, the
            procedure set forth in Section 4.3(b) above shall be repeated,
            unless Pfizer elects to terminate this Agreement in accordance with
            Section 13.3(a).

4.4   Additional FDA Requirements and Responses to FDA Inquiries Prior to First
      Approval. Prior to First Approval, as soon as practicable but in any event
      within four (4) Business Days of receipt by Neurocrine, Neurocrine will
      provide notice to Pfizer of any additional FDA requirements which FDA may
      impose with respect to the First Approval (including without limitation,
      additional clinical studies), and of all FDA inquiries requiring a
      response. This includes written, oral, electronic or any other requests
      received from FDA. Pfizer and Neurocrine shall mutually agree as a
      Consensus Matter upon any response to FDA. Promptly after receipt of any
      inquiry or the knowledge of a requirement, as the case may be, Neurocrine
      will provide Pfizer with copies of all

                                       33
<PAGE>
      correspondence from FDA. If such correspondence is an inquiry, the RC will
      discuss the FDA inquiry and outline the strategy for response. Neurocrine
      will draft the response to all inquiries promptly (the amount of time to
      generate the response will depend on the nature of the inquiry) and
      provide a draft to Pfizer. Pfizer will have ten (10) days in which to
      review and comment on the Neurocrine draft response. Neurocrine will
      review the Pfizer comments. If Neurocrine agrees with the Pfizer comments,
      Neurocrine will incorporate the comments and submit the response to the
      FDA. Neurocrine will contact the RC within three (3) days in the event
      Neurocrine disagrees with any Pfizer comment. If the members of the RC
      cannot agree on the matter it will be submitted to the JOC as a Consensus
      Matter. Immediately after filing any response with the FDA, and after
      producing contact reports with FDA, Neurocrine will provide copies of the
      same to Pfizer.

4.5   Labelling. Product labelling will bear Neurocrine's and Pfizer's trade
      dress and logo in substantially equal prominence and frequency, except as
      required by law. The parties will mutually agree upon any subsequent
      decisions prior to the First Approval with respect to the Product
      labelling for the first IR Product and the first MR Product as a Consensus
      Matter. Upon First Approval of each of the IR Product and MR Product,
      respectively, Pfizer shall have the sole responsibility for revising
      Product labelling for the approved Products, as needed, in consultation
      with the RC, as required by Law and shall notify Neurocrine in writing of
      the approval of any such labelling changes by FDA or any other
      Governmental Authority.

4.6   FDA Meetings. Neurocrine shall provide Pfizer with notice of all meetings,
      conferences, and discussions (including without limitation, Advisory
      Committee meetings or any other meeting of experts convened by regulatory
      authorities concerning any topic relevant to the Products) scheduled with
      FDA concerning any pending NDA or other regulatory matters relating to the
      Products within forty-eight (48) hours after the scheduling of such
      meeting, conference, or discussion. Pfizer shall be entitled to have an
      equal number of representatives present at all such meetings. Neurocrine
      and Pfizer, through the RC, shall use all reasonable efforts to agree in
      advance on the scheduling of such meetings and on

                                       34
<PAGE>
      the objectives to be accomplished at such meetings, conferences, and
      discussions and the agenda for the meetings, conferences, and discussions
      with FDA and other Governmental Authorities, and with respect to Advisory
      Committee Meetings, such items will agreed by the parties as a Consensus
      Matter as set forth in Section 4.1(c).

4.7   Data. To the extent not provided in Section 4.3 above, each party shall
      provide to the other party, through the RC, on a timely basis copies of
      all material pre-clinical and clinical data compiled in support of an NDA
      or other regulatory filings with respect to the Products.

4.8   Assignment of NDA. Subject to Section 3.4 and this Article 4, Neurocrine
      will submit an NDA to FDA for the first IR Product and the first MR
      Product under its name. Upon the First Approval for each of the IR Product
      and the MR Product, Neurocrine will promptly transfer the NDA and IND for
      such Product to Pfizer in accordance with all applicable FDA regulations,
      and thereafter, Pfizer will have full ownership, control of and
      responsibility for such NDA, the IND and for all subsequent FDA and other
      regulatory filings in the US Territory. Such transfer of ownership shall
      be commenced promptly following receipt of the respective Approval. Each
      of the parties shall take all reasonable steps to ensure an orderly
      transfer of each NDA following Approval.

4.9   ROW Regulatory Matters. After the Effective Date, Pfizer will assume sole
      ownership, control of and responsibility for all regulatory filings in the
      ROW Territory.

4.10  Clinical and Regulatory Matters after First Approval of Products.
      Following the First Approval of each of the IR Product and the MR Product:

      (a)   Subject to the oversight of the RC, Pfizer shall have exclusive
            responsibility and final authority for all matters relating to the
            nature and content of any NDA or supplemental NDAs submitted to the
            FDA for such Product.

                                       35
<PAGE>
      (b)   The IND, NDA and any other regulatory approval within the US
            Territory relating to Products shall be deemed the property of
            Pfizer and held in Pfizer's or its Affiliate's name.

      (c)   Pfizer shall have the sole responsibility for communicating with FDA
            about the Products, subject to the oversight of the RC.

      (d)   Pfizer, through the RC, will have final authority with regard to
            labelling discussions with FDA with respect to Products; and

      (e)   Pfizer, through the RC, shall provide Neurocrine with copies of all
            filings and submissions to and correspondence with Governmental
            Authorities relating to Products within ten (10) days of receipt,
            filing or submission by Pfizer.

4.11  Adverse Drug Experience Reports and Product Complaints Prior to First
      Approval.

      (a)   Neurocrine, as IND holder, shall be responsible for the
            surveillance, receipt, evaluation and reporting of product
            complaints and reports of Adverse Drug Experiences (as defined in 21
            CFR 314.80 or 312.23) until the First Approval for IR Product and MR
            Product. During such period preceding such First Approval,
            Neurocrine shall promptly investigate product complaints and reports
            of Adverse Drug Experiences associated with use of the Product.
            Prior to the First Approval of IR Product and MR Product, Neurocrine
            shall submit reports of all Adverse Drug Experiences associated with
            the use of the unapproved Products and other required safety
            information to the FDA and other Governmental Authorities, in
            accordance with applicable Law. Neurocrine shall provide a copy of
            each such report to Pfizer contemporaneously with its submission of
            the report to FDA or other Governmental Authorities.

      (b)   Registration Program. Neurocrine will notify Pfizer of all Serious
            Adverse Drug Experiences (as defined in 21 CFR 314.80 or 312.32)
            occurring in any Product study conducted, sponsored or monitored by
            Neurocrine as part of the

                                       36
<PAGE>
            Registration Program within two (2) Business Days of the time such
            Serious Adverse Drug Experience becomes known to Neurocrine; and of
            all other Adverse Drug Experiences occurring in any Product study
            conducted, sponsored or monitored by Neurocrine within seven (7)
            days of the time such Adverse Drug Experience Report becomes known
            to the Neurocrine. All follow-up investigations concerning Adverse
            Drug Experiences and Serious Adverse Drug Experiences occurring in
            any Product study conducted, sponsored or monitored by Neurocrine as
            part of the Registration Program shall be conducted by Neurocrine
            and the results of such follow-up investigations will be delivered
            to Pfizer within two (2) Business Days of the time such follow-up
            information is obtained by Neurocrine.

      (c)   Supplemental Program. In the event Pfizer shall conduct, sponsor or
            monitor any Product clinical trials pursuant to the Supplemental
            Plan prior to assignment of the Product IND to Pfizer, Pfizer will
            notify Neurocrine, ACY and DOV, of all Serious Adverse Drug
            Experiences arising out of any such clinical trial within two (2)
            Business Days of the time such Serious Adverse Drug Experience
            becomes known to Pfizer; and of all Adverse Drug Experience arising
            out of any such clinical trial within five (5) days of the time such
            Adverse Drug Experience Report becomes known to Pfizer. Following
            assignment of the IND and NDA to Pfizer, Pfizer will notify
            Neurocrine, ACY and DOV of all Serious Adverse Drug Experiences
            within two (2) Business Days of the time such experiences becomes
            known to Pfizer, and of all other Adverse Drug Experience within
            five (5) days of the time such experiences becomes known to Pfizer.
            All follow-up investigations concerning Adverse Drug Experiences and
            Serious Adverse Drug Experiences occurring in any study conducted,
            sponsored or monitored by Pfizer shall be conducted by Pfizer and
            the results of such follow-up investigations will be delivered to
            Neurocrine within seven (7) days of the time such follow-up
            information is obtained by Pfizer.

                                       37
<PAGE>
4.12  Adverse Events and Product Complaints After First Approval.

      (a)   After First Approvals, Pfizer shall be responsible for the
            surveillance, receipt, evaluation, and reporting of product
            complaints and reports of Adverse Drug Experiences, worldwide,
            associated with the Products. To enable Pfizer to meet its reporting
            obligations to FDA, Neurocrine shall provide Pfizer, upon First FDA
            Approval, with all adverse event information in a mutually
            agreed-upon format.

      (b)   Upon and following the First Approval of each of the IR Product and
            MR Product, all Product complaints and reports of Adverse Drug
            Experiences associated with the use of the Products, shall be
            directed by Neurocrine, its Affiliates, employees, and agents, to
            Pfizer. Such complaints and reports shall be provided to Pfizer
            within two (2) Business Days of their receipt by Neurocrine, its
            affiliate, employee, or agent, provided that any complaints received
            by the Neurocrine Field Force will be reported in accordance with
            such procedures used by the Pfizer Field Force. Neurocrine shall
            also provide Pfizer with notice of other material safety information
            about one or both Products that Neurocrine may become aware of.

      (c)   Pfizer shall submit reports of all Adverse Drug Experiences
            associated with the use of the approved Product(s) and other
            required safety information (including periodic safety update
            reports (PSUR's) and Annual Safety Reports) to the FDA and other
            Governmental Authorities, in accordance with applicable legal
            requirements. Pfizer shall submit a copy of each such report to
            Neurocrine, contemporaneously with its submission of the report to
            FDA or other Governmental Authorities.

      (d)   For purposes of this Agreement, it is contemplated that following
            the First Approval for either the IR or MR Product, all Adverse Drug
            Experiences associated with the use of any Product will be filed by
            Pfizer as part of the NDA for the approved Product. Further, it is
            contemplated that Neurocrine's reports of Adverse Drug Experiences
            associated with the use of unapproved Product will

                                       38
<PAGE>
            reference the safety information filed by Pfizer as part of the NDA
            for the approved Product. Neurocrine shall submit a copy of each
            such report to Pfizer, contemporaneously with its submission of the
            report to FDA or other Governmental Authorities.

      (e)   The parties will develop additional written procedures for the
            surveillance, receipt, evaluation, and reporting of Product
            complaints and Adverse Drug Experiences, in accordance with these
            provisions and subject to the oversight of the RC.

4.13  Construction of Terms related to Separate Filings. The provisions of this
      Article may be alternatively construed to reflect the fact that the INDs
      and NDAs may be maintained or filed with respect to the IR Product and MR
      Product either separately or together, and that as of the date hereof, no
      such final decisions have been made. Accordingly, the parties agree that
      to the extent that the language set forth herein does not work as a
      practical and logistical matter with respect to the filing or maintenance
      of the INDs or NDAs (as the case may be), the parties will meet in good
      faith to discuss changes to allocations of responsibilities in order to
      effectuate the intent of the provisions set forth in this Article 4 or to
      otherwise comply with applicable Law.

                                    ARTICLE 5

                               PRODUCT DEVELOPMENT

5.1   Development Program and Budget. Products in the US Territory will be
      developed pursuant to Development Program. Pfizer shall pay all
      Development Costs, subject to Section 5.3(a) below. The Development
      Program will consist of a Registration Program conducted by Neurocrine as
      described in Section 5.3(a) below, and a Supplemental Program conducted by
      Pfizer as described in Section 5.3(b) below. Each of the parties
      respective obligations for the Registration Program and the Supplemental
      Program will be carried out under the guidance of the DC as described in
      Section 5.2 below.

                                       39
<PAGE>
5.2   Development Committee. The DC will operate within the framework of the
      governance structure set forth in Article 3. The responsibilities of the
      DC include, but are not limited to, the following:

      (a)   Developing the Supplemental Program in coordination with the MC;

      (b)   Preparing annual Registration Plans and Supplemental Plans, each of
            which shall include a budget, for submission to the JOC consistent
            with the terms of the Registration Program and Supplemental Program,
            for approval each Year from the Effective Date until the
            Co-Promotion Term for the Products ends;

      (c)   Overseeing and monitoring the conduct of the annual Supplemental
            Plan by Pfizer as specified in Section 5.3(b);

      (d)   Overseeing and monitoring the conduct of the annual Registration
            Plan, together with the JOC, by Neurocrine as specified in Section
            5.3(a);

      (e)   Facilitating the exchange of all development information and data
            relating to all Product Studies;

      (f)   Review and approval of protocols and selection of clinical study
            sites for all Registration Program Product Studies other than those
            listed in Schedule 5.3(a) and for all Supplemental Program Product
            Studies, and for revising any Investigator's Brochure(s) based on
            results of the Registration Program and Supplemental Program Product
            Studies or any additional FDA requirements;

      (g)   Implementation of Phase IIIb Product Studies; and

      (h)   Providing updates on its activities and achievements to the JOC.

Neither party shall make any material change to any annual Developmental Plan,
or any of the Developmental Program Product Studies, without the prior approval
of the DC, and all Development Plans and Development Costs provided therein
shall be consistent with the terms of this Agreement.

                                       40
<PAGE>
5.3   Development Programs for the US Territory. Product development activities
      in the US Territory will consist of the following Development Programs,
      each of which will be prepared and overseen by the DC, the RC and the MC,
      as set forth and consistent with the provisions set forth below:

      (a)   Registration Program. The Phase III development with respect to the
            US Territory for IR Product and MR Product each will be conducted
            under the Registration Program. [***]. The Registration Program will
            consist of the clinical and other activities for the NDA filings as
            are set forth on Schedule 5.3(a), and will be carried out pursuant
            to the annual Registration Plan. Neurocrine will have responsibility
            and authority for conducting and completing the Registration
            Program, subject to input of the DC, in coordination with the RC,
            the MC and the JOC. Pfizer shall pay all Development Costs for the
            Registration Program, except that Neurocrine shall be liable for
            payment of $15 million in 2003 payable quarterly in equal
            instalments of $3.75 Million each payable on the last day of March,
            June, September and December of 2003. [***]. The Registration
            Program will terminate with respect to each of the IR Product and MR
            Product upon First Approval of the IR Product and MR Product,
            respectively.

      (b)   Supplemental Program. Phase IIIb and IV development and Product
            Studies in the US Territory will be conducted under the Supplemental
            Program. [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       41
<PAGE>
            The Supplemental Program activities will be conducted by Pfizer
            under the direction of the MC, in coordination with the DC and RC.
            An initial summary of the Supplemental Program is attached hereto as
            Schedule 5.3(b), subject to change by the MC (in coordination with
            RC and the DC) to take into account product positioning, product
            labelling and marketing strategies, feasibility of study design, or
            as otherwise required or advisable under applicable Law or in
            response to acts or requests by Governmental Authorities. The DC
            will consider in good faith whether Neurocrine, to the extent
            feasible and appropriate, shall undertake responsibility for
            execution of certain studies conducted under the Supplemental
            Program.

5.4   ROW Program. Pfizer will have the sole authority with respect to
      development and registration for IR Product and MR Product outside the US
      Territory ("ROW Program").

                                   ARTICLE 6 A

                 FIELD FORCE, LAUNCH, CO-PROMOTION AND DETAILING

6A.1  Neurocrine Sales Force.

      (a)   (i)   Neurocrine shall have a sales force of two hundred (200) full
                  time employees in the US Territory comprised of Sales
                  Representatives who will specialize in Detailing to
                  psychiatrists and to Sleep Specialists ("Neurocrine Field
                  Force") and such sales professionals as Neurocrine

                                       42
<PAGE>
                  shall hire in its sole discretion (collectively, the
                  Neurocrine Field Force and other sales professionals, the
                  "Neurocrine Sales Force").

            (ii)  Except as specifically provided herein, Neurocrine shall have
                  exclusive control over the Neurocrine Sales Force. Nothing in
                  this Agreement shall be construed to conclude that any agents
                  or employees of Neurocrine are agents or employees of Pfizer
                  or subject to Pfizer's direction and control. Neurocrine shall
                  have sole authority over the terms and conditions of its
                  agents' and employees' employment, and shall select, engage,
                  and discharge its agents and employees.

            (iii) Neurocrine will be solely responsible for compensating its
                  agents and employees whom it assigns to perform services under
                  this Agreement, including paying salaries and expenses;
                  providing benefits; deducting federal, state and local payroll
                  taxes, FICA contributions, FUI, SUI and any similar taxes; and
                  paying Workers' Compensation premiums, unemployment insurance
                  contributions and any other payments required by federal,
                  state or local law to be made on behalf of employees.

      (b)   Subject to section 6A.1(c), Pfizer will begin paying an Allowance
            Fee (as defined below) with respect to the Neurocrine Sales Force
            commencing on the filing of the NDA Package, twenty (20) days after
            receipt of notice from Neurocrine that it has commenced hiring of
            the Neurocrine Sales Force, Pfizer will pay the first quarterly
            installment of the Allowance Fee for the first Allowance Year
            ("Allowance Year 1") as set forth in Section 6A.1(d) and based on
            the amounts set forth in Schedule 6A.1(b) (the "Hiring Schedule").
            Pfizer shall pay Neurocrine any subsequent quarterly installments on
            each subsequent ninetieth (90th) day after receipt of such notice.

      (c)   In the event that the First Approval of MR Product is not received
            by [***], and Neurocrine is still in the process of hiring members
            of the Neurocrine Sales Force, Neurocrine shall suspend all further
            hiring of the Neurocrine Sales

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       43
<PAGE>
            Force until receipt of such First Approval (such period, the
            "Suspension Period"). During the Suspension Period, Pfizer shall
            continue to be responsible for payment of the Allowance Fee with
            respect to the actual members of the Neurocrine Sales Force hired
            prior to the commencement of the Suspension Period (the
            "Proportional Allowance"). Pfizer shall be entitled to a credit
            against future Allowances for the portion of the Proportional
            Allowance paid by Pfizer for the Suspension Period that is greater
            than the portion of Zoloft Net Sales in excess of the Baseline
            Threshold (as defined below), if any. If during the Suspension
            Period, Zoloft Net Sales in excess of the Baseline Threshold exceed
            the Proportional Allowance paid by Pfizer, Neurocrine will be
            entitled to payment as set out in Section 8.2(b) below. If the First
            Approval has not been received prior to the time Zoloft is no longer
            being Co-Promoted, Pfizer will receive a credit against future
            Allowances on a pro rata basis in respect of periods where neither
            Zoloft nor the Products are being Co-Promoted.

      (d)   Pfizer shall, for the duration of this Agreement, compensate
            Neurocrine for the Neurocrine Sales Force by paying to Neurocrine
            [***] (an "Allowance") each Allowance Year (as defined below),
            except that for the Allowance Year(s) in which hiring of the
            Neurocrine Sales Force commenced, such Allowance will be determined
            pro rata in accordance with such Hiring Schedule (the amount of the
            Allowance actually paid annually shall be referred to as an
            "Allowance Fee"). From the beginning of Allowance Year 1 until end
            of the Allowance Year in which Launch of the first Product occurs
            Pfizer will pay the Allowance Fee in quarterly installments. With
            respect to each Allowance Year after Launch of the first Product,
            Pfizer will pay the Allowance Fee beginning on each anniversary of
            Allowance Year 1. For each Allowance Year after Allowance Year 1,
            the Allowance Fee shall be increased [***]. Each three hundred and
            sixty-five (365) day period beginning when hiring of the Neurocrine
            Sales Force has commenced shall be referred to as an "Allowance
            Year".

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       44
<PAGE>

         (e)      Subject to Section 6A.1(f) below, for each Allowance Year
                  beginning in Allowance Year 1, Pfizer will pay a fee equal to
                  the following percentages of the Allowance Fee:

             YEAR                                           ALLOWANCE FEE (%)
             ----                                           -----------------
            [***]                                                [***]
--------------------------------------------------------------------------------
            [***]                                                [***]
--------------------------------------------------------------------------------
            [***]                                                [***]
--------------------------------------------------------------------------------
            [***]                                                [***]
--------------------------------------------------------------------------------

         (f)      In respect of the Allowance Fee for each quarterly installment
                  paid prior to an Allowance Year that begins after Launch,
                  Pfizer shall be entitled to a pro-rata credit against the
                  Allowance Fee in the following quarter, to the extent that
                  Neurocrine fails to hire the Neurocrine Sales Force that meets
                  or exceeds the quarterly goals set forth in the Hiring
                  Schedule in Schedule 6A.1(b).

         (g)      For the term of the Suspension Period, the reduction in
                  Allowance Fee based on Allowance Years as set forth in Section
                  6A.1(e) will be tolled such that no portion of the Suspension
                  Period will be counted toward Allowance Years as used to
                  determine Neurocrine's Allowance Fee hereunder.

6A.2     Product Sales. Pfizer shall be responsible for the distribution and
         sales of the Products in the Territory and shall book all sales for the
         Products. Pfizer shall have sole responsibility and authority in the US
         Territory for all decisions regarding the pricing of Products, and for
         all pricing and reimbursement approvals, subject to MC oversight.
         Pfizer shall have sole responsibility and authority in the ROW
         Territory for all decisions regarding the pricing of Products, and for
         all pricing and reimbursement approvals.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       45
<PAGE>
6A.3     Co-Promotion.

  a)    (i)      Marketing Activities. The parties shall Co-Promote
                 the Products in the US Territory during the
                 Co-Promotion Term in accordance with the terms of
                 this Agreement and the applicable Marketing Plan, and
                 in compliance with all Laws. In conducting
                 Co-Promotion activities, Pfizer shall use
                 Commercially Reasonable Efforts and Neurocrine shall
                 use its commercially reasonable efforts to promote
                 the sale of the Products in the US Territory.

        (ii)     Pfizer will provide the Sales Representatives from each field
                 force with target lists for Details. The district managers of
                 Pfizer and Neurocrine will agree upon call schedules for the
                 Neurocrine Field Force and the Pfizer Field Force, consistent
                 with the Marketing Plan and with Section 6A.3(a)(iii) below.

        (iii)    It is understood that the Neurocrine Field Force and Pfizer
                 Field Force are intended, to the extent practical, to have
                 overlapping territories and target lists. The Neurocrine Field
                 Force target lists will contain a distribution of medical
                 professionals with prescribing authority with roughly similar
                 prescribing habits as those provided to the Pfizer Field Force.
                 The target lists will contain the names and contact information
                 for medical professionals with prescribing authority (or
                 non-prescribing Sleep Specialists). The Neurocrine Field Force
                 and the Pfizer Field Force will Detail the Products to such
                 medical professionals in accordance with such target list.

 (b)     Marketing Committee. The Marketing Committee will operate
         within the framework of the governance structure set forth in
         Article 3 and will be responsible for promotional activities
         in the US Territory. The responsibilities of the Marketing
         Committee include, but are not limited to, the following:

                                       46
<PAGE>
         (i)      Preparing annually all aspects of the Marketing Plan and
                  Co-Promotion Budget as described in Section 6A.3(c) below for
                  submission to the JOC for approval, except following an event
                  described in Section 3.5(c);

         (ii)     Monitoring compliance with the Marketing Plan;

         (iii)    Developing the Supplemental Program, in coordination with the
                  DC;

         (iv)     Coordinating with the DC with respect to future Product
                  development activities to be undertaken pursuant to the
                  Development Programs;

         (v)      Coordinating with the RC with regard to regulatory issues;

         (vi)     Developing positioning and market strategies consistent with
                  the Marketing Plan, including decisions to seek or include any
                  new indication for the Product;

         (vii)    Developing advertising material and strategies and promotional
                  materials for the Pfizer Sales Representatives and the
                  Neurocrine Field Force for the Product, designing, packaging
                  the Product, and planning and overseeing educational and
                  professional symposia, and speaker and activity programs for
                  the Products in the US Territory;

         (viii)   Developing and implementing, together with the DC, a
                  publications strategy for the Product;

         (ix)     Allocating responsibilities for making Product presentations
                  and creating Product exhibits and booths at significant
                  medical meetings and promotional events;

         (x)      Scheduling periodic joint meetings for the Pfizer Field Force
                  and Neurocrine Sales Force;

         (xi)     Overseeing and implementing Phase IV Product Studies;

                                       47
<PAGE>
         (xii)    Reviewing and adjusting the target lists previously provided
                  pursuant to Section 6A.12 prior to Launch; and

         (xiii)   Providing updates on the MC's activities and achievements to
                  the JOC.

For the sake of clarity, it is understood and agreed that the MC will not
address the promotion or Detailing of Zoloft or any other Pfizer products.

(c)      Marketing Plan and Budget. The MC shall develop a Marketing Plan (a
         "Marketing Plan") and a marketing budget (a "Co-Promotion Budget") for
         each Year during the Co-Promotion Term consistent with the terms of
         this Agreement, except following an event described in Section 3.5(c).
         The Co-Promotion Budget will include all Out-of-Pocket Costs of each
         party arising out of the conduct of the Marketing Plan and all such
         costs will be borne by Pfizer. Neurocrine shall not engage in any
         Co-Promotion activities except as provided in the Marketing Plan and/or
         approved by the MC. The Marketing Plan and the Co-Promotion Budget will
         describe the plan for commercialization of the Products in the US
         Territory, including: (a) general strategies for the Detailing and
         marketing of the Products and allocation of responsibilities for
         marketing activities; (b) each party's training, Detail Requirement and
         sampling activities, if any; (c) market and sales forecasts; (d)
         pricing and discounting analysis; (e) advertising, public relations,
         disease management programs and other promotional programs, including
         professional symposia and speaker and activity programs to be used in
         the Co-Promotion of the Products; (f) Phase III(b) and IV Product
         Studies and (g) budgeted Medical and Marketing Expenses for each of the
         foregoing. The Marketing Plan shall not address sales force incentives
         or compensation, and, each party shall have sole authority and
         responsibility for designing and executing any such program for its
         sales force. The Marketing Plan and the Co-Promotion Budget may be
         updated throughout the Year as deemed appropriate by the MC.

                                       48
<PAGE>
6A.4   Reports.

      (a)   Each party shall also provide the other party and the MC with a
            report as soon as practicable but in no event later than forty-five
            (45) days following the end of each calendar month during the
            Co-Promotion Term setting forth, in such detail and form as the
            parties shall agree, the number of Product Details made and the
            amount of samples distributed by such party's respective Sales
            Representatives in the US Territory during such month (the
            "Detailing Report"), provided, however, that the Detailing Report
            for the twelfth (12th) such calendar month in each Year shall be
            cumulative and reflect the number of Product Details made and
            samples distributed by such party's respective Sales Representatives
            in the US Territory during such Year. Neurocrine covenants that it
            shall develop an internal system for the purpose of reporting the
            number of Details of its Sales Representatives, and that it shall
            have such system fully implemented by the time it begins Detailing
            the Products.

      (b)   In addition, no earlier than forty-five (45) days and no later than
            sixty (60) days of the end of each Year during which Neurocrine is
            Detailing the Products in either a First Position or Second
            Position, Neurocrine may request from Pfizer and Pfizer shall
            provide within thirty (30) days, the average number of Product
            Details (excluding any Combination Products) per Sales
            Representative in the Pfizer Field Force who Detailed Products
            (excluding any Combination Products) to psychiatrists and Sleep
            Specialists during such Year. For purposes of Section 6A.7 below,
            the actual Neurocrine Detail Requirement during such Year (the
            "Final Detail Requirement") shall equal the lesser of (i) [***],
            multiplied by [***], and (ii) [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       49
<PAGE>
      (c)   As the Year of Launch and the last Year during the Initial Five Year
            Period (each of the first and last Years, a "Partial Year") may not
            be full years, for purposes of calculating the Final Detail
            Requirement during the relevant period in each Partial Year (a
            "Detail Priority Period"), (i) Neurocrine shall also report in its
            cumulative Year - end report referred to in Section 6A.4(a) the
            number of Details performed during the such Detail Priority Period,
            and such number (as may be verified pursuant to Section 9.2) will be
            used in such Partial Year for purposes of calculating the number of
            reported Details in Section 6A.7(a), (ii) Pfizer shall report to
            Neurocrine upon its request in Section 6A.4(b) [***] number of
            Details in Section 6A.4(b)(i), (iii) the number in Section
            6A.4(b)(i) above shall equal [***], and (iv) the number in Section
            6A.4(b)(ii) above shall equal [***].

6A.5  Detailing. Neurocrine shall be responsible for performing its Detail
      Requirements with respect to the Products. During the Initial [***] Year
      Period, the Neurocrine Field Force will perform at least [***] of the
      Final Detail Requirement to be performed in respect of the Products, in a
      [***].

6A.6  Detail Priority.

      (a)   In the event a product other than Zoloft, a Pfizer Product and the
            Products is being Detailed by the Neurocrine Sales Force with [***],
            the Allowance Fee will be reduced by [***].

      (b)   In the event that neither Zoloft, a Pfizer Product nor a Product is
            being Detailed by the Neurocrine Field Force with [***], the
            Allowance Fee will be reduced to [***]. In addition, the Allowance
            Fee will be reduced to [***] in the event the Neurocrine Field Force
            markets a Competitive Product under Section 14.2(b)(ii). At the end
            of [***],

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       50
<PAGE>
      Neurocrine may reduce its Detail commitment with respect to Products to a
      level that is below [***] on notice to take effect to Pfizer at least (i)
      [***] prior to reduction if the reduction is to take effect when the
      Allowance is [***], and (ii) [***] prior to such reduction if the
      reduction is to take effect when the Allowance is [***] or less.

6A.7  Detail Shortfalls.

      (a)   In the event that Neurocrine fails to perform during the [***] at
            least [***] of its Final Detail Requirement with respect to the
            Products in a [***] (in the event of such failure, Neurocrine will
            be a "Shortfall Party") in any Year as reported pursuant to Section
            6A.4 and verified pursuant to Section 9.2, Neurocrine shall pay to
            Pfizer as liquidated damages, an amount equal to (i) [***] (the
            "Detail Cost"), multiplied by (ii) [***]; provided, however, that
            the Detail Shortfall Payment Amount shall not exceed the Detail
            Cost, multiplied by [***]. To the extent Neurocrine's Details are
            [***] of the Final Detail Requirement during the [***], in addition
            to the Detail Shortfall Payment Amount, Neurocrine's Commission
            Payment with respect to such Detail shortfall shall be reduced
            pursuant to Section 8.2(a)(ii).

      (b)   Pfizer shall give notice to Neurocrine that (i) Neurocrine is a
            Shortfall Party; or (ii) Pfizer wishes to verify Details pursuant to
            Section 9.2, in each case within one hundred and twenty (120) days
            of receipt of the last cumulative annual Detailing Report set forth
            in Section 6A.4(a) delivered after the end of each respective Year.
            Neurocrine shall pay the Detail Shortfall Payment Amount within
            thirty (30) days of notice and verification that it is a Shortfall
            Party, or within thirty (30)

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       51
<PAGE>
            days of the report by an independent accountant pursuant to Section
            6A.9, as applicable.

      (c)   The parties understand and agree that any Detail Shortfall Payment
            Amount or any reduction in the Commission Payment pursuant to
            Section 8.2(a)(ii) below shall be paid as liquidated damages and not
            as a penalty and that such sum represents a genuine pre-estimate of
            the loss the parties believe would be suffered as a result of such
            Detail shortfalls. Pfizer' right to receive payment of the Detail
            Shortfall Payment Amount under Section 6A.7(a) and any reduction in
            the Commission Payment pursuant to Section 8.2(a)(ii) shall be in
            lieu of any other compensation or remedy that Pfizer may have for
            such a shortfall, including for claim of breach of this Agreement on
            account of such Detail shortfall. In addition, reduction in the
            Commission Payment pursuant to Section 8.2(a)(ii) shall not survive
            termination of this Agreement, except in the event that at the time
            of such termination, Neurocrine's Commission Payment would already
            have or has already been permanently reduced pursuant to Section
            8.2(a)(ii)(B).

6A.8  Cost of Detailing/Sales Promotion. Subject to Section 6A.1, each party
      shall be solely responsible for its own costs and expenses incurred in
      providing the personnel necessary to provide the services described in
      this Article 6A.

6A.9  Audit. The number of Details shall be subject to external audit as
      provided in Article 9.

6A.10 Medical Claims. Neither party shall make any medical claim for the
      Products beyond the scope of the relevant regulatory approval(s) then in
      effect for the Products; provided that, both parties may distribute
      information concerning the Products or its use, including but not limited
      to scientific articles, reference publications, and healthcare economic
      information, to the extent such materials have been approved under a
      Marketing Plan.

6A.11 Third Party Reports. From time to time during the term hereof the MC shall
      agree upon the third party reports (such as those from IMS), to the extent
      permitted by such third party, which the parties wish to receive in
      connection with the Co-Promotion (and the

                                       52
<PAGE>
      determinations to be made under Section 6A.3(b) with respect to the
      Marketing Plan and Co-Promotion Budgets), and Neurocrine and Pfizer shall
      have equal access to such reports (to the extent permitted). The expenses
      of such reports shall be Medical and Marketing Expenses. Pfizer will
      provide to Neurocrine all Product market data, therapeutic segment data
      relevant to the Product that it is permitted to share by a third party
      provider through the MC (including IMS information and market research).

6A.12 Zoloft Co-Promotion.

      (a)   Upon the successful completion of training of the Neurocrine Sales
            Force (and as such Sales Representatives are successfully trained on
            a rolling basis) in accordance with Schedule 2.5, such Sales
            Representatives shall begin Detailing Zoloft in the US Territory
            until the earlier of (i) the Zoloft Patent Expiration Date and (ii)
            termination of this Agreement. Pfizer will provide Neurocrine with
            target lists for such Details. The target lists will contain the
            names and contact information for medical professionals with
            prescribing authority, and Neurocrine will be required to Detail
            Zoloft only to such professionals, unless Neurocrine obtains consent
            from Pfizer.

      (b)   Pfizer will also provide Neurocrine with all promotional materials
            and samples for Zoloft that it provides to its own Sales
            Representatives that Details Zoloft to psychiatrists with respect to
            Zoloft.

      (c)   Contract Sales Forces. Without the consent of Pfizer, Neurocrine may
            not use any contract sales force to Co-Promote or Detail Zoloft.

                                   ARTICLE 6B

                                  MANUFACTURING

6B.1  Product Supply Committee.

      (a)   Manufacturing activities prior to First Approval of IR Product and
            MR Product will occur under the supervision of the PSC, which shall
            be responsible for all

                                       53
<PAGE>
            Product pharmaceutical manufacturing and supply issues with respect
            to each of the IR Product and MR Product prior to First Approval of
            IR Product and First Approval of the MR Product, respectively,
            including, but not limited to, the following:

            (i)   Overseeing manufacturing activities under way as of the date
                  of signing, including formulation development, product
                  characterization studies, stability studies, and management of
                  clinical supplies of IR Product and MR Product as set forth in
                  the Manufacturing Plan attached hereto as Schedule 6B.1;

            (ii)  Overseeing the manufacturing of registration batches of
                  Product;

            (iii) Preparation and review of the CMC section of the NDA for each
                  of the IR Product and MR Product;

            (iv)  Overseeing manufacture of the Products for Launch;

            (v)   Establishing Specifications for purposes of the IR Product and
                  MR Product NDAs and for Launch of such Products;

            (vi)  Product manufacturing process validation and any pre-approval
                  inspection of the Product manufacturing subcontractors;

            (vii) Commencing and overseeing any new development activities and
                  manufacturing activities other than activities relating to (i)
                  through (vi) above;

            (viii) Coordinating with the RC and DC as appropriate;

            (ix)  amending the Manufacturing Plan on a periodic basis to reflect
                  the foregoing development activities of the parties; and

            (x)   Providing updates on the PSC's activities and achievements to
                  the JOC.

                                       54
<PAGE>
            (b)   Through the PSC, Neurocrine shall continue its work related to
                  formulation development, product characterization studies,
                  stability studies, clinical studies and registration batches
                  and other amounts of Products required by the CMC section of
                  the Product NDA and approved as part of the Manufacturing
                  Plan. All Out-of-Pocket Costs (other than Out-Of-Pocket Costs
                  incurred by Neurocrine prior to January 1, 2003) incurred in
                  the performance of the Manufacturing Plan will be borne by
                  Pfizer.

            (c)   Following First Approval, Pfizer, subject to Steering
                  Committee oversight, shall have final decision-making
                  authority with respect to the manufacture, supply, packaging
                  and distribution of Products, at its sole cost.

            (d)   Through the PSC prior to First Approval, the establishment of
                  Product specifications, new development and manufacturing
                  activities, including preparation of any materials for Launch,
                  Product manufacturing process validation prior to receipt of
                  NDA approval and any pre-approval inspection of the Product
                  manufacturing subcontractors will be decided as a Consensus
                  Matter. The "lock-down date" for CMC data is [***].

            (e)   Through the PSC, all decisions with respect to the regulated
                  starting materials and commercial manufacturing locations for
                  the Launch of the Product, will be decided as Consensus
                  Matters, provided that in the event such mutual agreement,
                  would delay filing of an NDA, Neurocrine shall have final
                  decision making authority consistent with the Manufacturing
                  Plan set forth on Schedule 6B.1.

            (f)   Neurocrine agrees that it will not amend, modify, supplement
                  or terminate any of its agreements with manufacturing
                  subcontractors, or enter into any agreements with
                  manufacturing subcontractors with respect to the Product,
                  without the consent of Pfizer.

6B.2  Assignment of Contracts. Promptly following the "lock-down date",
      Neurocrine will assign to Pfizer, and Pfizer will accept assignment of,
      all contracts between Neurocrine

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       55
<PAGE>
            and the manufacturing subcontractors set forth in the Product NDA.
            Pfizer may request prior to the "lock-down date" to be joined as a
            party to any contracts between Neurocrine and the manufacturing
            subcontractors. Thereafter, Pfizer will be responsible for all
            performance under those contracts (except to the extent Neurocrine
            is still a party to such agreements) and will make all decisions
            (except to the extent such decision is a Neurocrine decision
            pursuant to Section 3.9(a)) regarding those contracts and any future
            contracts Pfizer elects.

6B.3  Recalls, Market Withdrawals or Corrections. Each party will promptly
      notify the other if any batch or lot of Product is alleged or proved to be
      the subject of a recall, market withdrawal or correction in any country
      and the parties shall cooperate in the handling and disposition of such
      event. However, in the event of a disagreement as to any matters relating
      to such recall, market withdrawal or correction, Pfizer shall have the
      final authority, which shall be exercised reasonably and in good faith.
      Pfizer will bear all costs and expenses arising out of any recall, market
      withdrawal or correction, unless such recall, market withdrawal or
      correction arises or results directly and primarily from Neurocrine's
      Detailing and Promotion of the Products, in which case Neurocrine will
      bear such costs and expenses.

                                   ARTICLE 7

                               PAYMENT PROVISIONS

7.1   Payment Currency. All amounts due under this Agreement shall be paid to
      the designated party in United States dollars.

7.2   Payments. All payments under this Agreement shall be made on or before the
      due date by electronic transfer in immediately available funds to the
      respective account designated in writing by each party at least five (5)
      Business Days before the payment is due. Pfizer shall notify Neurocrine's
      Chief Financial Officer, or such other party as Neurocrine's Chief
      Financial Officer shall designate in writing, by facsimile transmission as
      to the date and amount of any payment that Pfizer shall make at least two
      (2) Business Days prior to such transfer. Neurocrine shall notify Pfizer's
      treasurer, or such other party as Pfizer's

                                       56
<PAGE>
      treasurer shall designate in writing, by facsimile transmission as to the
      date and amount of any payment that Neurocrine shall make at least two (2)
      Business Days prior to such transfer. All payments under this Agreement
      shall bear interest from the date due until paid at a rate equal to the
      prime rate of Citibank, NA as announced on the date such payment was due
      plus [***].

                                   ARTICLE 8

                    ZOLOFT AND PRODUCT CO-PROMOTION PAYMENTS

8.1   Net Sales Report.

      (a)   Pfizer shall deliver electronically to Neurocrine the monthly and
            Year-to-date gross sales for the Products and Net Sales of the
            Products in the US Territory on a calendar monthly basis, within
            fifteen (15) days following the end of each calendar month following
            the Launch during the term of this Agreement. In addition, within
            twenty (20) days following the end of each Pfizer Quarter following
            the Launch during the term of this Agreement, Pfizer shall deliver
            to Neurocrine a report setting forth (i) the gross sales and Net
            Sales (including specific deductions used at arriving at Net Sales)
            of the Products during said Pfizer Quarter by dosage form and unit
            size, the amount of Product Commission Payments and the deductions
            contained in the definition of "Net Sales" the DOV Sublicense, (ii)
            adjustments (including reimbursements, recoupment of prior
            deductions, if any, to Net Sales reported for any previous Pfizer
            Quarter and (iii) any reduction in Commission Payments pursuant to
            Section 8.2(a)(ii), if any, with respect to any previous Pfizer
            Quarter. Within thirty (30) days following the end of each Pfizer
            Quarter, Pfizer shall pay to Neurocrine the amounts set forth in
            Section 8.2(a) below:

      (b)   Zoloft Net Sales Report. Within twenty (20) days following the end
            of each Pfizer Quarter following the commencement of Zoloft
            Detailing by Neurocrine, Pfizer shall deliver to Neurocrine a report
            setting forth (i) Zoloft Net Sales during

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       57
<PAGE>
            said Pfizer Quarter by dosage form and unit size, and the amount of
            Zoloft Commission Payments (as defined in Schedule 8.2), and (ii)
            any adjustments (including reimbursements or recoupments of prior
            deductions), if any, to Zoloft Net Sales reported for the previous
            Pfizer Quarter. Within thirty (30) days after the end of each Pfizer
            Quarter, Pfizer shall pay the amounts set forth in Section 8.2(b)
            below.

8.2   Commission Payment. For each Year during the term of this Agreement,
      Pfizer shall pay to Neurocrine, on a Pfizer Quarterly basis in accordance
      with Section 7.2, the amounts set forth in Section 8.2(a) and 8.2(b)
      (together the "Commission Payments").

      (a)   In respect of the Products, (i) the Commission Payment will be
            calculated, except as provided in clause (ii) below, based on a
            percentage of the Net Sales of the Products in the US Territory in
            each full Year from Launch during the term of this Agreement, as
            follows:

<TABLE>
<CAPTION>
                                          Percentage of Net Sales to be a
 Sales Year                                   Commission Payment
 ----------                               -------------------------------
<S>                                       <C>
  Year 1-2                                          [***]
   Year 3                                           [***]
Year 4 to end of Term                               [***]
</TABLE>

            (ii)  Notwithstanding clause (i) above, (A) with respect to any Year
                  during the Initial Five Year Period that Neurocrine has
                  performed less than [***] of its Final Detail Requirement, the
                  Commission Payment shall be reduced during such Year as
                  follows:
<TABLE>
<CAPTION>
              If the Percentage of Final Detail  Percentage of Net Sales to be a
 Sales Year           Requirement is:                   Commission Payment:
 ----------   ---------------------------------  -------------------------------

<S>           <C>                                <C>
   [***]                    [***]                              [***]
</TABLE>

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       58
<PAGE>
<TABLE>
<CAPTION>
<S>           <C>                                <C>
                            [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]

   [***]                    [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]

   [***]                    [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]
                            [***]                              [***]
</TABLE>

provided that the reduction set forth in this clause (ii) shall not apply if
during the Initial Five Year Period, this Agreement terminates as a result of
Section 13.5 or upon a Change in Control.

and,

            (B)   If during the Initial Five Year Period, Neurocrine has
                  performed Details equal to less than [***] of its cumulative
                  Final Detail Requirement during the Initial Five Year Period,
                  the Commission Payment for the remainder of the Co-Promotion
                  Term shall be reduced as follows:

<TABLE>
<CAPTION>
                                                     Percentage of Net Sales to be a
If the Percentage of Final Detail Requirement is:          Commission Payment:
--------------------------------------------------   -------------------------------
<S>                                                  <C>
                  [***]                                           [***]
                  [***]                                           [***]
                  [***]                                           [***]
                  [***]                                           [***]
</TABLE>

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       59
<PAGE>
<TABLE>
<S>                                                  <C>
                  [***]                                           [***]
</TABLE>

            (1)   Notwithstanding this Clause (B), if Neurocrine fails to
                  perform at least [***] of its cumulative Final Detail
                  Requirement during the Initial Five Year Period, the reduction
                  in this Clause (B) shall not apply if (x) after 6 (six) full
                  years after US Launch, Neurocrine has averaged at least [***]
                  of its cumulative Final Detail Requirement, plus any Details
                  it performs pursuant to the Marketing Plan in the sixth (6th)
                  full year after US Launch.

            (2)   Any reduction pursuant to this clause (ii) shall be paid as an
                  adjustment to payments pursuant to Section 8.1(a) above.

            (3)   If during the Initial Five Year Period, Neurocrine has failed
                  to perform at least [***] of the Final Detail Requirement in
                  any Year but has averaged over the Initial Five Year Period at
                  least [***] of its cumulative Final Detail Requirement, Pfizer
                  shall repay to Neurocrine, as an adjustment, any amounts it
                  had previously been credited as an adjustment as a result of a
                  reduction pursuant to Section 8.2(b)(ii)(A).

      (b)   [***].

            For the avoidance of doubt, Pfizer shall have no obligation to pay
            the Zoloft Commission Payment to Neurocrine if Zoloft Net Sales in
            the US Territory fail to reach the Baseline Threshold nor shall
            Pfizer be permitted to credit, any shortfall against Zoloft
            Commission Payments payable to Neurocrine with respect to Zoloft Net
            Sales in the US Territory in future Years.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       60
<PAGE>
8.3   Development Costs and Medical and Marketing Expense Payments. Beginning
      with the first quarter of 2003, Neurocrine shall, within twenty (20) days
      following the end of each calendar quarter, prepare and deliver to Pfizer
      a statement of Development Costs, manufacturing costs and Medical and
      Marketing Expenses for such calendar quarter, which statement shall set
      forth the Development Costs and Medical and Marketing Expenses incurred or
      accrued during the calendar quarter and the amounts due from Pfizer to
      Neurocrine. Pfizer will pay Neurocrine such amounts owed within thirty
      (30) days from the end of the applicable Pfizer Quarter.

8.4   Milestone Payments and Co-Promote Fees. Subject to the terms and
      conditions of this Agreement, Pfizer shall pay to Neurocrine the
      following:

<TABLE>
<CAPTION>
                EVENT                                   [***]        [***]
--------------------------------------------------------------------------------
<S>                                       <C>           <C>          <C>
(a)   Signing of this Agreement, subject  $50,000,000
      to Section 3.03 of  the
      License Agreement.
--------------------------------------------------------------------------------
(b)   FDA Acceptance [***]                              [***]        [***]
--------------------------------------------------------------------------------
(c)   FDA Approval [***]                                [***]        [***]
--------------------------------------------------------------------------------
</TABLE>

         The parties understand and agree that each of the payments referenced
in this Section 8.4 shall only be made once, and is subject to the following
terms and conditions:

            (i)   With respect to the events and payments referenced in Section
                  8.4(b), mutual agreement on [***] in Section 4.3(c) (except to
                  the extent that neither party may object to such filing as
                  provided therein), is a condition to payment of such
                  milestone.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       61
<PAGE>
            (ii)  With respect to the events and payments referenced in Section
                  8.4(c) mutual agreement on [***] in Section 4.3(d) [***], is a
                  condition to payment of such milestone.

8.5   All amounts payable by either party pursuant to any section under this
      Agreement shall be paid without offset against any amounts due such party
      under those sections, provided that in the event that Pfizer makes any
      direct payments [***], the amount of any sums due pursuant to Section
      8.4(b) and (c) shall be reduced by the amount of any such direct payments
      by Pfizer.

8.6   In consideration for Pfizer lending or causing one or more of its
      Affiliates to loan proceeds and make other advances of credit pursuant to
      the Secured Loan Agreement, dated as of the date hereof, (the "Loan
      Agreement") by and between Neurocrine and Pfizer, Neurocrine hereby
      acknowledges and agrees that Pfizer shall, in the event of default (as
      defined in the Loan Agreement) shall have occurred and is continuing after
      any applicable cure period, be entitled, in its absolute and sole
      discretion, to offset, in part or in full, from time to time, any and all
      amounts due and unpaid by Pfizer under this Agreement against any and all
      amounts due and unpaid under the Loan Agreement.

                                   ARTICLE 9

                             ACCOUNTING AND REPORTS

9.1   Books and Records. Each party shall keep comprehensive books and records
      relating to this Agreement on a full accrual basis of accounting in
      accordance with GAAP. Such books and records shall document all Detailing
      Reports and Net Sales, authorized expenses incurred or paid and any other
      costs incurred (including Medical and Marketing Expenses and Development
      Costs) or revenues earned relating to this Agreement and include all
      information subject to audit pursuant to Section 9.2. All such books and
      records shall be maintained for five (5) Years following the relevant Year
      or such longer period as is required by Law.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       62
<PAGE>
9.2   Audits. These audit and adjustment provisions apply with respect to all
      payments due from one party to another pursuant to this Agreement,
      including amounts payable pursuant to Sections 2.8, 5.3(a), 6A.1(c) and
      8.2; the credits described in Sections 6A.1(c) or 6A.1(f); and number of
      Details performed under Section 6A.5 and, 6A.7. Each party, and DOV and
      ACY shall have the right to have the applicable books and records of the
      other party audited by an independent certified public accountant that is
      nationally recognized as having expertise in the pharmaceutical industry,
      selected by a party (as to which firm the other party has no reasonable
      objection), under appropriate confidentiality provisions, for the sole
      purpose of verifying the accuracy of all financial, accounting and
      numerical information and calculations under this Agreement. Any such
      audit shall be conducted no more than once each Year by each of Pfizer or,
      Neurocrine during the term of this Agreement, and upon at least thirty
      (30) days' advance notice during normal business hours and in a manner
      that does not interfere unreasonably with the business of the audited
      entity. The results of any such audit shall be delivered in writing to
      each party and shall be final and binding upon the parties, other than in
      the case of manifest error, with respect to the matters set forth therein.
      Any underpayment or overbilling determined by such audit shall promptly be
      paid or refunded by the audited party. If the audited party has underpaid
      or overbilled an amount due under this Agreement by more than five percent
      (5%), the audited party shall also reimburse the other party for the cost
      of such audit (with the cost of the audit to be paid by the auditing party
      in all other cases), plus interest at the interest rate set forth in
      Section 7.2, from the date of any such underpayment or overpayment. If the
      audited party is shown to be a Shortfall Party, the provisions of Section
      6A.7 of this Agreement shall control. Except as ACY may require under the
      ACY License, such accountants shall not reveal to the party seeking
      verification the details of its review, except insofar as is necessary to
      describe the underpayment, overbilling or level of Details.

9.3   Sales Force Efforts. For two (2) Years following each Year, each party
      shall keep records relating to Details made by its Sales Representatives,
      and Detailing Reports, during such Year, including sampling of the
      Products. Such records shall be available for

                                       63
<PAGE>
      inspection and audit in accordance with Section 9.2 above to determine
      compliance with the terms hereof.

                                   ARTICLE 10

                    INTELLECTUAL PROPERTY RIGHTS AND LABELING

10.1  Trademark and Corporate Logos.

      (a)   Subject to the provisions of this Section 10.1, each party shall
            retain all right, title and interest in and to its respective
            corporate name and logo.

      (b)   The Products. For the term of this Agreement and the License
            Agreement, Products shall be promoted and sold worldwide solely
            under the Trademarks and shall use Pfizer's and Neurocrine's trade
            dress and logo with substantially equal prominence and frequency, to
            the extent legally permissible in the relevant jurisdiction. For the
            Co-Promotion Term, Pfizer grants to Neurocrine the non-exclusive
            right, free of charge, to use the Trademarks and the Pfizer logo in
            the Territory solely for the purpose of Neurocrine's Co-Promotion of
            the Products in accordance with the terms of this Agreement.
            Neurocrine grants to Pfizer the nonexclusive right, right free of
            charge, to use Neurocrine's logo in the Territory solely for
            purposes contemplated by this Agreement and the License Agreement.
            Pfizer shall remain the owner of the Trademarks and the Pfizer logo
            and the goodwill pertaining thereto, and Pfizer shall be solely
            responsible for registering and maintaining the Trademarks in the
            Territory. Neurocrine shall remain the owner of the Neurocrine logo
            and the goodwill pertaining thereto. Except as contemplated herein,
            Neurocrine shall have no rights in or to the Pfizer logo or the
            goodwill pertaining thereto. Except as contemplated herein, Pfizer
            shall have no rights in or to the Neurocrine logo or the goodwill
            pertaining thereto. Neurocrine shall utilize the Trademarks only for
            Promotional Materials or Products-related materials approved by
            Pfizer or for internal use within Neurocrine, and in each case only
            for the purposes contemplated herein. Neurocrine agrees that upon
            termination or expiration of this Agreement it will,

                                       64
<PAGE>
            except as set forth in Section 9.05 of the License Agreement,
            discontinue forthwith all use of the Trademarks.

      (c)   Zoloft. Zoloft shall be promoted and sold solely under the Zoloft
            Trademark and shall use Pfizer's trade dress and logo. During such
            portion of the Co-Promotion Term that Neurocrine is co-promoting
            Zoloft, Pfizer grants to Neurocrine the non-exclusive right, free of
            charge, to use the Zoloft Trademark and the Pfizer logo in the US
            Territory solely for the purpose of Neurocrine's Co-Promotion of
            Zoloft in accordance with the terms of this Agreement. Pfizer shall
            remain the owner of the Zoloft Trademark and the Pfizer logo and the
            goodwill pertaining thereto, and Pfizer shall be solely responsible
            for registering and maintaining the Zoloft Trademark in the US
            Territory. Except as contemplated herein, Neurocrine shall have no
            rights in or to the Zoloft Trademark or to the Pfizer logo or the
            goodwill pertaining thereto. Neurocrine shall utilize the Zoloft
            Trademark only for Promotional Materials or Zoloft-related materials
            approved by Pfizer or for internal use within Neurocrine, and in
            each case only for the purposes contemplated herein. Neurocrine
            agrees that upon the earlier of termination of this Agreement or the
            Zoloft Patent Expiration Date, it will discontinue forthwith all use
            of the Zoloft Trademark.

      (d)   Other Pfizer Products. Any other Pfizer products promoted under this
            Agreement ("Pfizer Products") shall be promoted and sold solely
            under the applicable trademarks for such Pfizer Product and shall
            use Pfizer's trade dress and logo. During such portion of the
            Co-Promotion Term that Neurocrine is co-promoting or detailing such
            Pfizer Product, Pfizer grants to Neurocrine the non-exclusive right,
            free of charge, to use the applicable trademarks and the Pfizer logo
            in the US Territory solely for the purpose of Neurocrine's
            Co-Promotion of such Pfizer Product in accordance with the terms of
            this Agreement. Pfizer shall remain the owner of any applicable
            trademark and the Pfizer logo and the goodwill pertaining thereto,
            and Pfizer shall be solely responsible for registering and
            maintaining such trademarks in the US Territory. Except as
            contemplated herein,

                                       65
<PAGE>

            Neurocrine shall have no rights in or to trademark for the Pfizer
            Products or to the Pfizer logo or the goodwill pertaining thereto.
            Neurocrine shall utilize the trademarks for the Pfizer Products only
            for Promotional Materials or related materials approved by Pfizer or
            for internal use within Neurocrine, and in each case only for the
            purposes contemplated herein. Neurocrine agrees that upon the
            earlier of termination of this Agreement or termination of such
            co-promotion or detailing activities, it will discontinue forthwith
            all use of such trademarks.

      (e)   Neurocrine shall inform Pfizer promptly of any infringement of or
            challenge to the Trademarks, Zoloft Trademarks or Pfizer Product
            trademarks in the US Territory, in each case whether actual or
            threatened, which comes to the notice of Neurocrine. Pfizer shall
            have the exclusive right, at its sole cost and expense, to take
            action in respect of the registration, defense, infringement and
            maintenance of the Trademarks, Zoloft Trademarks or Pfizer Product
            trademarks, and Neurocrine shall provide reasonable assistance and
            co-operation as Pfizer may reasonably request, at Pfizer's sole cost
            and expense.

      (f)   Copyrights and Proprietary Programs. Pfizer shall own all copyrights
            and trademarks relating to Promotional Materials, and regarding all
            sales training, patient education and disease management programs
            related to the Products, as well as any modifications developed in
            the future which are not specific to the Products.

10.2  Third Party Agreements. Neurocrine covenants and agrees with Pfizer that
      Neurocrine:

      (a)   shall not execute or otherwise permit, and shall cause its
            Affiliates to refrain from executing or otherwise permitting, any
            amendment, modification or waiver to any of the licenses and
            agreements listed on Schedule 10.2 ("Third Party Agreements") which
            would have a material adverse effect on the Co-Promotion of the
            Products, without the prior written consent of Pfizer,

                                       66
<PAGE>
      (b)   shall not make any election or exercise any right or option (or omit
            to take any action which would), and shall cause its Affiliates to
            refrain from making any election or exercising any right or option
            (or omitting to take any action which would), terminate or
            relinquish in whole or in part any Third Party Agreements, if such
            election or exercise would have a material adverse effect on the
            Co-Promotion of the Products,

      (c)   shall comply, and shall cause its Affiliates to comply, with all of
            its or its Affiliates' obligations under the Third Party Agreements
            in all material respects,

      (d)   shall take, and shall cause its Affiliates to take, such reasonable
            actions as shall be necessary to keep in full force and effect the
            Third Party Agreements,

      (e)   shall give prompt notice to Pfizer, together with a review of
            outstanding issues if Pfizer so requests and subject to any
            obligations of confidentiality owed by Neurocrine or its Affiliates
            to the other party to such Third Party Agreements, of any actual or
            alleged defaults, breaches, violations, proposed amendments or
            proposed modifications of, or any proposed waivers under, any Third
            Party Agreement; and

      (f)   shall give prompt notice to Pfizer, together with a review of
            outstanding issues if Pfizer so requests and subject to any
            obligations of confidentiality owed by Neurocrine or its Affiliates
            to the other party to such Third Party Agreements, of any proposed
            amendments or proposed modifications of the Third Party Agreements
            which would conflict with Pfizer's rights hereunder.

                                   ARTICLE 11

                            CONFIDENTIAL INFORMATION

11.1  Treatment of Confidential Information. Until the earlier of (a) expiration
      of this Agreement or (b) if this Agreement is terminated prior to
      expiration, [***] following such termination, each party shall maintain
      Confidential Information (as

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       67
<PAGE>

      defined in Section 11.2) of the other party in confidence, and shall not
      disclose, divulge or otherwise communicate such Confidential Information
      to others, or use it for any purpose other than as permitted under this
      Agreement or in connection with the development, manufacture, marketing,
      promotion, distribution or sale of the Products pursuant to this Agreement
      or the License Agreement, and each party agrees to exercise its reasonable
      efforts to prevent and restrain the unauthorized disclosure of such
      Confidential Information by any of its directors, officers, employees,
      consultants, subcontractors, licensees or agents.

11.2  Confidential Information. "Confidential Information" means all materials,
      trade secrets or other information, including without limitation, any
      data, proprietary information and materials (whether or not patentable, or
      protectable as a trade secret) regarding a party's technology, Products,
      business information or objectives, which is disclosed in writing by a
      party to the other party and which is designated as confidential by the
      disclosing party. All information disclosed prior to the Effective Date by
      Neurocrine to Pfizer under or pursuant to the confidentiality agreement
      between the parties dated February 24, 2002, as amended, shall be deemed
      "Confidential Information" of Neurocrine. There should be excluded from
      the foregoing definition of Confidential Information such information or
      data which:

      (a)   was known by the receiving party prior to its date of disclosure to
            the receiving party as shown by the receiving party's written
            records; or

      (b)   either before or after the date of the disclosure to the receiving
            party is lawfully disclosed to the receiving party by third parties
            not in violation of any obligation to the other party; or

      (c)   either before or after the date of the disclosure to the receiving
            party becomes published or generally known to the public through no
            fault or omission on the part of the receiving party or its
            Affiliates; or

                                       68
<PAGE>
      (d)   is independently developed by or for the receiving party without
            reference to or reliance upon the Confidential Information; or

      (e)   is required to be disclosed by the receiving party to comply with
            applicable Laws, to defend or prosecute litigation or to comply with
            governmental regulations, provided that the receiving party provides
            prior notice of such disclosure to the other party and takes
            reasonable and lawful actions to avoid and/or minimize the degree of
            such disclosure.

11.3  Publications. During the course of this Agreement, each party will submit
      to the DC and MC for review and approval all peer-reviewed academic,
      scientific and medical publications relating to the Development Program
      and/or Products for review. The DC will have primary responsibility and,
      subject to Neurocrine's final decision-making authority in Section 3.9(a),
      will have final authority to approve all such publications as they
      primarily relate to the Registration Program, provided that the decision
      whether and how to publish as well as the timing of such publication shall
      be consistent with the publications strategy of the MC. With respect to
      all other such publications, MC will have primary responsibility and,
      subject to Pfizer's final decision-making authority in Section 3.9(c),
      will have final authority to approve all publications. The DC and MC shall
      each have no less than thirty (30) days to review each proposed
      publication. The review period may be extended for an additional thirty
      (30) days in the event the non-publishing party can demonstrate to the DC
      and MC a reasonable need for such extension including, but not limited to,
      the preparation and filing of patent applications. Such period may be
      further extended by the JOC. Pfizer and Neurocrine will each comply with
      standard academic practice regarding authorship of scientific publications
      and recognition of contribution of other parties in any publications
      relating to Development Programs and/or Products. Notwithstanding the
      foregoing, the parties shall endeavor as far as possible, for ease and
      convenience, to agree on a universal basis joint authorship in respect of
      such publications.

                                       69
<PAGE>
                                   ARTICLE 12

                 REPRESENTATIONS, WARRANTIES AND INDEMNIFICATION

12.1  Neurocrine's Representations. Neurocrine hereby represents and warrants as
      of the date hereof as follows:

      (a)   Neurocrine has the corporate power and authority to execute and
            deliver this Agreement and to perform its obligations hereunder, and
            the execution, delivery and performance of this Agreement has been
            duly and validly authorized and approved by proper corporate action
            on the part of Neurocrine, and Neurocrine has taken all other action
            required by law, its certificate of incorporation or by-laws or any
            agreement to which it is a party or to which it may be subject
            required to authorize such execution, delivery and performance
            (other than compliance with all applicable requirements of the HSR
            Act). Assuming due authorization, execution and delivery on the part
            of Pfizer, this Agreement constitutes a legal, valid and binding
            obligation of Neurocrine, enforceable against Neurocrine, in
            accordance with its terms, except as such enforceability may be
            limited by bankruptcy, insolvency, reorganization, moratorium and
            similar laws relating to or affecting creditors generally or by
            general equitable principles (regardless of whether such
            enforceability is considered in a proceeding in equity or at law).

      (b)   The representations and warranties of Neurocrine contained in the
            License Agreement are true and correct in all respects.

      (c)   All manufacturing operations conducted by Neurocrine and its
            Affiliates (or by third parties on their behalf) relating to the
            manufacturing of the Products are, to Neurocrine's knowledge (after
            reasonable due inquiry), being conducted in material compliance with
            GMP and other applicable requirements and standards of any
            Governmental Authority in which such manufacturing is being
            conducted, except where any failure to do so will not have a
            material adverse effect on the Registration Program.

                                       70
<PAGE>
      (d)   As of the date hereof, Neurocrine has disclosed to Pfizer all
            material information known to Neurocrine or its Affiliates relating
            to (i) the drug quality, including stability, variability,
            impurities and delivery performance in each case relating to the
            Compound, and (ii) changes made by Neurocrine or its Affiliates
            after the initiation of Phase III clinical trials for the Products
            relating to formulation, packaging and method of manufacture and
            formulation and to processing parameters, and (iii) the status of
            discussions with FDA or any Governmental Authorities directly
            relating thereto.

12.2  Pfizer's Representations. Pfizer hereby represents and warrants as of the
      date hereof as follows:

      (a)   Pfizer has the corporate power and authority to execute and deliver
            this Agreement and to perform its obligations hereunder, and the
            execution, delivery and performance of this Agreement has been duly
            and validly authorized and approved by proper corporate action on
            the part of Pfizer, and Pfizer has taken all other action required
            by law, its certificate of incorporation or by-laws or any agreement
            to which it is a party or to which it may be subject required to
            authorize such execution and delivery (other than compliance with
            all applicable requirements of the HSR Act). Assuming due
            authorization, execution and delivery on the part of Neurocrine,
            this Agreement constitutes a legal, valid and binding obligation of
            Pfizer, enforceable against Pfizer in accordance with its terms,
            except as such enforceability may be limited by bankruptcy,
            insolvency, reorganization, moratorium and similar laws relating to
            or affecting creditors generally or by general equitable principles
            (regardless of whether such enforceability is considered in a
            proceeding in equity or at law).

      (b)   The representations and warranties of Pfizer contained in the
            License Agreement are true and correct in all respects.

                                       71
<PAGE>
12.3  Limitation of Damages/Sole Remedy.

      This Agreement is subject to the terms and conditions of Article 10 of the
      License Agreement.

                                   ARTICLE 13

                              TERM AND TERMINATION

13.1  Term.

      (a)   Notwithstanding to the contrary any of the provisions of this
            Agreement but subject to Section 13.1(b) below, this Agreement shall
            only become effective upon the Effective Date, and prior to the
            Effective Date neither Neurocrine nor Pfizer shall have any rights
            or obligations hereunder. Subject to Section 13.1 as of the
            Effective Date, this Agreement shall commence and continue in force
            until the later of (i) fifteen (15) years following Launch or (ii)
            expiration of the last to expire of the Neurocrine Patent Rights
            with Valid Claims in the US Territory, unless sooner terminated as
            provided herein.

      (b)   Effective immediately as of the date first written above, Neurocrine
            covenants and agrees that it will not negotiate, engage in or
            otherwise enter into any one or more transactions involving (i) any
            sale or grant of any rights to any Neurocrine Patent Rights or
            Neurocrine Technical Information (including without limitation any
            licenses or sublicenses), or (ii) any joint venture, co-promotion or
            similar relationship involving any Neurocrine Patent Rights or
            Neurocrine Technical Information. Effective immediately as of the
            date first written above, each of Pfizer and Neurocrine covenant and
            agree that Article 15 shall be in full force and effect. The parties
            understand and agree that the obligations set forth in this Section
            13.1(b) shall terminate on the 90th day following the date of this
            Agreement if, but only, if the Effective Date has not occurred on or
            before such 90th day (other than with respect to liability for any
            breaches of this Section 13.1(b) prior to such 90th day (which shall
            survive such termination)).

                                       72
<PAGE>
13.2  Termination for Breach.

      (a)   If Pfizer materially breaches or materially defaults in the
            performance or observance of any of the provisions of this Agreement
            or the License Agreement, and such material breach or material
            default is not cured within ninety (90) days or, in the case of
            failure to pay any amounts due hereunder sixty (60) days after the
            giving of notice by Neurocrine specifying such breach or default,
            Neurocrine shall have the right to terminate this Agreement in full
            upon a further thirty (30) days' notice.

      (b)   If Pfizer terminates all of its development activities for a period
            of six (6) months or longer in the US Territory at any time after it
            has the final decision making authority with respect to the
            Development Program (other than for regulatory restraints), [***].
            If Pfizer terminates the Development Program with respect to any
            country in the ROW Territory or otherwise fails to conduct any
            development activities directed to any such country, [***], Pfizer
            will thereafter have six (6) months to present [***]. If Pfizer
            fails within thirty (30) days to notify Neurocrine [***], Neurocrine
            shall have the right to terminate this Agreement with respect to
            such country effective upon thirty (30) days notice.

      (c)   For purposes of this Agreement, materiality in all cases shall be
            considered in the context of this Agreement and the License
            Agreement taken as a whole; provided, however, no party shall be
            deemed to be in material breach or material default if its actions
            or omissions primarily resulted from: (i) compliance with any
            specific unanimous decision of a committee or subcommittee under
            this Agreement, or (ii) compliance with any directive by the
            non-defaulting party for a matter in which

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       73
<PAGE>
            the non-defaulting party or any of its designees, representatives or
            employees have exercised sole or final decision making authority
            under this Agreement, or (iii) compliance with the express terms of
            this Agreement or the License Agreement, or (iv) to the extent
            Pfizer uses efforts in substantial conformity with Commercially
            Reasonable Efforts or Neurocrine uses efforts in substantial
            conformity with commercially reasonable efforts consistent with
            Section 2.12. A material breach or material default in the
            performance of any of the provisions of this Agreement shall include
            a material inaccuracy in any representation or warranty contained
            herein.

      (d)   Upon the giving of any notice of default under Section 13.2(a), the
            parties will in good faith meet to see if a plan to remedy the
            alleged breach or default can be mutually agreed.

13.3  Other Termination:

      (a)   Discretionary. Upon one hundred and eighty (180) days prior notice
            to Neurocrine, Pfizer shall have the right at any time, without
            cause at Pfizer's sole discretion, to terminate this Agreement,
            whereupon this Agreement, together with the License Agreement, shall
            terminate one hundred and eighty (180) days after the date of such
            notice.

      (b)   Termination of License Agreement. This Agreement shall terminate
            following any termination by Pfizer of the License Agreement.

      (c)   Neurocrine. Subject to the terms hereof (including without
            limitation Section 13.3(a) above), upon the occurrence of any
            material default by Neurocrine:

            (i)   which material default or material breach relates to any of
                  the covenants and agreements of Neurocrine in Article 2 and 6A
                  (provided that, for the avoidance of doubt, the foregoing
                  shall exclude any breach of Neurocrine's obligations under
                  Section 6A.7(a) (such covenants and

                                       74
<PAGE>
                  agreements, the "Co-Promotion Covenants")), Pfizer may, upon
                  ninety (90) days prior notice, elect to terminate Neurocrine's
                  Co-Promotion rights with respect to Zoloft and any Pfizer
                  Products other than the Products, whereupon neither party
                  shall have any further rights or obligations with respect to
                  Zoloft or any Pfizer Products (other than Products), including
                  obligations under Article 2, Article 6A, Article 8, Article
                  10, Section 8.2(b) and Section 14.3, except for any
                  obligations that have accrued prior to such date of
                  termination, and in addition, the provisions of Section 3.12
                  will apply; and

            (ii)  which material default or material breach relates to any of
                  the covenants and agreements of Neurocrine under this
                  Agreement other than the Co-Promotion Covenants or under the
                  License Agreement, Pfizer may, upon ninety (90) days prior
                  written notice, elect that the provisions of Section 3.12 will
                  apply.

      All other terms and conditions of this Agreement, except as provided
      herein, shall remain in full force and effect. It is acknowledged and
      agreed by Pfizer that Pfizer shall not be entitled to terminate this
      Agreement for a material default covered by this Section 13.3(c), but
      Pfizer shall be entitled to indemnification and the right to obtain
      specific performance and other injunctive relief as provided in this
      Agreement.

      (d)   Upon sixty (60) days prior notice to Neurocrine, Pfizer shall have
            the right to terminate this Agreement upon an event described in
            Sections 13.5 or 13.7 hereunder, or upon a Change of Control. Upon
            termination of this Agreement pursuant to this Section 13.3, the
            provisions of Section 13.8 shall apply.

13.4  Bankruptcy. Each party may, in addition to any other remedies available to
      it by law or in equity, exercise the rights set forth below by written
      notice to the other party (the "Insolvent Party"), in the event the
      Insolvent Party shall have become insolvent or bankrupt, or shall have
      made a general assignment for the benefit of its creditors, or there shall
      have been appointed a trustee or receiver of the Insolvent Party or for
      all or a

                                       75
<PAGE>
      substantial part of its property, or any case or proceeding shall have
      been commenced or other action taken by or against the Insolvent Party in
      bankruptcy or seeking reorganization, liquidation, dissolution, winding-up
      arrangement, composition or readjustment of its debts or any other relief
      under any bankruptcy, insolvency, reorganization or other similar act or
      law of any jurisdiction now or hereafter in effect, and any such event
      shall have continued for sixty (60) days undismissed, unbonded and
      undischarged. All rights and licenses granted under or pursuant to this
      Agreement by Neurocrine and Pfizer are, and shall otherwise be deemed to
      be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses
      of rights to "intellectual property" as defined under Section 101 of the
      U.S. Bankruptcy Code. The parties agree that the parties as licensees of
      such rights under this Agreement shall retain and may fully exercise all
      of their rights and elections under the U.S. Bankruptcy Code. The parties
      further agree that, in the event of the commencement of a bankruptcy
      proceeding by or against either party under the U.S. Bankruptcy Code, the
      other party shall be entitled to a complete duplicate of (or complete
      access to, as appropriate) any such intellectual property and all
      embodiments of such intellectual property, and same, if not already in
      their possession, shall be promptly delivered to it (i) upon any such
      commencement of a bankruptcy proceeding upon its written request
      therefore, unless the party subject to such proceeding elects to continue
      to perform all of its obligations under this Agreement or (ii) if not
      delivered under (i) above, upon the rejection of this Agreement by or on
      behalf of the party subject to such proceeding upon written request
      therefore by the other party.

13.5  Neurocrine. In the event Neurocrine shall be an Insolvent Party, Pfizer
      may terminate this Agreement subject to Neurocrine's rights and Pfizer's
      obligations under Section 13.8.

13.6  Divestiture by Pfizer.

      (a)   If in connection with any proposed acquisition or merger or inquiry
            of Governmental Authority, Pfizer determines that in order to
            facilitate clearance or obtain approval from any Governmental
            Authority with responsibility for

                                       76
<PAGE>
            enforcing antitrust or competition Laws regarding such acquisition
            or merger or inquiry, it would be advisable, in Pfizer's business
            judgement, to assign or sublicense or otherwise transfer (any such
            assignment, sublicense or transfer, a "Divestiture Transaction")
            Pfizer's rights and obligations under this Agreement and the License
            Agreement to any third party, Pfizer shall notify Neurocrine thereof
            ("Notice of Divestiture"). The Notice of Divestiture shall not be
            required to disclose any details of any such proposed Divestiture
            Transaction.

      (b)   [***].

13.7  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       77
<PAGE>
13.8  Survival of Obligations. Notwithstanding any termination of this
      Agreement, (a) neither party shall be relieved of any obligations incurred
      prior to such termination, including the payment obligations, and (b) the
      obligations of the parties with respect to (I) the protection and
      nondisclosure of Confidential Information (Article 11) shall survive
      termination of this Agreement, and (II) each other Section or Schedule of
      this Agreement which is expressed to survive termination or which is
      required to give effect to such termination or the consequences of such
      termination shall survive termination, and (III) subject to Section
      10.04(c)(vi) and Section 10.06 of the License Agreement, termination of
      this Agreement shall not release either party from any obligation or
      liability which shall have accrued at the time of termination or preclude
      either party from pursuing all rights at law and in equity with respect to
      any default under this agreement, (c) unless this Agreement expressly
      provides that termination shall be the sole and exclusive remedy for a
      particular breach hereof, either party's right to commence an action, suit
      or other proceeding claiming breach of this Agreement by the other party
      shall survive termination, and (d) Pfizer's obligations under Sections
      2.2, 2.12, Article 7, Section 8.2(a), Article 9, Section 10.1(b), Article
      11, Section 15.4 and Section 15.9 shall survive until such time as the
      License Agreement shall terminate. Notwithstanding anything in this
      Agreement to the contrary, in the event this Agreement is terminated prior
      to termination of the License Agreement, Neurocrine shall be entitled to
      receive 100% of the amounts it would have otherwise received pursuant to
      Section 8.2(a), until such time as the License Agreement is terminated or
      expires. Upon a termination of this

                                       78
<PAGE>
      Agreement by Pfizer, Neurocrine shall promptly return to Pfizer all
      written Confidential Information previously disclosed by Pfizer, and all
      copies thereof, and Neurocrine shall have no further right with respect
      to, and shall cease all activities related to Co-Promotion of the Products
      and Zoloft. Upon any other termination of this Agreement and the License
      Agreement, each party shall promptly return to the other party all written
      Confidential Information, and all copies thereof, of such other party,
      except as specifically provided in this Agreement and the License
      Agreement.

                                   ARTICLE 14

                                 NON-COMPETITION

14.1  Pfizer Non-Competition. If during the term of this Agreement Pfizer or any
      of its Affiliates intends to Commercialize a prescription pharmaceutical
      product having an Insomnia Indication in the Territory (a "Competitive
      Product"):

      (a)   if such Competitive Product's [***]:

            (i)   [***]

            (ii)  [***].

      (b)   if such Competitive Product's [***]:

            (i)   [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       79
<PAGE>
            (ii)  [***].

      [***].

      (c)   If Pfizer Launches any Competitive Product defined in Section
            14.1(b)(ii) ("Section 14.1(b)(ii) Product"), then neither Pfizer or
            its Affiliates shall:

            (i)   Engage in "negative promotional activities", [***].

            (ii)  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       80
<PAGE>
            (iii) [***].

            (iv)  [***].

      (d)   Notwithstanding to the contrary any provisions of this Agreement or
            the License Agreement, in no event shall Pfizer be required under
            this Agreement or under the License Agreement to engage in any
            activity regarding a Product which Pfizer is prohibited from
            undertaking under Section 14.1(c) with respect to a Section
            14.1(b)(ii) Product, and Section 14.1(c) shall be applicable, on the
            same basis (mutatis mutandis), to promotional activities regarding
            the Product vis-a-vis any Competitive Product of Pfizer.

      (e)   In the event that [***] shall be deemed to be a Competitive Product,
            in addition to

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       81
<PAGE>
            Pfizer's obligations with respect to such Product in Section 14.1(b)
            above, Neurocrine will have the rights in the US Territory as set
            forth in Section 14.3 below.

14.2  Neurocrine Non-Competition. If, during the term of this Agreement,
      Neurocrine or any of its Affiliates proposes to Commercialize a
      Competitive Product in any country of the Territory other than a country
      in the EU, Neurocrine or such Affiliate shall:

      (a)   if such Competitive Product's primary mechanism of action is through
            binding with [***], divest such Competitive Product;

      (b)   if such Competitive Product's primary mechanism of action is other
            than through binding with [***], at its sole discretion either:

            (i)   divest (by license, sale or similar transaction) such
                  Competitive Product; or

            (ii)  only if such commercialization would begin after the [***],
                  Commercialize such Competitive Product and terminate its right
                  to Co-Promote Products hereunder pursuant to Section 13.8.

14.3  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       82
<PAGE>
14.4  Conflicts. For so long as this Agreement is in effect, in the event of any
      conflict between the provisions this Article 18 of this Agreement and
      Article 11 of the License Agreement, the provisions of Article 14 of this
      Agreement shall control.

                                   ARTICLE 15

                                  MISCELLANEOUS

15.1  Governing Law. This Agreement shall be governed by and interpreted in
      accordance with the internal laws of the State of New York, without regard
      to its conflicts of laws rules.

15.2  Jurisdiction. With respect to any suit, action or proceeding relating to
      this Agreement (each, a "Proceeding"), each party hereto irrevocably (i)
      subject to the final sentence of this Section 15.2, agrees and consents to
      be subject to (A) in the case of any Proceeding commenced by Pfizer, the
      exclusive jurisdiction of the United States District Court for the
      Southern District of California or any California state court sitting in
      San Diego, California, United States of America (any such court, the
      "California Court"), and (B) in the case of any Proceeding commenced by
      Neurocrine, the exclusive jurisdiction of the United States District Court
      for the Southern District of New York or any New York state court sitting
      in New York, New York, United States of America (any such court, the "New
      York Court") and (ii) waives any objection which it may have at any time
      to the laying of venue of any Proceeding brought in any such California
      Court or New York Court (collectively, the "Courts") as provided in this
      Section 15.2, waives any claim that such Proceeding has been brought in an
      inconvenient forum and further waives the right to object, with respect to
      such Proceeding, that such Court does not have any jurisdiction over such
      party. Notwithstanding the foregoing: (a) if the Court adjudicating such

                                       83
<PAGE>
      Proceeding refuses for any reason to exercise jurisdiction over the
      dispute, either party shall be free to bring such Proceeding in any other
      Court in such state as provided above and, in the event such other Courts
      refuse for any reason to exercise jurisdiction over the dispute, either
      party shall be free to bring such Proceeding in any other court, and (b)
      if any party (the "initiating party") commences a Proceeding in any Court,
      the other party (the "defendant party") shall possess and retain the right
      to assert in that same Proceeding all claims and defenses that the
      defendant party may have against the initiating party, including without
      limitation all counterclaims and setoffs, and (c) in the case of any suits
      for specific performance or other injunctive relief, the parties will seek
      to bring such actions in the Courts as provided in the first sentence of
      this Section 15.2, except where the applicable Courts as a result of
      jurisdictional requirements cannot issue the specific performance
      requested in a timely manner.

15.3  Waiver. Any term or condition of this Agreement may be waived at any time
      by the party that is entitled to the benefit thereof, but no such waiver
      shall be effective unless set forth in a written instrument duly executed
      by or on behalf of the party or parties waiving such term or condition.
      Neither the waiver by any party of any term or condition of this Agreement
      nor the failure on the part of any party, on one or more instances, to
      enforce any of the provisions of this Agreement or to exercise any right
      or privilege, shall be deemed or construed to be a waiver of such term or
      condition for any similar instance in the future or of any subsequent
      breach hereof. All rights, remedies, undertakings, obligations and
      agreements contained in this Agreement shall be cumulative and none of
      them shall be a limitation of any other remedy, right, undertaking,
      obligation or agreement.

15.4  Notices. All notices, instructions and other communications hereunder or
      in connection herewith shall be in writing, shall be sent to the address
      below and shall be: (a) delivered personally; (b) sent by registered or
      certified mail, return receipt requested, postage prepaid; (c) sent via a
      reputable nationwide overnight courier service; or (d) sent by facsimile
      transmission. Any such notice, instruction or communication shall be
      deemed to have been delivered upon receipt if delivered by hand, three (3)
      Business Days after it is sent by registered or certified mail, return
      receipt requested, postage prepaid, one (1)

                                       84
<PAGE>
      Business Day after it is sent via a reputable nationwide overnight courier
      service, or when transmitted with electronic confirmation of receipt, if
      transmitted by facsimile (if such transmission is on a Business Day;
      otherwise, on the next Business Day following such transmission).

      Notices to Pfizer shall be addressed to:

                       PFIZER INC.

                       235 East 42nd Street
                       New York, New York  10017-5755
                       Attention:  President, Pfizer Pharmaceutical Group
                       Fax:  212-808-8652

      with a copy to:  Senior Vice President and General Counsel
                       Fax:  212-808-8924

      Notices to Neurocrine shall be addressed to:

                       NEUROCRINE BIOSCIENCES, INC.

                       10555 Science Center Drive
                       San Diego, California 92121-1102

                       Attention:  Chief Executive Officer and President

                       Fax:  858-658-7605

      with a copy to:  General Counsel

Either party may change its address by giving notice to the other party in the
manner provided above.

15.5  Entire Agreement. This Agreement (including Schedules), together with the
      License Agreement, contains the complete understanding of the parties with
      respect to the subject matter hereof and supersedes all prior
      understandings and writings relating to the Co-Promotion of the Products.
      None of the terms or this Agreement shall be amended, supplemented or
      modified except in writing signed by the parties hereto.

                                       85
<PAGE>
15.6  Headings. Headings in this Agreement are for convenience of reference only
      and shall not be considered in construing this Agreement. References to
      Sections and Schedules are to Sections and Schedules of this Agreement
      unless otherwise specified.

15.7  Severability. If and solely to the extent that any provision of this
      Agreement shall be invalid or unenforceable, or shall render this entire
      Agreement to be unenforceable or invalid, such offending provision shall
      be of no effect and shall not effect the validity of the remainder of this
      Agreement or any of its provisions; provided, however, the parties shall
      use their respective reasonable efforts to renegotiate the offending
      provisions to best accomplish the original intentions of the parties.

15.8  Registration and Filing of the Agreement. To the extent, if any, that a
      party concludes in good faith that it is required under applicable Laws to
      file or register this Agreement or a notification thereof with any
      Governmental Authority, including without limitation the US Securities and
      Exchange Commission, or the US Federal Trade Commission, in accordance
      with applicable Laws, such party may do so and shall provide the other
      party to this Agreement with a written copy of all proposed filings or
      registrations to allow for a reasonably sufficient time for review and
      comment by the other party. The other party shall cooperate in such filing
      or notification and shall execute all documents reasonably required in
      connection therewith. In such situation, the parties will request
      confidential treatment of sensitive provisions of the Agreement, to the
      extent permitted by Law. The parties shall promptly inform each other as
      to the activities or inquiries of any such Governmental Authority relating
      to this Agreement, and shall cooperate to respond to any request for
      further information therefrom.

15.9  Assignment. This Agreement and all rights and obligations granted
      hereunder shall not be assignable by any party without the prior consent
      of the other, except that (a) Pfizer may assign this Agreement in
      connection with a Divestiture Transaction, and (b) Pfizer may assign this
      Agreement (and after all amounts under the Loan Agreement have been paid
      in full and terminated, Neurocrine may assign this Agreement), in whole or
      in part, to any Affiliate of such party or to any successor to
      substantially all of such party's business or assets; provided, however,
      in the case of Pfizer and Neurocrine, the assigning

                                       86
<PAGE>
      party shall remain responsible for all obligations hereunder if its
      Affiliate shall fail to perform hereunder.

15.10 Successors and Assigns. This Agreement shall be binding upon and inure to
      the benefit of the parties hereto and their respective successors and
      permitted assigns.

15.11 Counterparts. This Agreement may be executed in any number of
      counterparts, each of which, when executed, shall be deemed an original
      and all of which together shall constitute one and the same instrument.

15.12 Force Majeure. In the event of strikes, lock-outs or other industrial
      disturbances, rebellions, mutinies, epidemics, landslides, lightning,
      earthquakes, fires, storms, floods, sinking, drought, civil disturbances,
      explosions, acts or decisions of duly constituted municipal, state or
      national Governmental Authorities or of courts of law, as well as
      impossibility to obtain equipment, supplies, fuel or other required
      materials, in spite of having acted with reasonable diligence, or by
      reason of any other causes, which are not under the control of the party
      requesting the abatement of performance, or causes due to unexpected
      circumstances which may not be possible to eliminate or overcome with due
      diligence by such party ("Force Majeure"), the parties agree that, if
      either of them find themselves wholly or partially unable to fulfill their
      respective obligations in this Agreement by reasons of Force Majeure, the
      party affected will advise the other party in writing of its inability to
      perform giving a detailed explanation of the occurrence of the event which
      excuses performance as soon as possible after the cause or event has
      occurred. If said notice is given, the performance of the party giving the
      notification, except for the payment of funds and except as otherwise
      expressly provided in this Agreement, shall be abated, and any time
      deadlines shall be extended, for so long as performance may be prevented
      by such event of Force Majeure. Except as otherwise expressly provided in
      this Agreement and except for the payment of funds that are due and
      payable, neither party shall be required to make up any performance that
      was prevented by Force Majeure.

15.13 Non-Solicitation of Employees. During the Co-Promotion Term, neither party
      shall, directly or indirectly, recruit, or solicit any employee of the
      other party with whom such

                                       87
<PAGE>
      party has come into contact or interacted for the purposes of performing
      this Agreement, without the prior consent of the other party, except
      pursuant to general solicitations not targeted at such employees.

15.14 Press Releases.

      (a)   Coordination. The parties agree on the importance of coordinating
            their public announcements respecting this Agreement and the subject
            matter hereof. Neurocrine and Pfizer will, from time to time, and at
            the request of the other party discuss and agree on the general
            information content relating to this Agreement and the License
            Agreement which may be publicly disclosed.

      (b)   Announcements. The joint press release announcing the signing of the
            transactions contemplated by this Agreement and the License
            Agreement is attached hereto as Schedule 15.14 and will be promptly
            disseminated following signing.

      (c)   In addition, Pfizer acknowledges that certain events related to the
            progress of the Collaboration may be material to Neurocrine and
            therefore, the parties agree to make public disclosures, whether by
            press release or publication, regarding the fact of the completion
            of Phase III Product Studies and top line data therefrom, the filing
            of an NDA, the First Approval with respect to the IR Product and the
            MR Product and the occurrence of any serious adverse events. The
            above-referenced releases may be Neurocrine releases or joint
            Neurocrine/ Pfizer releases at Pfizer's option, and the parties
            agree to jointly draft and agree on the content of such disclosure.
            Except as otherwise provided in this Section 15.14, neither party
            will make any public announcement regarding the fact of execution of
            this Agreement by the parties hereof, the terms of or events related
            this Agreement, and/or the collaboration (other than the
            peer-reviewed publications which are subject to the publication
            provisions set forth in Section 11.3) without the prior consent of
            the other. Notwithstanding the foregoing, a party may make any
            disclosure where in a party's reasonable legal opinion it is
            required by applicable Law or applicable stock exchange regulation
            or order or other ruling of

                                       88
<PAGE>
            a competent court, provided that prior to such disclosure, the
            disclosing party shall use reasonable efforts to notify the other
            party prior to making such disclosure, and will provide the other
            party with an opportunity to review and comment prior to release,
            provided the disclosing party shall not be required to delay such
            disclosures by more than forty-eight (48) hours to receive and
            discuss such comments, so long as the disclosing party has provided
            to the other party as much advance notice as is reasonably
            practicable under the circumstances. Each party agrees that it shall
            reasonably cooperate with the other with respect to all disclosures
            regarding this Agreement to the Securities Exchange Commission and
            any other governmental or regulatory agencies, including requests
            for confidential treatment of proprietary information of either
            party included in any such disclosure.

15.15 Third Party Beneficiaries. None of the provisions of this Agreement shall
      be for the benefit of or enforceable by any third party, including,
      without limitation, any creditor of either party hereto. No such third
      party shall obtain any right under any provision of this Agreement or
      shall by reason of any such provision make any claim in respect of any
      debt, liability or obligation (or otherwise) against either party hereto.

15.16 Relationship of the Parties. Each party shall bear its own costs incurred
      in the performance of its obligations hereunder without charge or expense
      to the other except as expressly provided in this Agreement. Neither party
      shall have any responsibility for the hiring, termination or compensation
      of the other party's employees or for any employee compensation or
      benefits of the other party's employees. No employee or representative of
      a party shall have any authority to bind or obligate the other party to
      this Agreement for any sum or in any manner whatsoever, or to create or
      impose any contractual or other liability on the other party without said
      party's approval. For all purposes, and notwithstanding any other
      provision of this Agreement to the contrary, Neurocrine's legal
      relationship under this Agreement to Pfizer shall be that of independent
      contractor. Nothing in this Agreement nor the License Agreement shall be
      construed to establish a relationship of partners or joint venturers
      between the parties.

                                       89
<PAGE>
15.17 Further Assurances. Following the date hereof, Neurocrine and Pfizer
      shall, and shall cause each of their respective Affiliates to, from time
      to time, execute and deliver such additional instruments, documents,
      conveyances or assurances and take such other actions as shall be
      necessary or otherwise reasonably requested by Pfizer or Neurocrine, to
      confirm and assure the rights and obligations provided for in this
      Agreement, and render effective the consummation of the transactions
      contemplated thereby provided however that neither party will be required
      under this Section 15.17 to deliver instruments, documents, conveyances or
      assurances of any third party.

               [The remainder of this page is intentionally blank]

                                       90
<PAGE>
      IN WITNESS WHEREOF, the parties have signed this Agreement as of the
date first written above.

PFIZER INC.                                  NEUROCRINE BIOSCIENCES, INC.

By: /s/ Henry A. McKinnell                 By: /s/ Gary A. Lyons
   ----------------------------------         ----------------------------------
Name:   Henry A. McKinnell                 Name:   Gary A. Lyons
     --------------------------------           --------------------------------
Title:  Chairman of the Board              Title:  President and Chief
        and Chief Executive Officer                Executive Officer
      -------------------------------            -------------------------------

                                       91<PAGE>
                                                                    EXHIBIT 10.2

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                               LICENSE AGREEMENT

         THIS LICENSE AGREEMENT, dated as of December 18, 2002 (this
"Agreement"), between NEUROCRINE BIOSCIENCES, INC. ("Neurocrine"), a corporation
organized under the laws of the State of Delaware, 10555 Science Center Drive,
San Diego, California 92121-1102, and PFIZER INC., a corporation organized under
the laws of the State of Delaware, 235 East 42nd Street, New York, New York
10017 ("Pfizer").

         WHEREAS, Neurocrine owns or may acquire certain patents and patent
applications, licenses to patents and patent applications, know-how, trade
secrets and scientific and technical information relating to a compound referred
to as NBI-34060 (indiplon); and

         WHEREAS, Pfizer desires to acquire from Neurocrine exclusive licenses
and sublicenses under said patents and licenses and related know-how, trade
secrets and scientific and technical information, and Neurocrine is agreeable to
granting such licenses and sublicenses pursuant to the terms of this Agreement.

         NOW, THEREFORE, Pfizer and Neurocrine hereby agree as follows:

                                    ARTICLE 1

1.       DEFINITIONS. Any capitalized terms used herein which are not expressly
         defined in this Agreement shall have the meaning set forth in the
         Collaboration Agreement. For purposes of this Agreement, the following
         definitions shall also be applicable:

1.01     "Acceptable Safety Profile" means data with respect to a Product that
         demonstrates that such Product is safe and well-tolerated for use in
         humans.

         [***]

1.03     "Affiliate" means any entity directly or indirectly controlled by,
         controlling, able to control, or under common control with, a party to
         this Agreement, but only for so long as such control shall continue.
         For purposes of this definition, "control" (including, with

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
correlative meanings, "controlled by", "controlling" and "under common control
with") means possession, direct or indirect, of (a) the power to direct or cause
direction of the management and policies of an entity (whether through ownership
of securities or partnership or other ownership interests, by contract or
otherwise), or (b) at least 50% of the voting securities (whether directly or
pursuant to any option, warrant or other similar arrangement) or other
comparable equity interests. For the avoidance of doubt, neither of the parties
to this Agreement shall be deemed to be an "Affiliate" of the other solely as a
result of their entering into this Agreement.

1.04     "Approval" means receipt of a final Approval Letter from FDA
         authorizing marketing and sale of Products.

1.05     "Bankruptcy Code" means 11 U.S.C Sections 101-1330, as amended.

1.06     "Code" or "Codes" means the Code on Interactions with Healthcare
         Professionals promulgated by the Pharmaceutical Research and
         Manufacturers of America (PhRMA), and the American Medical Association
         Guidelines on Gifts to Physicians, as either of the foregoing may be
         amended from time to time.

1.07     "Collaboration Agreement" means the Collaboration Agreement, dated the
         date hereof, between Neurocrine and Pfizer, as the same shall be
         amended from time to time in accordance with the terms thereof.

1.08     "Combination Product" means any Product which contains, in addition to
         the Product, one or more other therapeutically active ingredients.

1.09     "Commercially Reasonable Efforts" means those efforts and resources
         that Pfizer would use were it promoting and detailing its own
         pharmaceutical products which are of similar market potential as the
         Products, taking into account product labeling, market potential, past
         performance, economic return, the regulatory environment and
         competitive market conditions in the therapeutic area, all as measured
         by the facts and circumstances at the time such efforts are due. In
         evaluating economic return, Pfizer shall not consider payments under
         this Agreement and the Collaboration Agreement to Neurocrine.

1.10     "Compound" means indiplon (NBI-34060), as more specifically described
         as Acetamide, N-Methyl-N-[3-[3-(2-thienylcarbonyl)-pyrazol- [1,5-a]
         pyrimidin-7-yl] phenyl] in any chemical form, including without
         limitation, salts, solvates, metabolites and prodrugs.

                                       2
<PAGE>
1.11     [***]

1.12     "DOV Sublicense" means the Sub-License and Development Agreement, dated
         June 30, 1998, between DOV and Neurocrine, as amended from time to
         time.

1.13     "DOV Technical Information" means all scientific or technical
         information relating to the Compound or the Products licensed to
         Neurocrine under the DOV Sublicense, including but not limited to: (a)
         medical, clinical, toxicological or other scientific data, and (b)
         processes and analytical methodology useful in the development,
         testing, analysis, manufacture or packaging of the Compound or
         Products.

1.14     "Effective Date" means the date upon which the applicable waiting
         period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
         as amended ("HSR Act") shall have expired or been terminated, with
         respect to this Agreement and the Collaboration Agreement, as
         applicable.

1.15     "FDA" means the United States Food and Drug Administration and any
         successor agency thereto.

1.16     "Generic Competition" shall exist during a given calendar quarter with
         respect to a Product in any country in the Territory if, during such
         calendar quarter, one or more Generic Products shall be commercially
         available in such country and shall have, in the aggregate, [***] or
         more share of total sales of the aggregate of Products and Generic
         Products (based on data provided by IMS International, or if such data
         is not available, such other reliable data source as reasonably
         determined by Pfizer and agreed by Neurocrine (such agreement not to be
         unreasonably withheld) as measured by unit sales. In the event IMS
         International data (or such other agreed data source) is not sufficient
         to determine the percentage market share for each country in the EU,
         the

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3
<PAGE>
         average percent market share of the EU countries for which data is not
         available will be deemed to be the percent market share for those
         countries in which the data is available.

1.17     "Generic Products" means any pharmaceutical products (other than
         Products developed and commercialized by Pfizer pursuant to this
         Agreement) that contain principally the same active chemical
         entity(ies) as a Product and can reasonably be or are reasonably used
         for the same indication as a Product.

1.18     "Governmental Authority" means any court, agency, department or other
         instrumentality of any foreign, federal, state, county, city or other
         political subdivision.

1.19     "IR" means the immediate release formulation of the Compound as more
         specifically described on Exhibit A or any formulation with equivalent
         release characteristics.

1.20     "IR Product" means a Product with the IR formulation.

1.21     "Joint Technology" means any Technology developed or invented jointly
         by Pfizer and Neurocrine relating to the Compound or the Products
         arising out of the Development Program (as defined in the Collaboration
         Agreement).

1.22     "Key EU Country" means any of the United Kingdom, France, Germany,
         Spain or Italy.

1.23     "Launch" means, on a country by country basis, the shipping of
         commercial quantities of a Product for commercial sale to unaffiliated
         third parties.

1.24     "Law" or "Laws" means all laws, statutes, rules, Codes, regulations,
         orders, judgments and/or ordinances of any Governmental Authority.

1.25     "MR" means the modified release formulation of the Compound as more
         specifically described on Exhibit A or any formulation with an
         equivalent kinetic profile.

1.26     "MR Product" means a Product with the MR formulation.

1.27     "NDA" means a New Drug Application filed with the FDA with respect to a
         pharmaceutical product.

1.28     "Net Sales" means (a) gross sales of Pfizer, its Affiliates and
         sublicensees of Product to unaffiliated third parties in the applicable
         country, less (i) bad debts related to the Product

                                        4
<PAGE>
         and (ii) sales returns and allowances, including, without limitation,
         trade, quantity and cash discounts and any other adjustments,
         including, but not limited to, those granted on account of price
         adjustments, billing errors; rejected goods, damaged or defective
         goods, recalls, returns, rebates, chargeback rebates, fees,
         reimbursements or similar payments granted or given to wholesalers or
         other distributors, buying groups, health care insurance carriers or
         other institutions, adjustments arising from consumer discount
         programs, [***], customs or excise duties, sales tax, consumption tax,
         and other taxes (except income taxes) or duties relating to sales, and
         any payment in respect of sales to any governmental or regulatory
         authority in respect of any government-subsidized program; and (b) in
         the case of Combination Products, (aa) If Pfizer and/or its Affiliates
         separately sells in such country during such Year when it sells such
         Combination Product both (x) one or more Products as a single chemical
         entity and (y) other products containing active ingredient(s) as a
         single entity that are also contained in such Combination Product, the
         Net Sales attributable to such Combination Product during such Year
         shall be calculated [***]; (bb) if Pfizer and/or its Affiliates
         separately sells, in such country during such Year when it sells such
         Combination Product, one or more Products as a single chemical entity
         but do not separately sell, in such country, other products containing
         active ingredient(s) that are also contained in such Combination
         Product, the Net Sales attributable to such Combination Product during
         such Year shall be calculated [***];

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       5
<PAGE>
         (cc) if Pfizer and/or its Affiliates do not separately sell each
         Products contained in the Combination Product, the Net Sales
         attributable to such Combination Product shall be calculated by [***].

         With respect to the determination of Net Sales of Combination Products
         above and in considering the financial feasibility of Launching a
         Combination Product, if one or both of the parties determines that the
         formula in (aa), (bb) or (cc), as the case may be, will result in
         commercialization of the Combination Product not being economically
         feasible or equitable, the parties will meet and discuss in good faith
         adjustments or alterations to the applicable formulas above to address
         the concerns of such party(ies).

1.29     "Neurocrine Patent Rights" means all Patent Rights, now or hereafter
         during the term of this Agreement, owned, licensed or controlled by
         Neurocrine or its Affiliates that claim Compound or the Products, or
         uses, formulations, indications, compositions or methods of
         manufacturing thereof including, without limitation, the patents and
         patent applications set forth on Exhibit B. For the purpose of this
         Section 1.29, Neurocrine Patent Rights will also include [***].

1.30     "Neurocrine Technical Information" means all scientific or technical
         information and related know-how and trade secrets, now or hereafter
         during the term of this Agreement, owned or controlled by Neurocrine or
         its Affiliates relating directly to the Compound or the Products,
         including but not limited to: (a) medical, clinical, toxicological or
         other

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                        6
<PAGE>
         scientific data, (b) processes and analytical methodology used in the
         development, formulation, testing, analysis, manufacture or packaging
         of the Compound or Products, (c) uses or indications of Products and
         Product compositions, and (d) Neurocrine's interest in any Joint
         Technology.

1.31     "Patents Rights" means the rights and interest in and to all issued
         patents and pending patent applications in any country, including,
         without limitation, all divisionals, continuations, renewals,
         continuations-in-part, patents of addition, supplementary protection
         certificates, extensions, registration or confirmation patents and
         reissues thereof.

1.32     "Payment Computation Period" means each of the periods ending on each
         of the four (4) thirteen (13) week periods as used by Pfizer in filings
         with the Securities and Exchange Commission (a "Pfizer Quarter")
         commencing on January 1 of any year. For sake of clarification, outside
         the United States, Net Sales are computed for a three month period,
         which ends one month prior to the end of the relevant Pfizer Quarter.

1.33     "Pfizer Technical Information" means all scientific or technical
         information and related know-how and trade secrets owned or controlled
         during the term of this Agreement by Pfizer or its Affiliates arising
         in the course of the development of Products by Pfizer and development
         of Products by Neurocrine and Pfizer under the Collaboration Agreement,
         in each case relating directly to Compounds or Products, including but
         not limited to: (a) medical, clinical, toxicological or other
         scientific data, (b) processes and analytical methodology used in the
         development, formulation, testing, analysis, manufacture or packaging
         of the Compound or Products, (c) uses or indications of Products and
         Product compositions, and (d) Pfizer's interest in any Joint
         Technology.

1.34     "Price Approval" means, in countries where governmental or regulatory
         authorities authorize for reimbursement, or approve or determine
         pricing for pharmaceutical products for reimbursement or otherwise,
         such authorization, approval or determination.

1.35     "Products" means all pharmaceutical formulations and dosage forms,
         which contain the Compound either alone or in combination with other
         therapeutically active ingredients.

                                       7
<PAGE>
1.36     "Regulatory Authority" means any Governmental Authority with
         responsibility for granting any licenses or approvals necessary for the
         marketing and sale of pharmaceutical products including, without
         limitation, any drug regulatory authority of countries of the European
         Union, Japan and the FDA, and where the context admits any ethics
         committee or any equivalent review board.

1.37     [***].

1.38     [***] means [***] data contained in the final report of [***], that
         demonstrate that [***]; except that if FDA informs Neurocrine that data
         from a different combination of the above-listed trials or other data
         [***], data that meets such FDA requirements shall be required for
         purposes of demonstrating [***].

1.39     [***] means final FDA labeling (package insert) for the Product which
         in the indication statement reflects effective use for [***].

1.40     "Statistically Significant Difference" means [***].

1.41     "Territory" means all countries of the world, as in existence from time
         to time.

1.42.    "Technology" shall mean information and all intellectual property,
         including but not limited to, trade secrets, know-how, inventions and
         technology, whether patentable or not, and Patent Rights in each case
         directed to products, processes, formulations and/or methods but which
         term shall specifically exclude copyright and all registered and
         unregistered trademarks.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       8
<PAGE>
1.43     [***].

1.44     [***].

1.45     "Valid Claim" means any claim from an issued and unexpired patent or
         pending application (which has been pending for less than 7 years in
         Japan and for less than 5 years in any other country) included within
         the Patent Rights which has not been revoked or held unenforceable or
         invalid by a decision of a court or other Governmental Authority of
         competent jurisdiction, and which has not been disclaimed, denied or
         admitted to be invalid or unenforceable through reissue or disclaimer
         or otherwise.

1.46     "Year" means each calendar year during the term of this Agreement.

                                    ARTICLE 2

2.       LICENSES.

2.01     LICENSE. Subject to the terms of this Agreement, Neurocrine hereby
         grants to Pfizer, and Pfizer hereby accepts: (a) an exclusive license
         under the Neurocrine Patent Rights to make, have made, use, sell, offer
         for sale, import, and have imported Products in the Territory; (b) an
         exclusive license under the Neurocrine Technical Information to use in
         the Territory all Neurocrine Technical Information in connection with
         the manufacture,

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       9
<PAGE>
         use or sale of Products in the Territory; (c) with respect to the DOV
         Sublicense, an exclusive sublicense under all Patent Rights and DOV
         Technical Information licensed to Neurocrine thereunder to make, have
         made, use, sell, offer for sale, import, and/or have imported Products
         in the Territory; and (d) [***], an exclusive sublicense to the
         Compound and Licensed Product [***], to make, have made, use, sell,
         offer for sale, import and/or have imported Products in the Territory.
         It is understood and agreed that the foregoing exclusive licenses and
         exclusive sublicenses grant to Pfizer the rights enumerated to the
         exclusion of all other parties, including Neurocrine and its
         Affiliates.

2.02     LICENSE GRANT TO NEUROCRINE. Pfizer hereby grants to Neurocrine a
         non-exclusive right and license under the Pfizer Technical Information,
         Neurocrine Technical Information and Neurocrine Patent Rights to carry
         out its activities under the Development Program (as defined in the
         Collaboration Agreement).

2.03     SUBLICENSING. With respect to the licenses and sublicenses granted to
         Pfizer under Section 2.01, Pfizer shall have the right to grant
         sublicenses (a) to its Affiliates, (b) within the United States to
         non-Affiliate third parties which shall be subject to Neurocrine's
         prior approval, which approval may not be unreasonably withheld, and
         (c) outside the United States to non-Affiliate third parties. All
         sublicenses will be consistent with the terms of this Agreement and
         shall not relieve Pfizer of its obligations hereunder.

2.04     CROSS LICENSE OF TRADEMARKS. In order to enable each Party to perform
         its obligations under the Collaboration Agreement, each Party hereby
         grants to the other party a non-assignable, non-sublicensable,
         non-exclusive, royalty free right and license to use the Neurocrine
         corporate logos and trademarks, and (a) the Pfizer corporate logo and
         trademark as well as (b) Pfizer's trademarks for Products (in the case
         of (b) only, the "Pfizer Trademarks").

                                    ARTICLE 3

3.       MILESTONE PAYMENTS, LICENSE FEES AND ROYALTIES.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       10
<PAGE>
         In consideration of the licenses granted to Pfizer hereunder and the
         disclosure to Pfizer of Neurocrine Technical Information, and subject
         to the provisions of this Agreement, Pfizer shall pay to Neurocrine
         milestone payments, license fees and royalties as follows:

3.01     MILESTONE PAYMENTS AND LICENSE FEES. Subject to the terms and
         conditions of this Agreement, Pfizer shall pay to Neurocrine the
         following:

<TABLE>
<CAPTION>
                           EVENT                                   [***]   [***]
<S>                                                 <C>            <C>     <C>
         (a)  Signing of this Agreement,            $50,000,000
              subject to Section 3.03 below.
         (b)  [***]                                                [***]   [***]
         (c)  [***]                                                        [***]
         (d)  FDA Acceptance [***]                                 [***]   [***]
         (e)  FDA Approval of [***]                                [***]   [***]
         (f)  FDA Approval [***]                                   [***]   [***]
</TABLE>

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       11
<PAGE>
<TABLE>
<S>                                                      <C>      <C>      <C>
         (g)  FDA Approval [***]                                  [***]    [***]
         (h)  FDA Approval [***]                                           [***]
         (i)  1st Launch [***]                           [***]
         (j)  Launch [***]                               [***]
</TABLE>

         The parties understand and agree that each of the payments referenced
in this Section 3.01 shall only be made once, and is subject to the following
terms and conditions:

         (i)      Unless otherwise set forth below, all payments pursuant to
                  this Section 3.01 shall be made by Pfizer within twenty (20)
                  days of receipt from Neurocrine of notice of achievement
                  (together with supporting documentation) of the applicable
                  event referenced above; provided, however, with respect to the
                  events referenced in Section 3.01 (b), or (c), which payment
                  shall be made within twenty (20) days of Pfizer's confirmation
                  that the applicable event has been achieved which confirmation
                  shall be provided or withheld in its reasonable discretion
                  (and if withheld, the reasons therefore provided to
                  Neurocrine), within twenty (20) days following Pfizer's
                  receipt of the applicable final study report(s)).

         (ii)     With respect to the events and payments referenced in Section
                  3.01 (b) or (c), if Pfizer reasonably believes such events
                  have not been satisfied or met, Pfizer shall be entitled to
                  refrain from paying the applicable amount unless and until
                  [***],

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       12
<PAGE>
                  as the case may be, pursuant to Section 4.3 of the
                  Collaboration Agreement, at which time Pfizer shall pay the
                  applicable milestone amount.

         (iii)    With respect to the events and payments referenced in Section
                  3.01(d), [***] in Section 4.3(c) of the Collaboration
                  Agreement (except to the extent that neither party may object
                  to such filing as provided therein), is a condition to payment
                  of such milestone

         (iv)     With respect to the events and payments referenced in Section
                  3.01(e), mutual agreement on [***] in Section 4.3(d) of the
                  Collaboration Agreement [***], is a condition to payment of
                  such milestone.

3.02     ROYALTIES.

   (a)   Subject to the terms and conditions of this Agreement, Pfizer shall pay
         royalties to Neurocrine based on Net Sales on a country by country
         basis in accordance with the following:

         (i)      With respect to Net Sales of Product in the United States, a
                  royalty equal to the sum of (A) [***] of such Net Sales in
                  consideration of Neurocrine Patent Rights if the Product sold
                  is embraced within any Valid Claim under Neurocrine Patent
                  Rights in the United States, (B) [***] of such Net Sales in
                  consideration of, and during any period of, product
                  exclusivity for new chemical entities (as provided for in 21
                  C.F.R. 314.108(b)) for the Product in the United States, and
                  (C) [***] of such Net Sales in consideration of Neurocrine
                  Technical Information for a period equal to [***] following
                  Launch of the first Product; provided, however, that in no
                  event may the sum of (A), (B) and (C) exceed a [***] royalty;

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       13
<PAGE>
         (ii)     With respect to Net Sales of Product in Japan, a royalty of
                  [***] of such Net Sales in consideration of Neurocrine Patent
                  Rights and Neurocrine Technical Information for a period equal
                  to the longer of (A) [***] following Launch of the first
                  Product in Japan, and (B) such date the Product is no longer
                  embraced within any Valid Claim under Neurocrine Patent Rights
                  in Japan; and

         (iii)    With respect to Net Sales of Product in each country of the
                  Territory other than the United States and Japan, a royalty of
                  [***] of such Net Sales in consideration of Neurocrine Patent
                  Rights and Neurocrine Technical Information for a period in
                  each such country equal to the longer of (A) [***] following
                  Launch of the first Product in such country, and (B) such date
                  the Product is no longer embraced within any Valid Claim under
                  Neurocrine Patent Rights in such country.

         After the expiration of the above-referenced payment periods with
         respect to Neurocrine Technical Information, Pfizer, its Affiliates and
         sublicensees shall have a fully paid-up non-exclusive license with
         regard to Neurocrine Technical Information for use in such country.

   (b)   (i)      If, during a given calendar quarter, there is Generic
                  Competition in any country in the Territory, then, for each
                  such country in which there is Generic Competition, the
                  royalties on Neurocrine Patent Rights and Neurocrine Technical
                  Information payable to Neurocrine for the Net Sales of such
                  Product in such country during such calendar quarter will be
                  reduced by [***].

         (ii)     [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       14
<PAGE>
   (c)   [***].

3.03     HSR. Promptly following signing of this Agreement and the Collaboration
         Agreement, Pfizer and Neurocrine will take (i) all actions necessary to
         make the filing required under the Hart-Scott-Rodino Act ("HSR Act"),
         and (ii) reply at the earliest possible date with any requests for
         information received from the Federal Trade Commission ("FTC") or
         Antitrust Division of the Department of Justice ("DoJ") pursuant to the
         HSR Act. The parties will, to the extent reasonably practicable,
         consult with one another prior to making any filings, responses to
         inquiries or other contacts with the FTC or DoJ concerning the
         transactions contemplated hereby. Payment of the signing fees in
         Section 3.01(a) and Section 8.4(a) of the Collaboration Agreement may
         be deferred until such time as Pfizer receives notice of clearance from
         the FTC or DoJ until the waiting period (and any extension thereof)
         applicable to this Agreement under the HSR Act shall have been
         terminated or shall have expired, at which time Pfizer shall pay within
         ten (10) days such signing fees, plus interest thereon from the date
         that is twenty (20) days after signing of this Agreement to the date of
         payment, at the one year U.S. dollar LIBOR rate as published in The
         Financial Times effective for the date on which this Agreement was
         signed, and computed on an actual/360 basis.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       15
<PAGE>
                                    ARTICLE 4

4.       ACCOUNTING, PROCEDURES FOR PAYMENTS, AND REPORTS.

         Payments hereunder shall be subject to the following provisions:

4.01     Sales between or among Pfizer, its Affiliates or sublicensees shall not
         be subject to royalties under Article 3; royalties shall only be
         calculated upon Net Sales to an independent third party. Pfizer shall
         be responsible for payments on Net Sales by its Affiliates or
         sublicensees.

4.02     Pfizer shall make royalty payments to Neurocrine on Net Sales with
         respect to each Payment Computation Period within thirty (30) days
         after the end of each such period, and each payment shall be
         accompanied by a report, on a country-by-country basis, identifying the
         Product, gross sales, Net Sales, the specific deductions used in
         arriving at Net Sales, the amount of royalties payable to Neurocrine,
         and the deductions contained in the definition of "Net Sales" in the
         DOV Sublicense. In addition, upon any termination of the Collaboration
         Agreement where this Agreement does not terminate, Pfizer shall forward
         to Neurocrine the information listed on Exhibit C. Said reports shall
         be kept confidential by Neurocrine and not disclosed by Neurocrine to
         any party other than DOV, ACY and their respective accountants,
         officers and Boards of Directors (solely to the extent Neurocrine in
         its good faith opinion believes it is obligated to make any such
         disclosure under the terms of the DOV Sublicense), and Neurocrine
         covenants that Neurocrine, and shall use reasonable efforts to insure
         that DOV and ACY, and its or their respective accountants, officers and
         Board members shall be obligated to keep such information confidential
         and such information and reports shall only be used for the purposes of
         determining payments under this Agreement.

4.03     All payments made hereunder shall be made in U.S. Dollars and shall be
         made by electronic transfer in immediately available funds via either a
         bank wire transfer, an ACH (automated clearing house) mechanism, or any
         other means of electronic funds transfer, at Pfizer's election, to such
         bank account as Neurocrine shall designate in writing at least five (5)
         business days before the payment is due. For the purposes of
         determining the

                                       16
<PAGE>
         amount of royalties due for the relevant Payment Computation Period,
         the amount of Net Sales in any foreign currency shall be computed by
         (a) converting such amount for the relevant Payment Computation Period
         into U.S. dollars at the Average Exchange Rate for the Payment
         Computation Period (the "Average Exchange Rate" means, for each Payment
         Computation Period for each currency in which Products sales to third
         parties are denominated, the average of the prevailing commercial rate
         of exchange for purchasing U.S. Dollars with such currency on the last
         Business Day of each Pfizer accounting period in the relevant Pfizer
         Quarter as published in The Wall Street Journal), and (b) deducting the
         amount of any governmental tax, duty, charge or other fee actually paid
         by Pfizer or its Affiliates in respect of such conversion into and
         remittance of U.S. dollars. All payments under this Agreement shall
         bear interest from the date due until paid at a rate equal to the prime
         rate of Citibank, NA as announced on the date such payment was due plus
         two percent (2%).

4.04     All payments under this Agreement will be made without any deduction or
         withholding for or on account of any tax unless such deduction or
         withholding is required by applicable law or regulations. If the paying
         party is so required to deduct or withhold such party will (i) promptly
         notify the other party of such requirement, (ii) pay to the relevant
         authorities the full amount required to be deducted or withheld
         promptly upon the earlier of determining that such deduction or
         withholding is required or receiving notice that such amount has been
         assessed against the other party, (iii) promptly forward to the other
         party an official receipt (or certified copy) or other documentation
         reasonably acceptable to the other party evidencing such payment to the
         authorities. In case the other party can not take a full credit against
         its tax liability for the withholding tax deducted or withheld by the
         paying Party, then such other party may propose a change to the then
         current arrangement with respect to the flow of moneys under this
         Agreement in order to reduce or eliminate the extra cost for any party
         and the parties, with no obligation as to outcome, shall discuss such
         proposal in good faith.

4.05     Pfizer shall, and shall cause its Affiliates and sublicensees to, keep
         full and accurate books and records setting forth, on a
         country-by-country basis, gross sales, Net Sales, the specific
         deductions in arriving at Net Sales, and royalties payable to
         Neurocrine. Pfizer

                                       17
<PAGE>
         shall permit Neurocrine, at Neurocrine's sole expense (or ACY or DOV at
         their expense) by independent qualified public accountants employed by
         Neurocrine (or by ACY or DOV, as the case may be) and acceptable to
         Pfizer, to examine such books and records at any reasonable time, but
         not later than five (5) years following the rendering of any such
         reports, accountings and payments. The foregoing right of ACY and DOV
         to authorize such examination shall be subject to the good faith legal
         judgment by counsel to Neurocrine that is legally entitled thereto
         under the terms of the DOV Sublicense. The foregoing right of review
         may be exercised only once by Neurocrine with respect to any such
         periodic report and payment. Such accountants may be required by Pfizer
         to enter into a reasonably acceptable confidentiality agreement, and in
         no event shall such accountants disclose to Neurocrine, DOV or ACY any
         information other than such as relates to the accuracy of reports and
         payments made or due hereunder. The opinion of said independent
         accountants regarding such reports, accountings and payments shall be
         binding on the parties hereto. In the event any payment by Pfizer shall
         prove to have been incorrect by more than five percent (5%) to
         Neurocrine's detriment, Pfizer will pay the reasonable fees and costs
         of the independent auditor(s) for conducting such audit.

4.06     If at any time conditions or legal restrictions exist which conditions
         or restrictions prevent the prompt remittance of the royalties due
         hereunder, or if conversion into United States Dollars pursuant to the
         provisions of Section 4.03 hereof cannot be effectuated, the parties
         shall cooperate fully with each other and make reasonable efforts to
         permit such remittance; if such efforts shall be unsuccessful, Pfizer,
         its Affiliates or sublicensees shall then, as long as such conditions
         or restrictions shall exist in such countries, pay the royalties in the
         currency of the country of sale to such person, company or bank in said
         country, as shall be nominated by Neurocrine.

4.07     In consideration for Pfizer lending or causing one or more of its
         Affiliates to loan proceeds and make other advances of credit pursuant
         to the Secured Loan Agreement, dated as of the date hereof, (the "Loan
         Agreement") by and between Neurocrine and Pfizer, Neurocrine hereby
         acknowledges and agrees that Pfizer shall, in the event a default shall
         have occurred and is continuing after any applicable cure period, be
         entitled, in its absolute and sole discretion, to offset, in part or in
         full, from time to time, any and all

                                       18
<PAGE>
         amounts due and unpaid by Pfizer under this Agreement against any and
         all amounts due and unpaid under the Loan Agreement.

4.08     In the event the Collaboration Agreement terminates, on a quarterly
         basis Pfizer shall provide to Neurocrine a report summarizing Pfizer's
         developmental, regulatory, manufacturing and commercialization
         activities with respect to the Products. Pfizer also agrees to provide
         quarterly to Neurocrine the information set forth on Exhibit C hereto.

                                    ARTICLE 5

5.       TECHNICAL AND OTHER INFORMATION.

5.01     Promptly following the Effective Date, and thereafter periodically
         during the term of this Agreement (periodically shall mean, except as
         otherwise provided in the Collaboration Agreement, at least quarterly),
         (a) Neurocrine shall provide to Pfizer reports disclosing all
         Neurocrine Technical Information not previously disclosed (it being
         understood between the parties that upon completion of the Registration
         Program (as defined in the Collaboration Agreement) it is unlikely that
         Neurocrine will conduct any research or development activities with
         respect to Compound or Products and it is therefore, unlikely that any
         new Neurocrine Technical Information will arise thereafter), and (b) so
         long as the Collaboration Agreement shall remain in effect, Pfizer
         shall provide to Neurocrine reports disclosing all Pfizer Technical
         Information not previously disclosed. For so long as the Collaboration
         Agreement is in effect the reports by each party shall be done through
         reports of the Committees. Each report will be in the format and in the
         level of detail as shall be agreed between the parties. All Neurocrine
         Technical Information and Pfizer Technical Information heretofore
         disclosed by each to the other shall be deemed to have been disclosed
         pursuant to this Agreement and shall be subject to the provisions of
         this Agreement, including but not limited to this Section 5.

                                       19
<PAGE>
5.02     Until the earlier of (a) expiration of this Agreement, and (b) if this
         Agreement is terminated prior to expiration, [***] following such
         termination, each party shall maintain Confidential Information (as
         defined in Section 5.03) of the other party in confidence, and shall
         not disclose, divulge or otherwise communicate such Confidential
         Information to others or use it for any purpose other than as permitted
         under this Agreement or in connection with the development,
         manufacture, marketing, promotion, distribution or sale of the Products
         pursuant to this Agreement or the Collaboration Agreement, and each
         party agrees to exercise its reasonable efforts to prevent and restrain
         the unauthorized disclosure of such Confidential Information by any of
         its directors, officers, employees, consultants, subcontractors,
         licensees or agents.

5.03     For purposes of this Article 5, "Confidential Information" means all
         materials, trade secrets or other information, including without
         limitation, any data, proprietary information and materials (whether or
         not patentable, or protectable as a trade secret) regarding a party's
         technology, Products, business information or objectives, which is
         disclosed in writing by a party to the other party and which is
         designated as confidential by the disclosing party. All information
         disclosed prior to the Effective Date by Neurocrine to Pfizer under or
         pursuant to the confidentiality agreement between the parties dated
         February 24, 2002 as amended, shall be deemed "Confidential
         Information" of Neurocrine. There shall be excluded from the foregoing
         definition of Confidential Information such information or data which:

                  (i)      was known by the receiving party prior to its date of
                           disclosure to the receiving party as shown by the
                           receiving party's written records; or

                  (ii)     either before or after the date of the disclosure to
                           the receiving party is lawfully disclosed to the
                           receiving party by third parties not in violation of
                           any obligation to the other party; or

                  (iii)    either before or after the date of the disclosure to
                           the receiving party becomes published or generally
                           known to the public through no fault or omission on
                           the part of the receiving party or its Affiliates; or

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       20
<PAGE>
            (iv)  is independently developed by or for the receiving party
                  without reference to or reliance upon the Confidential
                  Information; or

            (v)   is required to be disclosed by the receiving party to comply
                  with applicable Laws, to defend or prosecute litigation or to
                  comply with governmental regulations, provided that the
                  receiving party provides prior notice of such disclosure to
                  the other party and takes reasonable and lawful actions to
                  avoid and/or minimize the degree of such disclosure.

5.04  PUBLIC ANNOUNCEMENTS.

      (a)   Coordination. The parties agree on the importance of coordinating
            their public announcements respecting this Agreement and the subject
            matter thereof. Neurocrine and Pfizer will, from time to time, and
            at the request of the other party discuss and agree on the general
            information content relating to this Agreement and the Collaboration
            Agreement which may be publicly disclosed.

      (b)   Announcements. The joint press release announcing the signing of the
            transactions contemplated by this Agreement and the Collaboration
            Agreement is attached to the Collaboration Agreement as Schedule
            15.14 thereto and will be promptly disseminated following signing.

      (c)   In addition, Pfizer acknowledges that certain events related to the
            progress of the collaboration contemplated hereunder and under the
            Collaboration Agreement may be material to Neurocrine and therefore
            the parties agree to make public disclosures, whether by press
            release or publication, regarding the fact of the completion of
            Phase III Product Studies and top line data therefrom, the filing of
            an NDA, the First Approval with respect to the IR Product and the MR
            Product, and the occurrence of any serious adverse events. These
            releases may be Neurocrine releases or joint Neurocrine/ Pfizer
            releases at Pfizer's option, and the parties agree to jointly draft
            and will agree on the content of such disclosure. Except as
            otherwise provided in this Section 5.04, neither party will make any
            public announcement regarding this Agreement and/or the
            collaboration (other

                                       21
<PAGE>
            than the peer-reviewed publications which are subject to the
            publication provisions set forth in Section 11.3 of the
            Collaboration Agreement).

      Notwithstanding the foregoing, a party may make any disclosure where in
      such party's reasonable legal opinion it is required by applicable Law or
      applicable stock exchange regulation or order or other ruling of a
      competent court, provided that prior to such disclosure, the disclosing
      party shall use reasonable efforts to notify the other party prior to
      making such disclosure, and will provide the other party with an
      opportunity to review and comment prior to release provided the disclosing
      party shall not be required to delay any such disclosure by more than
      forty-eight (48) hours to receive and discuss comments, so long as the
      disclosing party has provided to the other party as much advance notice as
      is reasonably practicable under the circumstances. Each party agrees that
      it shall reasonably cooperate with the other with respect to all
      disclosures regarding this Agreement to the Securities Exchange Commission
      and any other governmental or regulatory agencies, including requests for
      confidential treatment of proprietary information of either party included
      in any such disclosure.

5.05  The confidentiality obligations of the parties under this Section 5 shall
      be applicable to such parties, as well as their respective Affiliates,
      employees, directors, agents, independent contractors and consultants.

                                    ARTICLE 6

6.    PATENTS.

6.01  Neurocrine and Pfizer shall cooperate in connection with the continued
      prosecution and maintenance by Neurocrine of the Neurocrine Patent Rights
      listed on Exhibit B [***]. Pfizer shall pay all reasonable and customary
      expenses, including all reasonable fees for patent counsel, incurred by
      Neurocrine in connection with annuities and other routine maintenance for
      Neurocrine Patent Rights in the Territory. Neurocrine shall not abandon
      any Neurocrine Patent Rights without at least ninety (90) days' prior
      notice of such abandonment to Pfizer. If

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       22
<PAGE>
      Neurocrine decides to abandon a Neurocrine Patent, Pfizer shall have the
      option to obtain ownership of such Neurocrine Patent and related
      applications free of charge and to continue the prosecution and
      maintenance of such Neurocrine Patent and related applications in its own
      name and at its expense. If Pfizer desires that Neurocrine file any
      application for a patent in specific countries other than those enumerated
      in Exhibit B hereto, or file any patent applications on improvements and
      variations upon inventions disclosed in the Neurocrine Patent Rights or
      otherwise relating to the Compound or the Products, Pfizer shall advise
      Neurocrine of such countries or improvements, variations or inventions, as
      the case may be. Neurocrine shall thereupon file patent applications as
      requested, and Pfizer shall pay reasonable expenses, including reasonable
      fees for patent counsel, for filing and prosecuting such requested patent
      applications. Pfizer shall have reasonable access to all documentation,
      filings and communications to or from the respective patent offices and
      shall be kept fully advised as to the status of all pending applications
      to the extent pertaining to the Compound or any Products. Neurocrine, its
      agents and attorneys will give due consideration to all suggestions and
      comments of Pfizer regarding any aspect of such patent prosecutions. In
      addition, Neurocrine shall take all necessary steps and pay all expenses
      necessary to maintain for the full life thereof all Neurocrine Patent
      Rights, except that Pfizer shall pay expenses as provided above. [***].

6.02  If Pfizer (a) reasonably determines in good faith with respect to any
      country in the Territory that, in order to avoid infringement of any
      patent not licensed hereunder, it is reasonably necessary to obtain a
      license in order to make, use, sell, offer for sale or import IR or MR
      Product and to pay a royalty or other payment under such license
      (including, without limitation, in connection with settlement of a patent
      infringement claim), or (b) shall be subject to a final court or other
      binding order or ruling requiring the payment of a royalty or other
      payment to a third party patent holder in respect of sales of any Product,
      then the amount of Pfizer's royalty payments under Section 3.02 with
      respect to Net Sales in such country shall be reduced by the lesser of (i)
      [***] of the amount of the royalty paid under such other license or (ii)
      [***] of the sum of the amounts payable by Pfizer under Section 3.02(a)
      hereof and Section 8.2(a) of the Collaboration Agreement

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       23
<PAGE>
      with respect to each such country, provided, however, in no event shall
      royalty reduction under this Section 6.02, when aggregated with any
      reduction in royalties due to Section 3.02(b), result in Pfizer paying
      royalties under Section 3.02(a)(i) and Section 8.2 (a) of the
      Collaboration Agreement of less than [***] in the United States, and
      royalties under Section 3.02(a) (ii) or (iii), as applicable, of less than
      [***] when Generic Competition exists or [***] when no Generic Competition
      exists, in each case with respect to all other countries in the Territory.

6.03  If any third party shall in the reasonable opinion of either party, within
      any country in the Territory, infringe any Neurocrine Patent Rights, the
      party learning of such infringement shall promptly notify the other party
      and provide it with any available evidence of such possible infringement.
      Pfizer shall have the exclusive right to bring suit and to take action
      against any infringer of the Neurocrine Patents in its own name, or in the
      name of Neurocrine where necessary, in which case Pfizer shall control the
      prosecution of any such suit or claim, including without limitation the
      choice of counsel, and shall have the exclusive right to settle or dispose
      of any such suit or claim. In this connection it is understood, without
      limitation, that Pfizer shall have the unlimited right, with prior
      consultation with Neurocrine, to commence an action for infringement of
      any Neurocrine Patent within the forty-five (45) day period described in
      Act (as defined in the Collaboration Agreement) against any applicant for
      approval to sell a drug product in the United States which applicant makes
      a certification, of the type referred to in section 505 (b) of the Act, to
      the effect that any Neurocrine Patent is invalid or not infringed by the
      drug product for which such applicant is seeking approval. Neurocrine
      shall, at Pfizer's request, take all action reasonably necessary to assist
      in any such suit, including joining as a party. In the event Pfizer shall
      exercise its right to bring suit against any such infringer, Pfizer shall
      bear the entire costs of such suit; provided, however, that if Neurocrine
      is a party to any such suit and decides to be represented by its own
      counsel, it shall be responsible for the fees of such counsel. The
      proceeds of any recovery, court award or settlement of such action shall
      first be applied to reimburse the parties for the costs and expenses of
      such prosecution and the balance shall be paid [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       24
<PAGE>
6.04  In case any actions, claims, demands, suits or other legal proceedings
      ("Patent Claims") are brought or threatened to be brought against Pfizer
      by a third party for infringement of such third party's patent(s) relating
      to Product by virtue of Pfizer's manufacture, use, sale or offer for sale
      of the Product hereunder, Pfizer shall notify Neurocrine forthwith of the
      threat or existence of such actions with sufficient evidence thereof, to
      enable the parties to prepare an appropriate defense strategy. The parties
      shall consult together as to the action to be taken and as to how the
      defense will be handled. Each party shall be entitled to participate in
      the defense of Patent Claims and to be represented in such matters by
      counsel of its choice. Each party shall be responsible for the fees of its
      counsel. Subject to the other terms of this Section 6.04, Pfizer shall
      have the right to manage the defense of Patent Claims consistent with this
      Article 6.

                                    ARTICLE 7

7.    REPRESENTATIONS, WARRANTIES AND COVENANTS.

7.01  Neurocrine Representations and Warranties. Neurocrine hereby represents
      and warrants, as of the date hereof, to Pfizer as follows:

(a)         To Neurocrine's knowledge and except as disclosed to Pfizer in
            Exhibit B, the issued patents encompassed within Neurocrine's Patent
            Rights are valid and enforceable patents, no third party is
            infringing any such patents and the manufacture, use, sale, offer
            for sale or importation by Pfizer or Neurocrine of Compound or
            Product does not and will not infringe any issued patents of third
            parties, or patent applications which would, if issued, infringe the
            rights of any third party. Neurocrine has furnished to Pfizer all
            material information in its possession requested by Pfizer as to the
            foregoing. Except as listed on Exhibit B [***] of all Neurocrine
            Patent Rights and all Neurocrine Technical Information, and no other
            person, firm, corporation or other entity has any right, interest or
            claim in or to, and Neurocrine has not entered into any agreement
            granting any right, interest or claim in or to, the Neurocrine
            Patent Rights or Neurocrine Technical Information

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       25
<PAGE>
            [***]. Exhibit E contains a complete list of all agreements
            presently in effect in connection with the development and
            manufacture of Products. Exhibit B contains a complete and correct
            list of all patents and patent applications in the Territory owned
            by or licensed to Neurocrine or any of its Affiliates (and
            indicating which are owned and which are licensed) relating to the
            manufacture, use, sale, offer for sale or importation of the
            Compound or any Product. Neurocrine or its Affiliates own or possess
            adequate licenses or other valid rights to use all patents, patent
            rights and know-how (collectively, "Intellectual Property")
            reasonably believed by Neurocrine as necessary to manufacture the
            Products in the Territory, and to distribute, use and sell the
            Products in the Territory, all free of any lien, encumbrance,
            liability or other restriction [***].

      (b)   Neurocrine has heretofore disclosed to Pfizer all material
            information, known to it or its Affiliates, with respect to (i) the
            safety or efficacy of the Compound or the Product or (ii) [***].

      (c)   Neurocrine has the corporate power and authority to execute and
            deliver this Agreement, the Collaboration Agreement and [***] and to
            perform its obligations hereunder and thereunder, and the execution,
            delivery and performance of this Agreement, the Collaboration
            Agreement and [***] by Neurocrine have been duly and validly
            authorized and approved by proper corporate action on the part of
            Neurocrine, and Neurocrine has taken all other action required by
            law, its certificate of incorporation or by-laws or any agreement to
            which it is a party or to which it may be subject required to
            authorize such execution, delivery and performance (other than
            compliance with all applicable requirements of the HSR Act).
            Assuming due authorization, execution and delivery on the part of
            Pfizer [***], each of this Agreement and the Collaboration Agreement
            and [***] constitutes a legal, valid and binding obligation of
            Neurocrine, enforceable against Neurocrine in accordance with its

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       26
<PAGE>
            respective terms, except as such enforceability may be limited by
            bankruptcy, insolvency, reorganization, moratorium and similar laws
            relating to or affecting creditors generally or by general equitable
            principles (regardless of whether such enforceability is considered
            in a proceeding in equity or at law).

      (d)   The execution and delivery of this Agreement, the Collaboration
            Agreement and [***] by Neurocrine and the performance by Neurocrine
            contemplated hereunder and thereunder will not violate any
            ordinance, law, decree or government regulation or any order of any
            court or other governmental department, authority, agency or
            instrumentality therein.

      (e)   Except for filings pursuant to the HSR Act, neither the execution
            and delivery of this Agreement or the Collaboration Agreement or
            [***] nor the performance hereof or thereof by Neurocrine requires
            Neurocrine to obtain any permits, authorizations or consents from
            any governmental body or from any other person, firm or corporation,
            and such execution, delivery and performance will not result in the
            breach of or give rise to any termination of any agreement or
            contract to which (i) Neurocrine may be a party which relates to the
            Neurocrine Patent Rights, Neurocrine Technical Information, the
            Compound or the Product or (ii) [***] which relates to the
            Neurocrine Patent Rights, Neurocrine Technical Information, the
            Compound or the Product.

      (f)   There is no action, claim, demand, suit, proceeding, arbitration,
            grievance, citation, summons, subpoena, inquiry or investigation of
            any nature, civil, criminal, regulatory or otherwise, in law or in
            equity, pending or relating to or, to Neurocrine's knowledge,
            threatened against Neurocrine, or, to Neurocrine's knowledge, any
            action, claim, demand, suit, proceeding, arbitration, grievance,
            citation, summons, subpoena, inquiry or investigation of any nature,
            civil, criminal, regulatory or otherwise, in law or equity, pending
            or relating to or threatened [***], in each case in connection with
            the Compound, the Product or any Neurocrine Patent Rights or

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       27
<PAGE>
            Neurocrine Technical Information or against or relating to the
            transactions contemplated by this Agreement or the Collaboration
            Agreement.

      (g)   [***], there are no agreements to which Neurocrine or any of its
            Affiliates is a party pursuant to which Neurocrine or any of its
            Affiliates has a license, or an option to obtain a license, or holds
            an immunity from suit, with respect to patents which (i) are
            pending, applied for, granted or registered, and (ii) but for
            Neurocrine's rights under such agreements, could be asserted by
            third parties to be infringed by the manufacture, distribution, use,
            sale, offer for sale or importation of the Products in the
            Territory. Neurocrine has previously disclosed and provided complete
            copies to Pfizer of all of Neurocrine's agreements with any third
            parties regarding supply and manufacture of all goods and services
            relating to the Compound and the Products, none of which have been
            modified, supplemented or amended.

      (h)   [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       28
<PAGE>
      (i)   Exhibit E sets forth all sources of funding, grants or loans
            Neurocrine has received and, [***] in connection with the discovery,
            research and development of the Compound and any Product.

      (j)   Exhibit F sets forth a complete and accurate listing of all
            pre-clinical and clinical studies, together with the dates and brief
            descriptions of such studies, previously or currently undertaken or
            sponsored by Neurocrine, [***] and their respective Affiliates and
            by any third-party investigator with any contact with Neurocrine,
            [***], data and reports relating to which true and complete copies
            have been previously provided to Pfizer. Neurocrine has heretofore
            disclosed to Pfizer all material correspondence and contact
            information between Neurocrine and the FDA and other Regulatory
            Authorities regarding the Compound and the Products, [***] and FDA
            and other Regulatory Authorities relating thereto.

      (k)   No person owns fifty percent (50%) or more of the voting securities
            of Neurocrine. Neurocrine has no subsidiaries other than
            subsidiaries whose financial statements are reported on a
            consolidated basis with Neurocrine.

      For purposes of this Section 7.01, "to Neurocrine's knowledge" shall mean
to Neurocrine's knowledge after reasonable due inquiry.

7.02  Pfizer Representations and Warranties. Pfizer hereby represents and
      warrants, as of the date hereof, to Neurocrine as follows:

      (a)   Pfizer has the corporate power and authority to execute and deliver
            this Agreement and the Collaboration Agreement and to perform its
            obligations hereunder and thereunder, and the execution, delivery
            and performance of this Agreement and the Collaboration Agreement by
            Pfizer have been duly and validly authorized and approved by proper
            corporate action on the part of Pfizer, and Pfizer has taken all

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       29
<PAGE>
            other action required by law, its certificate of incorporation or
            by-laws or any agreement to which it is a party or to which it may
            be subject required to authorize such execution, delivery and
            performance (other than compliance with all applicable requirements
            of the HSR Act). Assuming due authorization, execution and delivery
            on the part of Neurocrine, each of this Agreement and the
            Collaboration Agreement constitutes a legal, valid and binding
            obligation of Pfizer, enforceable against Pfizer in accordance with
            its respective terms, except as such enforceability may be limited
            by bankruptcy, insolvency, reorganization, moratorium and similar
            laws relating to or affecting creditors generally or by general
            equitable principles (regardless of whether such enforceability is
            considered in a proceeding in equity or at law).

      (b)   The execution and delivery of this Agreement and the Collaboration
            Agreement and the performance by Pfizer contemplated hereunder and
            thereunder will not violate (subject to obtaining appropriate
            governmental health, pricing and reimbursement approvals) any state,
            federal or other statute or regulation or any order of any court or
            other governmental department, authority, agency or instrumentality
            therein.

      (c)   There is no action, claim, demand, suit, proceeding, arbitration,
            grievance, citation, summons, subpoena, inquiry or investigation of
            any nature, civil, criminal, regulatory or otherwise, in law or in
            equity, pending or relating to or, to the knowledge of Pfizer,
            threatened against Pfizer in connection with or relating to the
            transactions contemplated by this Agreement or the Collaboration
            Agreement, and assuming the accuracy of the representations and
            warranties of Neurocrine contained herein Pfizer is unaware and has
            no reason to be aware of any basis for the foregoing.

      (d)   Except for filings pursuant to the HSR Act, neither the execution
            and delivery of this Agreement or the Collaboration Agreement nor
            the performance hereof or thereof by Pfizer requires Pfizer to
            obtain any permits, authorizations or consents from any governmental
            body, (subject to obtaining all necessary governmental

                                       30
<PAGE>
            approvals with respect to the manufacture, use, sale, offer for sale
            or importation of the Product) or from any other person, firm or
            corporation and such execution, delivery and performance will not
            result in the breach of or give rise to any termination of any
            agreement or contract to which Pfizer may be a party, except that
            may reasonably be expected to adversely affect the ability to
            perform its obligations under this Agreement.

7.03  Covenants.

      (a)   Neurocrine covenants and agrees with Pfizer that Neurocrine shall
            maintain the [***] in good standing and shall not take any actions
            (or omit or fail to take any actions) which would result in a [***].
            Neurocrine agrees that (i) it shall not amend, modify or supplement
            the [***] or (ii) agree to or consent to any amendment, modification
            or supplement to the [***], in such case without the consent of
            Pfizer. In addition, Neurocrine shall not sell, assign, convey,
            pledge, hypothecate or otherwise transfer the [***] or Neurocrine's
            rights or obligations thereunder, or otherwise make any commitments
            in a manner that conflicts with Pfizer's rights hereunder without
            the consent of Pfizer. Neurocrine shall immediately notify Pfizer
            upon receipt by Neurocrine or its Affiliates of any notice from
            [***], or otherwise take any action which may affect Pfizer's rights
            under this Agreement.

      (b)   Pfizer agrees to cooperate with Neurocrine in connection with
            Neurocrine's [***] and will provide what NBI reasonably believes is
            required, provided, however, Pfizer shall have no obligations or
            liabilities under the [***].

      (c)   Pfizer covenants and agrees that it will use Commercially Reasonable
            Efforts to develop and commercialize the Product in the Territory,
            subject to the provisions of the Collaboration Agreement.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       31
<PAGE>
                                    ARTICLE 8

8.    TERM. Subject to Section 9.01, this Agreement shall be effective as of the
      Effective Date and shall remain in effect for so long as Pfizer is
      obligated to make payments under Section 3 hereof, unless earlier
      terminated as provided herein.

                                    ARTICLE 9

9.    EFFECTIVENESS AND TERMINATION.

9.01  Effectiveness.

      (a)   Notwithstanding to the contrary any of the provisions of this
            Agreement but subject to Section 9.01(b) below, this Agreement shall
            only become effective upon the Effective Date, and prior to the
            Effective Date neither Neurocrine nor Pfizer shall have any rights
            or obligations hereunder.

      (b)   Effective immediately as of the date first written above, Neurocrine
            covenants and agrees that it will not negotiate, engage in or
            otherwise enter into any one or more transactions involving (i) any
            sale or grant of any rights to any Neurocrine Patent Rights or
            Neurocrine Technical Information (including without limitation any
            licenses or sublicenses), or (ii) any joint venture, co-promotion or
            similar relationship involving any Neurocrine Patent Rights or
            Neurocrine Technical Information. Effective immediately as of the
            date first written above, each of Pfizer and Neurocrine covenant and
            agree that Article 11 shall be in full force and effect. The parties
            understand and agree that the obligations set forth in this Section
            9.01(b) shall terminate on the 90th day following the date of this
            Agreement if, but only, if the Effective Date has not occurred on or
            before such 90th day (other than liability with respect to any
            breaches prior to such 90th day under this Section 9.01(b) which
            shall survive such termination).

                                       32
<PAGE>
9.02  Termination For Breach.

      (a)   (i)   If either Pfizer or Neurocrine materially breaches or
                  materially defaults in the performance or observance of any of
                  the provisions of this Agreement, and such material breach or
                  material default is not cured within ninety (90) days or, in
                  the case of failure to pay any amounts due hereunder sixty
                  (60) days, after the giving of notice by the other party
                  specifying such breach or default, the other party shall have
                  the right to terminate this Agreement in full upon a further
                  thirty (30) days' notice.

            (ii)  If Pfizer terminates all of its development activities for a
                  period of six (6) months or longer in the US Territory at any
                  time after it has the final decision making authority with
                  respect to the Development Program (other than for regulatory
                  restraints) and [***].

            (iii) If Pfizer terminates the Development Program with respect to
                  any country in the ROW Territory or otherwise fails to conduct
                  any development activities directed to any such country,
                  [***], Pfizer will thereafter have six (6) months [***]. If
                  Pfizer fails within thirty (30) days to notify Neurocrine
                  [***], Neurocrine shall have the right to terminate this
                  Agreement with respect to such country effective upon thirty
                  (30) days notice.

      (b)   For purposes of this Agreement, materiality in all cases shall be
            considered in the context of this Agreement and the Collaboration
            Agreement taken as a whole; provided, however, no party shall be
            deemed to be in material breach or material

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       33
<PAGE>
            default if its actions or omissions primarily resulted from: (i)
            compliance with any specific unanimous decision of a committee or
            subcommittee under the Collaboration Agreement, or (ii) compliance
            with any directive by the non-defaulting party for a matter in which
            the non-defaulting party or any of its designees, representatives or
            employees have exercised sole or final decision making authority
            under the Collaboration Agreement, or (iii) compliance with the
            express terms of this Agreement or the Collaboration Agreement, or
            (iv) to the extent Pfizer uses efforts in substantial conformity
            with Commercially Reasonable Efforts or Neurocrine uses efforts in
            substantial conformity with commercially reasonable efforts
            consistent with Section 2.12 of the Collaboration Agreement. A
            material breach or material default in the performance of any of the
            provisions of this Agreement shall include a material inaccuracy in
            any representation or warranty contained herein.

      (c)   Upon the giving of any notice of default under Section 9.02(a), the
            parties will in good faith meet to see if a plan to remedy the
            alleged breach or default can be mutually agreed.

      (d)   Upon any termination under this Section 9.02, the provisions of
            Section 9.05 shall apply.

9.03  Other Termination.

      (a)   Upon one hundred and eighty (180) days prior notice to Neurocrine,
            Pfizer shall have the right at any time, without cause at Pfizer's
            sole discretion, to terminate in full this Agreement, whereupon this
            Agreement together with the Collaboration Agreement (if still in
            effect) shall terminate one hundred and eighty (180) days after the
            date of such notice.

      (b)   This Agreement shall terminate following any termination by Pfizer
            of the Collaboration Agreement, except this Agreement shall not
            terminate if Pfizer terminates the Collaboration Agreement due to
            the events described under Sections

                                       34
<PAGE>
            13.5 or 13.7 thereunder or upon a Change in Control (as defined in
            the Collaboration Agreement).

      (c)   Upon one hundred and eighty (180) days prior notice to Neurocrine,
            Pfizer shall have the right at any time or times, without cause at
            its sole discretion, to terminate the licenses granted hereunder by
            Neurocrine on a country-by-country basis other than with respect to
            the United States and Japan. Upon a termination of licenses in any
            country, the provisions of Section 9.05 shall apply with respect to
            such country terminated.

      (d)   This Agreement shall automatically terminate upon termination by
            Neurocrine of the Collaboration Agreement pursuant to Section
            13.2(a) thereof or pursuant to the first sentence of Section 13.2(b)
            thereof with respect to the US Territory.

      (e)   Upon any termination of this Agreement pursuant to this Section
            9.03, the provisions of Section 9.05 shall apply.

9.04  Bankruptcy. Each party may, in addition to any other remedies available to
      it by law or in equity, exercise the rights set forth below by written
      notice to the other party (the "Insolvent Party"), in the event the
      Insolvent Party shall have become insolvent or bankrupt, or shall have
      made a general assignment for the benefit of its creditors, or there shall
      have been appointed a trustee or receiver of the Insolvent Party or for
      all or a substantial part of its property, or any case or proceeding shall
      have been commenced or other action taken by or against the Insolvent
      Party in bankruptcy or seeking reorganization, liquidation, dissolution,
      winding-up arrangement, composition or readjustment of its debts or any
      other relief under any bankruptcy, insolvency, reorganization or other
      similar act or law of any jurisdiction now or hereafter in effect, and any
      such event shall have continued for sixty (60) days undismissed, unbonded
      and undischarged. All rights and licenses granted under or pursuant to
      this Agreement by Neurocrine and Pfizer are, and shall otherwise be deemed
      to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
      licenses of rights to "intellectual property" as defined under Section 101
      of the U.S. Bankruptcy Code. The parties agree that the parties as
      licensees of such rights under this Agreement shall retain and may fully
      exercise all of

                                       35
<PAGE>
      their rights and elections under the U.S. Bankruptcy Code. The parties
      further agree that, in the event of the commencement of a bankruptcy
      proceeding by or against either party under the U.S. Bankruptcy Code, the
      other party shall be entitled to a complete duplicate of (or complete
      access to, as appropriate) any such intellectual property and all
      embodiments of such intellectual property, and same, if not already in the
      their possession, shall be promptly delivered to them (i) upon any such
      commencement of a bankruptcy proceeding upon its written request
      therefore, unless the party subject to such proceeding elects to continue
      to perform all of their obligations under this Agreement or (ii) if not
      delivered under (i) above, upon the rejection of this Agreement by or on
      behalf of the party subject to such proceeding upon written request
      therefore by the other party. In the event Neurocrine shall be an
      Insolvent Party, Pfizer may retain the licenses set forth herein subject
      to the payment of all milestones, license fees, royalties and other
      payments or reimbursements set forth herein subject to Section 13.8 of the
      Collaboration Agreement and Section 9.07 below.

9.05  Termination of Pfizer. In the event that this Agreement is terminated in
      accordance with Sections 9.02 or 9.03, on a country-by-country basis:

      (a)   All licenses granted by Neurocrine to Pfizer in this Agreement will
            revert to Neurocrine;

      (b)   Pfizer will pay to Neurocrine such amounts required to complete any
            on-going Product Studies (including the Registration Program Product
            Studies) plus any non-cancelable obligations with respect to future
            Product Studies approved by a Committee;

      (c)   Pfizer will provide to Neurocrine, at no cost to Neurocrine, all
            remaining clinical quantities of Product supplies and all remaining
            commercial quantities of Product (including intermediates and work
            in progress);

      (d)   Pfizer will disclose to Neurocrine all Pfizer Technical Information
            generated prior to the date of termination of this Agreement not
            previously disclosed to Neurocrine;

                                       36
<PAGE>
      (e)   Pfizer will assign to Neurocrine all filings with Governmental
            Authorities relating to Products worldwide;

      (f)   Pfizer will grant to Neurocrine a perpetual, irrevocable,
            non-exclusive, royalty-free, fully-paid, license under any Pfizer
            Technical Information and Pfizer Trademarks, together with any
            Patent Rights owned by Pfizer and used in connection with the
            research, development, manufacture, use and sale of the Products;

      (g)   Pfizer will provide to Neurocrine any other assignable contracts
            relating to the Products, reasonably required to allow Neurocrine to
            continue the research and development of Products with no delay,
            provided Pfizer shall have no continuing liability or obligation
            thereunder.

9.06  Divestiture by Pfizer.

      (a)   If in connection with any proposed acquisition or merger or inquiry
            of a Governmental Authority, Pfizer determines that in order to
            facilitate clearance or obtain approval from any Governmental
            Authority with responsibility for enforcing antitrust or competition
            Laws regarding such acquisition or merger or inquiry, it would be
            advisable, in Pfizer's business judgement, to assign or sublicense
            or otherwise transfer (any such assignment, sublicense or transfer,
            a "Divestiture Transaction") Pfizer's rights and obligations under
            this Agreement to any third party, Pfizer shall notify Neurocrine
            thereof ("Notice of Divestiture"). The Notice of Divestiture shall
            not be required to disclose any details of any such proposed
            Divestiture Transaction.

      (b)   [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       37
<PAGE>
9.07  Survival of Obligations. Notwithstanding any termination of this
      Agreement, (a) neither party shall be relieved of any obligations incurred
      prior to such termination, including the payment obligations, and (b) the
      obligations of the parties with respect to (I) the protection and
      nondisclosure of Confidential Information (Article 5) and Indemnification
      (Article 10) shall survive termination of this Agreement, and (II) each
      other Section or schedule of this Agreement which is expressed to survive
      termination or which is required to give effect to such termination or the
      consequences of such termination shall survive termination, and (c)
      subject to Section 10.04(c)(vi) and Section 10.06, termination of this
      Agreement shall not release either party from any obligation or liability
      which shall have accrued at the time of termination or preclude either
      party from pursuing all rights at law and in equity with respect to any
      default under this Agreement, and (d) unless this Agreement expressly
      provides that termination shall be the sole and exclusive remedy for a
      particular breach hereof, either party's right to commence an action, suit
      or other proceeding claiming breach of this Agreement by the other party
      shall survive termination. Upon a termination of this Agreement by Pfizer,
      Neurocrine shall promptly return to Pfizer all written Confidential
      Information previously disclosed by Pfizer, and all copies thereof. Upon
      any other termination of this Agreement, each party shall promptly return
      to the other party all

                                       38
<PAGE>
      written Confidential Information, and all copies thereof, of such other
      party, except as specifically provided in this Agreement.

                                   ARTICLE 10

10.    INDEMNIFICATION.

10.01 Pfizer. Subject to the terms and conditions of this Agreement, Pfizer will
      indemnify, defend and hold harmless Neurocrine and its Affiliates, (each,
      a "Neurocrine Indemnified Party") from and against any and all Liability
      (as defined below) which:

      (a)   is incurred, suffered or sustained by a Neurocrine Indemnified Party
            or to which a Neurocrine Indemnified Party becomes subject (whether
            or not in connection with any claim by any Third Party (as defined
            in Section 10.05 below)), arising out of or resulting from (i) any
            misrepresentation or breach of any representation or warranty made
            by Pfizer in this Agreement or the Collaboration Agreement, or (ii)
            any breach of any of the covenants or agreements of Pfizer in this
            Agreement or the Collaboration Agreement; and/or

      (b)   the Neurocrine Indemnified Party may be required to pay to one or
            more Third Parties resulting from or arising out of any claims of
            any nature (i) solely in connection with the Supplemental Program
            (including without limitation any Product Liability related thereto)
            or (ii) directly resulting from Pfizer's failure to manufacture, or
            to cause third parties to manufacture, Products in accordance with
            the then-existing Specifications as determined in accordance with
            the terms of the Collaboration Agreement but in the case of this
            clause (ii) only to the extent [***] (collectively, the Liabilities
            described in this Section 10.01(b) are referred to as the "Pfizer
            Liability").

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       39
<PAGE>
      [***]

10.02 Indemnification by Neurocrine. Subject to the terms and conditions of this
      Agreement, Neurocrine will indemnify, defend and hold harmless Pfizer and
      its Affiliates (each, a "Pfizer Indemnified Party") from and against any
      and all Liability which:

      (a)   is incurred, suffered or sustained by a Pfizer Indemnified Party or
            to which a Pfizer Indemnified Party becomes subject (whether or not
            in connection with any claim by any Third Party), arising out of or
            resulting from (i) any misrepresentation or breach of any
            representation or warranty made by Neurocrine in this Agreement or
            the Collaboration Agreement, or (ii) any breach of any of the
            covenants or agreements of Neurocrine in this Agreement or the
            Collaboration Agreement; and/or

                                       40
<PAGE>
      (b)   the Pfizer Indemnified Party may be required to pay to one or more
            Third Parties arising out of any claims of any nature: (i) solely in
            connection with Neurocrine's development of the Product prior to the
            Effective Date and the Registration Program (including without
            limitation any Product Liability related thereto) or (ii) directly
            resulting from Neurocrine's failure to manufacture, or to cause
            third parties to manufacture, Products in accordance with the
            then-existing Specifications as determined in accordance with the
            terms of the Collaboration Agreement but in the case of this clause
            (ii) only to the extent (***) (collectively, the Liabilities
            described in this Section 10.02(b) are referred to as the
            "Neurocrine Liability").

      [***].

      [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       41
<PAGE>
      Notwithstanding anything to the contrary contained herein, Pfizer shall be
      entitled, at all times, to avail itself of the right to obtain specific
      performance and other injunctive relief in relation to all matters under
      this Agreement and/or the Collaboration Agreement [***]. In connection
      with any litigation referenced in this paragraph, Neurocrine hereby agrees
      to waive all defenses involving laches and statutes of limitations. [***].

      [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       42
<PAGE>
      [***]:

      (i)   [***].

      (ii)  [***].

10.03 Definitions of Liability and Product Liability. For purposes of this
      Agreement, "Liability" shall mean, subject to Section 10.06, any and all
      (a) claims, losses, liabilities, damages, fines, royalties, governmental
      penalties or punitive damages, deficiencies, interest, awards, and
      judgements, and (b) with respect to third parties, settlement amounts and
      all of the items referred to in clause (a) above which, in accordance with
      Section 10.06, include special, indirect, incidental and consequential
      damages (including without limitation lost profits), and (c) in connection
      with all of the items referred in clauses (a) and (b) above, any and all
      costs and expenses (including reasonable attorneys' fees and all other
      expenses reasonably incurred in investigating, preparing or defending any
      litigation or proceeding, commenced or threatened). For purposes of this
      Agreement, "Product Liability" shall mean any and all Liability and claims
      of Third Parties relating to any actual or alleged death or bodily injury
      caused or allegedly caused by the use of the Products; it being understood
      and agreed that all Liability as and to the extent referenced in Section
      10.01 or Section 10.02 or breaches of any representations or warranties in
      this Agreement or the Collaboration Agreement shall be excluded from the
      definition of

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       43
<PAGE>
      "Product Liability" as used herein, except with respect to Product
      Liability as specifically provided in Sections 10.01(b)(i) and
      10.02(b)(i).

10.04 Co-Indemnity and Neurocrine Contractual Indemnity.

      (a)   Product Liability.

            (i)   Notwithstanding anything to the contrary contained herein
                  (except with respect to Product Liability as specifically
                  provided in Sections 10.01(b)(i) and 10.02(b)(i)), the Parties
                  understand and agree that all indemnification obligations for
                  Product Liability shall be governed by the provisions of this
                  Section 10.04 (but not be governed by the provisions of either
                  Sections 10.01 or 10.02).

            (ii)  Subject to the timing of payments as provided in Section
                  10.04(c) below and the provisions of this sentence, Neurocrine
                  shall indemnify, defend and hold the Pfizer Indemnified
                  Parties harmless under the terms hereof from and against [***]
                  of the amount of any and all Product Liability as and when
                  such Product Liability arises on and after the Effective Date,
                  and Pfizer shall indemnify, defend and hold Neurocrine
                  Indemnified Parties harmless under the terms hereof from and
                  against [***] of the amount of any and all of such Product
                  Liability as and when such Product Liability arises on and
                  after the Effective Date; it being understood and agreed that
                  (X) the purpose of the provisions of this sentence is that
                  Neurocrine and Pfizer shall pay for and otherwise share the
                  cost of all Product Liability [***] and [***], respectively,
                  and (Y) in the event of any termination in full of
                  Co-Promotion activities by Neurocrine under the Collaboration
                  Agreement, Pfizer shall indemnify, defend and hold Neurocrine
                  Indemnified Parties harmless under the terms hereof from and
                  against [***] of the amount of any and all of any Product
                  Liability directly resulting from Products sold after the date
                  of termination in full of Co-Promotion activities by
                  Neurocrine as and when

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       44
<PAGE>
                  such Product Liability arises, and (Z) in the event of any
                  termination of the Collaboration Agreement where, as a result,
                  this Agreement terminates, Neurocrine shall indemnify, defend
                  and hold Pfizer Indemnified Parties harmless under the terms
                  hereof from and against [***] of the amount of any and all of
                  any Product Liability directly resulting from Products sold
                  after the date of termination of this Agreement by or on
                  behalf of or under the authority of Neurocrine as and when
                  such Product Liability arises.

            (iii) For purposes of this Agreement, Pfizer shall be entitled to
                  become the "Indemnifying Party" as that term is used in
                  Section 10.05 and therefore Pfizer shall have full control of
                  any such claim from a Third Party involving Product Liability
                  as contemplated in Section 10.05 (other than in respect of
                  circumstances where Section 10.04(a)(ii)(Z) shall apply) so
                  long as the Litigation Conditions are satisfied.

      (b)   IP Liability.

            (i)   Notwithstanding anything to the contrary contained herein, the
                  Parties understand and agree that all indemnification
                  obligations for IP Liability shall be governed by the
                  provisions of this Section 10.04 (but not be governed by the
                  provisions of either Sections 10.01 or 10.02).

            (ii)  Subject to the timing of payments as provided in Section
                  10.04(c) below and the provisions of this sentence, Neurocrine
                  shall indemnify, defend and hold the Pfizer Indemnified
                  Parties harmless under the terms hereof from and against [***]
                  of the amount of any and all IP Liability as and when such IP
                  Liability arises, and Pfizer shall indemnify, defend and hold
                  Neurocrine Indemnified Parties harmless under the terms hereof
                  from and against [***] of the amount of any and all of such IP
                  Liability as and when such IP Liability arises; it being
                  understood and agreed that (X) the purpose of the provisions
                  of this sentence is that Neurocrine and Pfizer shall pay for
                  and otherwise share the cost of all IP

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       45
<PAGE>
                  Liability [***] and [***], respectively, and (Y) in the event
                  of any termination in full of Co-Promotion activities by
                  Neurocrine under the Collaboration Agreement, Pfizer shall
                  indemnify, defend and hold Neurocrine Indemnified Parties
                  harmless under the terms hereof from and against [***] of the
                  amount of any and all of any IP Liability directly resulting
                  from Products sold after the date of termination in full of
                  Co-Promotion activities by Neurocrine as and when such IP
                  Liability arises, and (Z) in the event of any termination of
                  the Collaboration Agreement where, as a result, this Agreement
                  terminates, Neurocrine shall indemnify, defend and hold Pfizer
                  Indemnified Parties harmless under the terms hereof from and
                  against [***] of the amount of any and all of any IP Liability
                  directly resulting from Products sold after the date of
                  termination of the Collaboration Agreement by or on behalf of
                  or under the authority of Neurocrine as and when such IP
                  Liability arises.

            (iii) For purposes of this Agreement, Pfizer shall be entitled to
                  become the "Indemnifying Party" as that term is used in
                  Section 10.05 and therefore Pfizer shall have full control of
                  any such claim from a Third Party involving IP Liability as
                  contemplated in Section 10.05 (other than in respect of
                  circumstances where Section 10.04(b)(ii)(Z) shall apply) so
                  long as the Litigation Conditions are satisfied.

      (c)   [***]:

            (i)   [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       46
<PAGE>
            (ii)  [***].

            (iii) [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       47
<PAGE>
            (iv)  [***].

            (v)   [***].

            (vi)  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       48
<PAGE>
            (vii) [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       49
<PAGE>
10.05 Indemnification Procedure.

      (a)   A party seeking indemnification pursuant to Article 10 (an
            "Indemnified Party") shall give prompt notice to the party from whom
            such indemnification is sought (the "Indemnifying Party") of the
            commencement or assertion of any claim from any unaffiliated third
            party (a "Third Party") (which in no event includes any claims by
            any Pfizer Indemnified Party or any Neurocrine Indemnified Party) in
            respect of which indemnity may be sought hereunder, shall give the
            Indemnifying Party such information with respect thereto as the
            Indemnifying Party may reasonably request, and shall not make any
            admission concerning such claim from a Third Party, unless such
            admission is required by applicable Law or legal process, including
            in response to questions presented in depositions or
            interrogatories. Any admission made by the Indemnified Party, except
            for an admission required by applicable Law or legal process, or the
            failure to give such notice shall relieve the Indemnifying Party of
            any liability hereunder only to the extent that the ability of the
            Indemnifying Party to defend such claim from a Third Party is
            prejudiced thereby. The Indemnifying Party shall have the right,
            exercisable by written notice to the Indemnified Party within thirty
            (30) days of receipt of notice from the Indemnified Party of the
            commencement or assertion of a claim from a Third Party, to assume
            and conduct the defense of such claim from a Third Party, with
            counsel selected by the Indemnifying Party and reasonably acceptable
            to the Indemnified Party, provided that (i) other than with respect
            to claims for Product Liability and IP Liability for which Pfizer
            has assumed the defense as provided herein (which shall not include
            Product Liability as set forth in Section 10.02), the claim from a
            Third Party does not seek (and continues not to seek) specific
            performance of the Indemnified Party; and (ii) the Indemnifying
            Party expressly agrees in writing that as between the Indemnifying
            Party and the Indemnified Party, the Indemnifying Party shall be
            solely obligated to satisfy and discharge the claim from a Third
            Party in full, subject to Section 10.04 (where Pfizer only shall be
            responsible for Product Liability and IP Liability as provided
            herein). (The conditions set forth above are collectively referred
            to as the "Litigation Conditions"). Subject to the initial and
            continuing satisfaction in full

                                       50
<PAGE>
            of the Litigation Conditions and the terms and conditions of Article
            10, the Indemnifying Party shall have full control of such claim
            from a Third Party, including settlement negotiations and any legal
            proceedings. If the Indemnifying Party does not assume the defense
            of such claim from a Third Party in accordance with this Section
            10.05 or the Litigation Conditions are not at any time then
            satisfied in full, the Indemnified Party may defend the claim from a
            Third Party.

      (b)   The Indemnifying Party or the Indemnified Party, as the case may be,
            shall have the right to participate in (but not control), at its own
            expense (subject to the immediately succeeding sentence), the
            defense of any claim from a Third Party which the other is defending
            as provided in this Agreement. The Indemnifying Party shall not be
            liable for any litigation costs or expenses incurred, without its
            consent, by the Indemnified Party where the action or proceeding is
            under the control of the Indemnifying Party and the Indemnifying
            Party is conducting such defense diligently; provided, however, that
            if (i) the Litigation Conditions have not been met or cease to be
            met in full, or (ii) the Indemnifying Party fails in any material
            way to take reasonable steps necessary to defend diligently such
            claim from a Third Party, the Indemnified Party may assume its own
            defense, and the Indemnifying Party will be liable for all
            reasonable costs or expenses paid or incurred in connection
            therewith.

      (c)   The Indemnifying Party, if it shall have assumed the defense of any
            claim from a Third Party as provided in this Agreement, shall not
            consent to a settlement of, or the entry of any judgment arising
            from, any such claim from a Third Party to the extent such claim
            from a Third Party involves equitable or other non-monetary relief
            from the Indemnified Party. No party shall, without the prior
            written consent of the other parties, enter into any compromise or
            settlement which commits the other parties to take, or to forbear to
            take, any action.

      (d)   Whether or not the Indemnifying Party chooses to defend or prosecute
            any claim from a Third Party, all the parties hereto shall cooperate
            in the defense or prosecution thereof and shall furnish such
            records, information and testimony, and

                                       51
<PAGE>
            attend such conferences, discovery proceedings, hearings, trials and
            appeals, as may be reasonably requested in connection therewith.

      (e)   Any indemnification hereunder shall be made net of any insurance
            proceeds recovered by the Indemnified Party from Third Party;
            provided, however, that if, following the payment to the Indemnified
            Party of any amount under this Article 10, such Indemnified Party
            recovers any such insurance proceeds in respect of the claim for
            which such indemnification payment was made, the Indemnified Party
            shall promptly pay an amount equal to the amount of such proceeds
            (but not exceeding the amount of such indemnification payment) to
            the Indemnifying Party.

10.06 Limitation of Damages/Sole Remedy. IN NO EVENT SHALL PFIZER OR NEUROCRINE
      BE LIABLE UNDER THIS AGREEMENT OR THE COLLABORATION AGREEMENT FOR (X)
      SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT
      LIMITATION, LOSS OF PROFITS) SUFFERED BY ANY NEUROCRINE PARTIES OR ANY
      PFIZER PARTIES, RESPECTIVELY, OR [***], EXCEPT (A) TO THE EXTENT ANY SUCH
      DAMAGES ARE PAID TO A THIRD PARTY AS PART OF A THIRD PARTY CLAIM, AND (B)
      IN THE EVENT OF AN INTENTIONAL AND WILLFUL BREACH IN BAD FAITH OF ANY
      REPRESENTATION, WARRANTY, COVENANT OR AGREEMENT BY NEUROCRINE OR PFIZER
      (AS THE CASE MAY BE) OF THIS AGREEMENT. EXCEPT FOR SUITS FOR SPECIFIC
      PERFORMANCE OR OTHER INJUNCTIVE RELIEF AND EXCEPT AS EXPRESSLY PROVIDED IN
      THIS AGREEMENT AND THE COLLABORATION AGREEMENT, INDEMNIFICATION PURSUANT
      TO THIS ARTICLE 10 SHALL BE THE SOLE AND EXCLUSIVE REMEDY (WHETHER BASED
      ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY) AVAILABLE TO NEUROCRINE OR
      PFIZER FOR ANY MISREPRESENTATION UNDER OR BREACH OF THIS AGREEMENT OR THE
      COLLABORATION AGREEMENT. [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       52
<PAGE>
10.07 Insurance. Pfizer will name Neurocrine, [***] as additional insureds on
      its product liability insurance, which insurance shall provide coverage of
      not less than [***]. Promptly after the Effective Date Pfizer will supply
      Neurocrine with evidence of such coverage and during the term of this
      Agreement, Pfizer will inform Neurocrine of any modifications to such
      coverages.

                                   ARTICLE 11

11.   NON-COMPETITION.

11.01 Pfizer Non-Competition. If during the term of this Agreement Pfizer or any
      of its Affiliates intends to Commercialize (as hereinafter defined) a
      prescription pharmaceutical product having an Insomnia Indication in the
      Territory (a "Competitive Product"):

      (a)   If such Competitive Product's [***]:

            (i)   [***]

            (ii)  [***].

      (b)   If such Competitive Product's [***]:

            (i)   [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       53
<PAGE>
            (ii)  [***]:

                  [***].

      (c)   If Pfizer Launches any Competitive Product defined in Section
            11.01(b) ("Section 11.01(b) Product"), then neither Pfizer or its
            Affiliates shall:

            (i)   Engage in negative promotional activities, [***]

            (ii)  [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       54
<PAGE>
            (iii) [***].

            (iv)  [***].

      (d)   Notwithstanding to the contrary any provisions of this Agreement or
            the Collaboration Agreement, in no event shall Pfizer be required
            under this Agreement or under the Collaboration Agreement to engage
            in any activity regarding a Product which Pfizer is prohibited from
            undertaking under Section 11.01(c) with respect to a Section
            11.01(b) Product, and Section 11.01(c) shall be applicable, on the
            same basis, mutatis mutandis, to promotional activities regarding
            the Product vis-a-vis any Competitive Product of Pfizer.

11.02 Neurocrine Non-Competition. If, during the term of this Agreement,
      Neurocrine or any of its Affiliates proposes to Commercialize a
      Competitive Product in the Territory, Neurocrine or such Affiliate shall,
      if such Competitive Product's primary mechanism of

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       55
<PAGE>
      action is through binding with [***], divest (by license, sale or similar
      transaction) such Competitive Product.

11.03 [***].

11.04 For purpose of this Section 11 "Commercialize" means directly or
      indirectly to market, sell, detail, promote or distribute, but in no event
      shall include an out-license or other divestiture of intellectual property
      rights to a person who markets sells details, promotes or distributes.

                                   ARTICLE 12

12.   MISCELLANEOUS.

12.01 Force Majeure. No party shall be liable for failure of or delay in
      performing obligations set forth in this Agreement, and no party shall be
      deemed in breach of its obligations, if such failure or delay is due to
      natural disasters or any causes reasonably beyond the control of such
      party.

12.02 Assignment. This Agreement and all rights and obligations granted
      hereunder shall not be assignable by any party without the prior consent
      of the other, except that (a) Pfizer may in connection with a Divestiture
      Transaction assign this Agreement, (b) Pfizer may assign this Agreement,
      and after all amounts due under the Loan Agreement have been paid in full
      and the Loan Agreement has been terminated, Neurocrine may assign this
      Agreement, in each case, in whole or in part, to any Affiliate of such
      party or to any successor to substantially all of such party's business or
      assets; provided, however, in the case of Pfizer and Neurocrine, the
      assigning party shall remain responsible for all obligations hereunder if
      its Affiliate shall fail to perform hereunder.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       56
<PAGE>
12.03 Governing Law. This Agreement shall be governed by the laws of the State
      of New York without regard to its conflict of laws rules.

12.04 Jurisdiction. With respect to any suit, action or proceeding relating to
      this Agreement (each, a "Proceeding"), each party hereto irrevocably (i)
      subject to the final sentence of this Section 12.04, agrees and consents
      to be subject to (A) in the case of any Proceeding commenced by Pfizer,
      the exclusive jurisdiction of the United States District Court for the
      Southern District of California or any California state court sitting in
      San Diego, California, United States of America (any such court, the
      "California Court"), and (B) in the case of any Proceeding commenced by
      Neurocrine, the exclusive jurisdiction of the United States District Court
      for the Southern District of New York or any New York state court sitting
      in New York, New York, United States of America (any such court, the "New
      York Court") and (ii) waives any objection which it may have at any time
      to the laying of venue of any Proceeding brought in any such California
      Court or New York Court (collectively, the "Courts") as provided in this
      Section 12.04, waives any claim that such Proceeding has been brought in
      an inconvenient forum and further waives the right to object, with respect
      to such Proceeding, that such Court does not have any jurisdiction over
      such party. Notwithstanding the foregoing: (a) if the Court adjudicating
      such Proceeding refuses for any reason to exercise jurisdiction over the
      dispute, either party shall be free to bring such Proceeding in any other
      Court in such state as provided above and, in the event such other Courts
      refuse for any reason to exercise jurisdiction over the dispute, either
      party shall be free to bring such Proceeding in any other court, and (b)
      if any party (the "initiating party") commences a Proceeding in any Court,
      the other party (the "defendant party") shall possess and retain the right
      to assert in that same Proceeding all claims and defenses that the
      defendant party may have against the initiating party, including without
      limitation all counterclaims and setoffs, and (c) in the case of any suits
      for specific performance or other injunctive relief, the parties will seek
      to bring such actions in the Courts as provided in the first sentence of
      this Section 12.04, except where the applicable Courts as a result of
      jurisdictional requirements cannot issue the specific performance
      requested in a timely manner.

                                       57
<PAGE>
12.05 Notices. All notices, instructions and other communications hereunder or
      in connection herewith shall be in writing, shall be sent to the address
      below and shall be: (a) delivered personally; (b) sent by registered or
      certified mail, return receipt requested, postage prepaid; (c) sent via a
      reputable nationwide overnight courier service; or (d) sent by facsimile
      transmission. Any such notice, instruction or communication shall be
      deemed to have been delivered upon receipt if delivered by hand, three (3)
      Business Days after it is sent by registered or certified mail, return
      receipt requested, postage prepaid, one (1) Business Day after it is sent
      via a reputable nationwide overnight courier service, or when transmitted
      with electronic confirmation of receipt, if transmitted by facsimile (if
      such transmission is on a Business Day; otherwise, on the next Business
      Day following such transmission).

If to Pfizer:                                 If to Neurocrine:

PFIZER INC.                                   NEUROCRINE BIOSCIENCES, INC.
235 East 42nd Street                          10555 Science Center Drive
New York, New York  10017-5703                San Diego, California  92121-1102

Fax:  212-808-8652                            Fax: 858-658-7605

Attention: President, Pfizer                  Attention:  President
           Pharmaceuticals Group
                                              CC; General Counsel

With a copy to: Senior Vice President
                and General Counsel

Fax: 212-808-8924

In case any party changes its address at which notice is to be received, notice
of such change shall be given without delay to the other party.

12.06 Entire Agreements; Amendments. This Agreement, together with the
      Collaboration Agreement, sets forth the entire agreement and understanding
      among the parties hereto as to the subject matter hereof and all
      agreements or understandings, verbal or written, made between Neurocrine
      and Pfizer before the date hereof with respect to the subject matter
      hereof. None of the terms or this Agreement shall be amended, supplemented
      or modified except in writing signed by the parties hereto.

                                       58
<PAGE>
12.07 Severability. If and solely to the extent that any provision of this
      Agreement shall be invalid or unenforceable, or shall render this entire
      Agreement to be unenforceable or invalid, such offending provision shall
      be of no effect and shall not effect the validity of the remainder of this
      Agreement or any of its provisions; provided, however, the parties shall
      use their respective reasonable efforts to renegotiate the offending
      provisions to best accomplish the original intentions of the parties.

12.08 Waivers. Any term or condition of this Agreement may be waived at any time
      by the party that is entitled to the benefit thereof, but no such waiver
      shall be effective unless set forth in a written instrument duly executed
      by or on behalf of the party or parties waiving such term or condition.
      Neither the waiver by any party of any term or condition of this Agreement
      nor the failure on the part of any party, on one or more instances, to
      enforce any of the provisions of this Agreement or to exercise any right
      or privilege, shall be deemed or construed to be a waiver of such term or
      condition for any similar instance in the future or of any subsequent
      breach hereof. All rights, remedies, undertakings, obligations and
      agreements contained in this Agreement shall be cumulative and none of
      them shall be a limitation of any other remedy, right, undertaking,
      obligation or agreement.

12.09 Binding Effect. This Agreement shall be binding upon and inure to the
      benefit of the parties hereto and their respective heirs, successors and
      permitted assigns.

12.10 Further Assurances. Following the date hereof, Neurocrine and Pfizer
      shall, and shall cause each of their respective Affiliates to, from time
      to time, execute and deliver such additional instruments, documents,
      conveyances or assurances and take such other actions as shall be
      necessary or otherwise reasonably requested by Pfizer or Neurocrine, to
      confirm and assure the rights and obligations provided for in this
      Agreement, and render effective the consummation of the transactions
      contemplated thereby provided however that neither party will be required
      under this paragraph 11.09 to deliver instruments, documents, conveyances
      or assurances of any third party.

12.11 Third Party Beneficiaries. None of the provisions of this Agreement shall
      be for the benefit of or enforceable by any third party including, without
      limitation, any creditor of either party hereto. No third party shall
      obtain any right under any provision of this

                                       59
<PAGE>
      Agreement or shall by reasons of any such provision make any claim in
      respect of any debt, liability or obligation (or otherwise) against either
      party hereto.

12.12 Counterparts. This Agreement may be executed in any two or more
      counterparts, each of which, when executed, shall be deemed to be an
      original and all of which together shall constitute one and the same
      document.

12.13 Headings. Headings in this Agreement are included herein to ease of
      reference only and shall have no legal effect. References to Sections and
      Schedules are to Sections and Schedules of this Agreement unless otherwise
      specified.

12.14 Registration and Filing of the Agreement. To the extent, if any, that a
      party concludes in good faith that it is required under applicable Laws to
      file or register this Agreement or a notification thereof with any
      Governmental Authority, including without limitation the US Securities and
      Exchange Commission, or the US Federal Trade Commission, in accordance
      with applicable Laws, such party may do so and shall provide the other
      party to this Agreement with a written copy of all proposed filings or
      registrations to allow for a reasonably sufficient time for review and
      comment by the other party. The other party shall cooperate in such filing
      or notification and shall execute all documents reasonably required in
      connection therewith. In such situation, the parties will request
      confidential treatment of sensitive provisions of the Agreement, to the
      extent permitted by Law. The parties shall promptly inform each other as
      to the activities or inquiries of any such Governmental Authority relating
      to this Agreement, and shall cooperate to respond to any request for
      further information therefrom.

12.15 Non-Solicitation of Employees. During the term of this Agreement, neither
      party shall, directly or indirectly, recruit, or solicit any employee of
      the other party with whom such party has come into contact or interacted
      for the purposes of performing this Agreement, without the prior consent
      of the other party, except pursuant to general solicitations not targeted
      at such employees.

                                       60
<PAGE>
               [The remainder of this page is intentionally blank]

                                       61
<PAGE>
      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date first written above by their duly authorized officers.

                                   NEUROCRINE BIOSCIENCES, INC.

                                   By:  /s/ Gary A. Lyons
                                       -------------------------------
                                   Name:   Gary A. Lyons
                                   Title:  President and Chief Executive
                                           Officer

                                    PFIZER INC.

                                   By:  /s/ Henry A. McKinnell
                                       -------------------------------
                                   Name:   Henry A. McKinnell
                                   Title:  Chairman of the Board and
                                           Chief Executive Officer

                                       62

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]